var title_f23_17_23824="Perihepatitis in Chlamydia";
var content_f23_17_23824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perihepatitis in chlamydia infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammation of the liver capsule and adjacent peritoneum can be seen via laparascope as an uncommon finding in women with Chlamydial infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from the Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23824=[""].join("\n");
var outline_f23_17_23824=null;
var title_f23_17_23825="Vitiligo";
var content_f23_17_23825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the depigmented skin around the anus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23825=[""].join("\n");
var outline_f23_17_23825=null;
var title_f23_17_23826="Pathophysiology ASD";
var content_f23_17_23826=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of atrial septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23826=[""].join("\n");
var outline_f23_17_23826=null;
var title_f23_17_23827="Seborrheic keratosis inflamed";
var content_f23_17_23827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflamed seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflamed and hyperpigmented seborrheic keratosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23827=[""].join("\n");
var outline_f23_17_23827=null;
var title_f23_17_23828="Patient adherence and the treatment of hypertension";
var content_f23_17_23828=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient adherence and the treatment of hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23828/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23828/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23828/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23828/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23828/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23828/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/17/23828/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The latest National Health and Nutrition Examination Survey found that about 72 percent of hypertensive patients in the United States are being treated and 69 percent of those being treated have their blood pressure well controlled (below",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg) (",
"    <a class=\"graphic graphic_table graphicRef82423 \" href=\"UTD.htm?33/26/34219\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important reason for this shortfall is lack of patient adherence with therapy, although this is difficult to ascertain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/2\">",
"     2",
"    </a>",
"    ]. This problem persists even though individual programs have shown excellent adherence to and results from both non-drug [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/3\">",
"     3",
"    </a>",
"    ] and drug regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/4\">",
"     4",
"    </a>",
"    ]. However, as reported in a 2004 systematic review of 25 studies, convincing empirical evidence is lacking to support the hypothesis that poor compliance accounts for inadequate blood pressure control in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/5\">",
"     5",
"    </a>",
"    ]. A subsequent report from the ANBP2 hypertension trial in elderly patients found that patients who answered yes to the question \"Did you ever forget to take your medication?\" were, compared with those who answered no, significantly more likely to experience a cardiovascular event or death (hazard ratio 1.28, 95% CI 1.04-1.57) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the major issues related to nonadherence with antihypertensive therapy. A more complete discussion of noncompliance is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19111?source=see_link\">",
"     \"Compliance with lipid altering medications and recommended lifestyle changes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REASON FOR NONADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is associated with many factors that have been found to reduce adherence (",
"    <a class=\"graphic graphic_table graphicRef76642 \" href=\"UTD.htm?15/44/16075\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patient and disease characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypertension have special problems related to the nature of their disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many are largely unaware of the definition, possible causes, sequelae, and therapeutic needs of hypertension.",
"     </li>",
"     <li>",
"      Being asymptomatic, they often have little motivation to seek or follow treatment.",
"     </li>",
"     <li>",
"      Many are found to have high BP at the age (late 30s and early 40s) when the threat of a loss of vigor and vitality is insidiously beginning.",
"     </li>",
"     <li>",
"      The recognition of hypertension often provokes a strong denial reaction. Furthermore, the diagnosis carries considerable economic and social threat &mdash; loss of job, insurance, and sexual potency &mdash; that may further inhibit the patient from accepting the diagnosis and dealing with the problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapy of hypertension has all the wrong characteristics for adherence, which are often compounded by clinical practices such as the use of multiple daily doses of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/7\">",
"     7",
"    </a>",
"    ]. In particular, side effects are common and discourage adherence. Examples include impotence and overt or subtle effects on mood and psychologic functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/8\">",
"     8",
"    </a>",
"    ]. The latter findings can only be identified by careful testing. Although patients are usually faulted for poor compliance, physicians frequently do not prescribe additional therapy when BPs are clearly above the goal of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assessment of adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most physicians are confident that they can predict the adherence of their patients with antihypertensive therapy, their predictions are no more accurate than can be obtained by the toss of a coin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/10\">",
"     10",
"    </a>",
"    ]. Although there are multiple ways to assess patients' adherence, none has been found to be particularly accurate. More sophisticated techniques, such as electronic medication monitors, are not currently available for clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/11\">",
"     11",
"    </a>",
"    ], and may not be feasible in primary care. A brief questionnaire regarding adherence may be a reasonable alternative. This was suggested by one study in which respondents who claimed adherence had better blood pressure control [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Methods to improve adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In reviews of the literature, very few proven ways to improve the goals of health care were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/13\">",
"     13",
"    </a>",
"    ]. The situation has been summarized by the following statement: \"The interventions that were effective were complex, including various combinations of more convenient care, information, counseling, reminders, self-monitoring, reinforcement, family therapy, and other forms of additional supervision or attention. Even the most effective interventions did not lead to substantial improvements in adherence. It is time that additional efforts be directed towards developing and testing innovative approaches to assist patients to follow treatment prescriptions\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines to improve patient adherence are listed in Figure 3 (",
"    <a class=\"graphic graphic_table graphicRef77847 \" href=\"UTD.htm?34/12/35020\">",
"     table 3",
"    </a>",
"    ). A few of these suggestions deserve more emphasis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Educate and maintain contact with the patient and the patient's family [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/15\">",
"       15",
"      </a>",
"      ]. Information about medications, when written in simple language and attractively presented, is useful [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/16\">",
"       16",
"      </a>",
"      ]. Broken appointments to clinics have been reduced by mail, telephone, and physician reminders and by establishing a contract with the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Keep care inexpensive and simple. The minimum effective doses should be prescribed, generic brands should be used, and larger doses of tablets should be broken in half with readily available pill cutters. Fortunately, an increasing number of once-a-day formulations are available so that fewer tablets are needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of less expensive medications is being emphasized in an attempt to reduce the costs of health care and to ensure that the indigent are not denied needed medications whenever there is no safety net in place. Although the indigent can often be provided medications through pharmaceutical company programs, the cost of therapy remains a barrier to the management of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, simplistic comparisons of costs based purely on the costs per tablet may be misleading. As an example, in a survey of hypertensive patients in South Carolina, the experiences of 947 who were given three 60-mg doses of short-acting generic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    per day were compared to the experiences of 301 given one 180-mg dose of the more expensive brand of long-acting diltiazem per day [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23828/abstract/19\">",
"     19",
"    </a>",
"    ]. Those on the once a day dose required fewer concomitant antihypertensive drugs, adhered more closely to therapy, and required less use of and expenditures for physician and hospital services. Although their drug costs were higher, their total costs of health care were less.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       \"Patient information: Dealing with side effects from medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294136220\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of patient adherence with antihypertensive therapy is an important reason for poor blood pressure control among treated patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reasons for nonadherence are many (",
"      <a class=\"graphic graphic_table graphicRef76642 \" href=\"UTD.htm?15/44/16075\">",
"       table 2",
"      </a>",
"      ), and include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Many patients are unaware of the definition, causes, and sequelae of hypertension, and since most patients are asymptomatic, they often have little motivation to seek or follow treatment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient and disease characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antihypertensive regimens are sometimes complex (with multiple daily doses), and the drugs used are often associated with side effects. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physicians cannot reliably assess adherence to antihypertensive therapy, nor can they accurately predict which patients will be adherent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Assessment of adherence'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suggestions for improving patient adherence to antihypertensive therapy include educating and maintaining contact with patients and their families, keeping medications regimens inexpensive and simple, as well as others (",
"      <a class=\"graphic graphic_table graphicRef77847 \" href=\"UTD.htm?34/12/35020\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/1\">",
"      Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/2\">",
"      Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/3\">",
"      Beckmann SL, Os I, Kjeldsen SE, et al. Effect of dietary counselling on blood pressure and arterial plasma catecholamines in primary hypertension. Am J Hypertens 1995; 8:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/4\">",
"      Stason WB, Shepard DS, Perry HM Jr, et al. Effectiveness and costs of veterans affairs hypertension clinics. Med Care 1994; 32:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/5\">",
"      Wetzels GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/6\">",
"      Nelson MR, Reid CM, Ryan P, et al. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006; 185:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/7\">",
"      Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep 2000; 2:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/8\">",
"      Dimsdale JE. Reflections on the impact of antihypertensive medications on mood, sedation, and neuropsychologic functioning. Arch Intern Med 1992; 152:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/9\">",
"      Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/10\">",
"      Stephenson BJ, Rowe BH, Haynes RB, et al. The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA 1993; 269:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/11\">",
"      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/12\">",
"      Fodor GJ, Kotrec M, Bacskai K, et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. J Hypertens 2005; 23:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/13\">",
"      McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288:2868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/14\">",
"      Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/15\">",
"      Daniels PR, Kardia SL, Hanis CL, et al. Familial aggregation of hypertension treatment and control in the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Am J Med 2004; 116:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/16\">",
"      Baker D, Roberts DE, Newcombe RG, Fox KA. Evaluation of drug information for cardiology patients. Br J Clin Pharmacol 1991; 31:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/17\">",
"      Macharia WM, Leon G, Rowe BH, et al. An overview of interventions to improve compliance with appointment keeping for medical services. JAMA 1992; 267:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/18\">",
"      Shulman NB, Levinson RM, Dever GE, et al. Impact of cost problems on morbidity in a hypertensive population. Am J Prev Med 1991; 7:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23828/abstract/19\">",
"      Sclar, DA, Tessier, GC, Skaer, TL, et al. Effect of pharmaceutical formulation of diltiazem on the utilization of Medicaid and health maintenance organization services. Curr Ther Res 1994; 55:1136.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3845 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23828=[""].join("\n");
var outline_f23_17_23828=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H294136220\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REASON FOR NONADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patient and disease characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assessment of adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Methods to improve adherence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H294136220\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3845\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3845|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/26/34219\" title=\"table 1\">",
"      Hypertension awareness and Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/44/16075\" title=\"table 2\">",
"      Causes of noncompliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/12/35020\" title=\"table 3\">",
"      Methods to improve compliance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19111?source=related_link\">",
"      Compliance with lipid altering medications and recommended lifestyle changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_17_23829="Quinidine: Patient drug information";
var content_f23_17_23829=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Quinidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     see \"Quinidine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=see_link\">",
"     see \"Quinidine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Quinidine&reg;;",
"     </li>",
"     <li>",
"      BioQuin&reg; Durules&trade;;",
"     </li>",
"     <li>",
"      Novo-Quinidin;",
"     </li>",
"     <li>",
"      Quinate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used to treat unsafe fast heartbeats only. It may cause risky side effects. You will be closely watched when starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691950",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat malaria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702840",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to quinidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A slow heartbeat without a working pacemaker, low platelet count, or myasthenia gravis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695321",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11418 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7EC3A6EE76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23829=[""].join("\n");
var outline_f23_17_23829=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216499\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028170\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028172\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028171\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028176\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028177\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028179\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028174\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028175\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028180\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028181\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=related_link\">",
"      Quinidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=related_link\">",
"      Quinidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_17_23830="Lymphoblasts FAB L3";
var content_f23_17_23830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphoblasts in acute lymphoblastic leukemia FAB L-3 morphologic type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAbEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDz3xf4jm1XVbi7AXldgw2PlHTI9a89vbqW6kWORtwAzzViSZpEOCR6E+lUTlchh854yPSv0rRJJbHdipppKOiIXAaIv0UHjFREHyQwAwO5qzGoEbKB8pOdxFCwLIm1G/OpknJadjzvZtj9LjXIc7Sc4+bpitWFbYzu9wFW3IONo6/SqOm2zFnRWQDHc1NcyMttAjKMITyByc1pFWglbY66S5IXZKunWd3cxrbtKAzAYKZySe2K9k0T4WatoyWmqwyu6BgVyMlR1ziuP+DXhy48SeK4UUNHHGwbzBxwOa+tGv8AUrYSwXNopVVIjcAhTXn47GSw8lClZt73PPxdbkmo07eY7TPDWj3GlW9zdRLcSyIDuk43E097TULaON7S1tbVYAVSMcgDua1YdkelLc3m1WCZHGMHHHFUbfVWSxn1G/SUKi+UVAwD7rnqa+YVSpJt7q/X8kcznKaSZyj+I7/VNbFh9igubd0Me5QdynP3ia1ZdN8jSljtAEaylEhuJ+FODk4963fCaacLSK4htfsc02SFkG129TXz/wDFr4kprPiiTTrO4ZtKs32r5XIlcdSfUeld1GLxFb2VGPKo7nThcE8TLR2R33iH4k2uhXMsej6R9s1KYqXmP3GP1Hp6V5nrPxh8ZwapcXEl1Z2ibPLjg2Ern1+vvXNa/NDJDbx2UpgMxDviT7rfTsan1fQzYQWi3UkV/IwDbv7oPqa9algaEN43b76nvwwFCnFQ5RZvHF/r/h6a21K4Ec8e5lKH75Pam6f4hvx/ZkF7J9mt4Y9w+XB/Guf1xLXS5kDGO7CjanlcKPxqKPXhcMk17F9omC7I4sYVQP612qlG3urQ3lBWsjvY2l1C7muVkv7mSI9IwWR1PbI9q6JtdttfuNLtG06SG0smBdmTPOayvA+rajfWc0VjZwwiR8xvvwsZ96v6Ze2MUOo6RrF0Iri4VmnvSAinjGFz1rkqrXbY56lNpNS1aH6/r2la7e23h+bS4Ft7i9QRyWo4cZwcnsfavcdSs7bTNNt7CxjEcMYARAOleB/AjSLXUPihNJb+bc6fpUBKSOvymToD9a951ctcaggRjuU4ABx+Jr4TiyrGPLQh6kxpxjUSjslc52/urTRrZrvUHVIs4fHQ/T615n44+Pdvod5LY+FraO6nUczSghUJ65HcipP2ifEEvh+7stOt2jkkn2t5B53DPU+leNNo9rNcm5ubeQy3Umzaowik9811cOcN0Z044mur32McTiOZ8sTtE+JHiPXXiuNe1N47Y/MLe1G0Y9TU8Ov2T6x5mlXd3IobJXO5gfT3HvWJ4c0Ax389iDCcp5bM7/wE9veupt4orHS2i8P2/ksJRFLeSJkhfQe/pX2qo0qS5YKwqdrWSOw8AanH4d8WWs+rFbe1v4maMynLL/hXS+PNa0XxLFG2nywTR2Ugkmnb1H8C+pryxNOsJLmS3h1Tzbvqiy4yD/s+1UIrTV0jmOoKIbaJi+9ONzdjXJLCQnVVa9pIcqSfvXJvEtkt3KZkCAvKGSJDg7fQiuivrbSvFvhqxghgTTUjGw7++PvHB6muTtJ7SHVJX1M+Qk8YZZicMrdtvtXu/wANPBdgdCF7qG28ubkEiU4ICn0rTF4mOFgpyb02OLE0Fy3jv0PMLw6R4d8L3kWnwm+jmcJG8ozuI6muR123M8TQws0VxJGCEiGQuPWtf413Efg3U7Sw0+eOeNZDIyOckZ5x+Fc/pfiKON2vsyvcyMPN2ruUrXTTvKKqx1vqVl65FzI1/D+gxS6KL3SVh5/4+DdHDs3otWvD3ihbzVrnR7XT1hhjQ7lAJ3N65p8tvcXbSMqpDayjdEXbYGz2+tV2a10KSAJIlpfXA8uZXOQPcGofvXvqz1Yrmeu5N4lOnXtnZ21yyPfI38BzhvwqbxFYSXOhW1sZliml+8pcdBxnHasvS5NMTUC1xcJA7Z2SqRgt2PtWBrWoaj/aIS5mRhE2TcqD8y5zj61UYNtJdBtNyW5FLp1zo93NFc3EpYY8mQ8K2f516F4bC6TYJ9tiWdmj3yEclfyqG/1F/EZtYZ7e0t7RYgUlYYxjqc9zReK8FjJJZzxMwO0RNj5gO5qZyc0lLQq/NHlkrGhFr9lHrtnHdW8QsJIicY6n3rNtr21m8QwyxRBrON8xKw9apiGXWLmzXUUigdfl8+MfJj0+tejfC7wro1xZXj3hJeB9oZiB+fvWFWpDDxc3cwxNOk6TckdL4p8L6Bd+EZr9Aon8res4xuY46f8A1q8q1KK8u7iwUXUAt2IjkjPDA16novhe11VXczyC3Vv3WxsgGlk+EOivdTXUl1dGV8cluAB0H51wUMbSw14VZtvzWx87yyUnyo8+kdPD16NN0TUojPMN8i4zt/LoK0xqM10Sbu+idIkxlO3rTb2x8H+GNfN5dXrXt3jYI1IP6CuW8R6/HZ3ZttJtglvIN+5gMlj/AA4rvio1Wmk/Vqx1Up15rYu3fiDR7fUElVp55c4Z+woOu3l9LI+m2U8jMQskoQ7CB6GuXt9TuYLofbTELbacYUdPcV6T/wAJtd2djYpClsbaRcYC44/wq6sVTtyxu/X/AIBs6eIeiNTwb4IGqx2t5qFq9vahtwhbILY7mvX4o0hiWOJQqKMBR0Arw5fihf2wiSJCY1OzYY+evc1u6f8AE2ZopW1OOG1UD5WbjNeFjcLiq8uZ2t0Qvq1WneUlds9Dvr+yhuDbz3cUcpXJRnAOPpULpbsyul1Hluh3g59hXzB4n1Ga81efXArzyyKRG5b5MD1FcdBF4ga4jubXVLhZVIZEDEDk5x9KwfCUK3ve0s/Qaq1aS96Nj7cSENCYpFVomUqVIyCDXgvxN+DNzbSTar4GHyvlp7Et277PXvxVLwr8RviCL8adDp9rqiW6DzBGhJUe5Heu18I/GrTtTvZrDXLG50m+hbayyrhQazw2X5hlEnKlaceqWunoT7RSlzRdpHjmja3peH064tm07ULddmZRtbd9D0qzFBdzXEl1cslwHUohDcg+tfQ/ijwN4a8ZRx3Gp2UczsMpcRnDcjrmuNb4J2NvHKmm6tdQo/3VfDAV6VPPsJL4m4vqn/mdlPFyTvNa90ef+B7myt72U6kzwsHAA9T7VH4mke+12RdKsnZyDtKgkjNdXpPgL7R4gfSra6jvVtCftl4q4SBscRgkfM/qB93uQcA+x6B4esNHgKW8asxOS5AyTRVzfDQlzQfM+wVcTd80UfOn/CI+M/8Anw/nRX03t9/1orD+2JfyI5/a1O/4H5vthhsAO0dSe/tVue0e1jUSqrNKoKrn7tQLGW5JOAe9Xrq4t3treKGBlmXhnP8AFX1qTR2qCesjOuENuodhtfOAv9ajtZjHLujjVjgghx+oqZ7eSeZPOO1CSSzdxUsYVQAg3MGBDHp+NaKLbuc0oNt9hxs5ZLnYm2PcAwU1au40vTI1tEY2QBdueDjvmpYpw7P9pZRhSgLccmnwSJDOtrO7LASpLY6/lWyV9ETUtD3melfAW+j0DXp59TDw25hYgryAexr6G8O6vB4vEd0rSi1s2xkfLuYdyPSvnTSL+HULNJYR5lvBKFCjjeegA9a+kfBcKeH9Hgt9Q2JcSruECDJUfz/Gvnc6pwj+8S996L9TyKk3Od3pc37+BriaO3RlCAhmDL1HoKuX2m297AkVwpaNeQvbPrUFjdwsY1RogB8qr0IHYYrVr5Sc5waW1jajCEk2cR8V0Fn4Mv8AUouLq0t2CPnG0EYJ/KvkB7K3t4I5LC/W9HVo0TJBPTn+dfU37R+rf2X8LNRVXVZbplt1B6tuPOB9K+c/CFnc6RpDQxRpumiMku7llHavpckclQbff+v1PbwP7tNxQ2HR4raNJ76WIXch8wIvIX2Pv7VDqGrX0rSxKZQgX5on+7t+tU9UuLmKIwzqCGHmHdxn1xUUMd34gm+yWiiGNRks/Gfxr3Uusj0OZrVnP3IedmZSQoOcY+VRVyKeN4WCITJjhgO2K6CPQI49ODyRzSQu+0yID19DVfVD/Yqxm3tAsc3Chup/z6VSmugrNJzY/wAO679gtTHnyYm6u2efwrc13xHZG7gvhbrfttCbgMqD2GK4eKwutTieUsGkVv8AVj0/qa9h+B/wmutTu4dZ1sGHS4n3JCchpWGCOPSuPGV6WHg6tR2Jq1IuPPLY9K+CHhm78KeELy/1TbHd6k/n+WBjYuOB9a6S3uXkluZ0XLpGzIpOBkCtDxJdBWWEcIOODXMa1E8fhPVZInEZ2Fmc8EJ3/GvyLGYh5hjLy6tI54u0HUluz5E8X6hqGseML59Zm8y8i3LlDwMdhXb6eRcW1haXF7bW80QBjjB5Ye9eeava3Gn60Whi3QyOJY2JyWXPHNdzEoh0QXgsY2nmkAllZxlMnlQOvvX7JRhGnRikebZ1JtBdXM1trrtBvDsfLXAwpb61raXPrt3qqaCW+yySASIp4Ur610TW+l2N3Z6ZBcIZJoxOA/O1sctU/iddMl/0m5F1LPgLBPANuD2rF1L6WO6KSsl1PT9K8A+Ejou+8iVbojDzs+HB9c15Fr62GheIr3RWuJNR00De5HIQ+1QXniLxPGJbZJoTGm1AzDnaehJ9a9h+Euh6DPoUjtFDNeSNunYsGLHFeZJzwcZVasnJPp2/yFODpR5pu9z5pv4LjV/tGo6ijwWSIYLcMCufQCvon9nG3vrTw3d2uoT3EgQgokikKoOfunvXmHj9pNT8RyabHGYtLtbgOrCPooP+FfSPhXWdJ1PQYX065ie2SPaeQMADnNTm1dvDKKj8X4EYpt043VrnkGofCKz8ea7PfyXEsFlHO3zZyzHPQe1O8UfBq30vRdmizuki5ZmJxwK6jw5488L+GribQp7t4ikzCOWTlZMnIwa6TxPqsuq6HfxaFatdy+U67nUqvI7Hv+Fc88XjIVop3UOl9Fb1PLhNUuvyPlK41LVLc22nakxuraN8K6/djOeorcurPR9csLm4iuJJr2IY3Nxkn0NcFbvqTNNCIdkcbsJg2Rz9a9A8IWlzq0dtaacIYjbkNLLHyW9q+jrQ9mubY9SjXTVmzKsdAitkWS4tpN8jfIJjnFJq0dzGkXnhHimyCy/wgetdl4st5oblDqEbzIv3GTjPrmqs9/BY2815HYwXaTIFEDN/qlA5P1rBVG7Pc7HVUrWOU0q6jvkitJJ/LZRlHb7i/WtvSfC9trMEtyNTuVEZ/etjt7VqeHLXTvEfh+VYbeS0naTbGVT5WPSrF9b6h4ZtINMjVjdyIRI69FHbNTKpq4x0ZMsS17qdmRXc02jaUILN3mSNwwUrnBzxWlp2n6jp8D30Nw32i+w72/TP4dqjMtydNt7OLbES2+SWQck+gpIdVEU73OowvAAvlq+evuM1lq1Zf8OT7TR3fqev/DS6hXQJ0kWOCG2bk5wBxk1wvjX4vSSXc+n+G4TdKuQ0oU8jHb1rzD4ka7FbPHonh3UJHtmXzLt92S5PYfyrnIdbvLdrbS9LZWlVMHuGNZ08phzuvPW+qT6ebPIpU3iajlsr/eb/APaXmap9qkt4lkbAzLwE9/rTvFl4+jC1lsJYLsytuc/ebd2qG3sZ7+zD3IFskfy3EhIBZvQCrT21mkNs9rhrkOEjUc+axPA+ue1drsmj3KdKKSe5l6KNQ1S91Cd3gSdF3tE/Tp29ado+sTWsNxcSpLJKTtSPZuCelQyyW13eKLz/AEFSxMskfByOK6vw9etZafPb6RALi3m+TfMvzc8fnRN2WxpNKN9DGs9buJQE+xzvfyuDFhSUJ9zWtqN5ZpNPceK5BNLbrlLaI4QN2zUcF5qOk22USKaBHLCQ9c+grAtY7jU7+e41M+Y103yoFxn0zUJJu/Ql+9ubfim+tRb6fM8Qjt7nlki+6F+vY1Seea30iYWMazpIdsUzcleOtX/D9q9/cXul3UX7mBPkXuD6DNQ6fYyW8c9tEhVIxmRmPXPahNR93scdSmrcp758D9FtdK8C2k0DiW4vMzTzd3bJ6/SvEP2otCk0rxnY6xYIQL5D5o6KWXH616J8IdUk8L6dNb6tdRLpEkm6B2bHlk9Rk+9aHjK00b4q+IdK0e1uWntdMk+2XUsXKEdAmfU4rxqUqmFx8q09YO935f1ZHizdrJbp7f1955F8JPjRL4Xh+weJFnn0xkJgdUJKEA/Lnv8AWtbwJ8X9a8Y6qnhzWr2HTvt8zBL2BNsgU5xAvZWPCh+o9CSCPV/ip8Ph4l8OWOj2E9lpGkW7ma4l8vdJhR8qIOBgkkkk8YHB5rivgBpOg6XeTWk+n2w1tCTHcyjdI6+qk/d/4DivFzSEMaqmKoU7W39e/wDmdFKo4yUJPU9U0+3j0mxjsNMhjtrWBdqxoOAOp68knnJ6knPWtaxuGZgCwAA6d6o6giR3ACinWJYuueuc4r4uNSSlds9WUIyhdGnvoqvu91/OivX+szOGyPgrX9MukaTNpJHATkPjANYYmYMq9QBgE9q+yPEfhDQvFVlPeWk7WE+1iyOdqsMdcV4x4d+DV9rd1dLZ3cTCLlZB656V+o0cdTnFyk+W29yljKU1zXszyNZA0akcsnO0+nrSSSPBbs6BjHKOMrjGK9j/AOFD6xa6vE16yi1DgFk+Y/Wu8+IHwnhTSrdNLZ5JFwgQgAMT/KtXmFBOMeZO5lPFxva/zPl+WUxx7pA0k7jhield54V8ELqsFhmdp9Vu5VP2VOVWPOMt6V6LoH7P9zbSW76rdRBS4by423FR3BOK9s8N+EdJ8IafcS6YqtMykl5GGRgdM9qzxedUKMbUXeT7bHnVa3P8JR8E/C/R9BRLi5hWS7VgwxwikdMCuq1e4t9JRrs2z3FzJ+7RUXJY9hXO+I/iToei2f7y4SWcj/VxsGKn3wa8i8R/FybWPMWwJtY4RgyM23DDoRXz9LB4zHVPa1r289BxSdnFXPZrG5WWdJpY4ra/ZCJBKdpjU1xXjH4wJokrWdhNBeXMIbcVGRn+Hn+deDf8JrdytO0ha4k3f60k8/jVzS2WSK5u7+3g8poy4bH3j6Zr1o5PThLmqa+R0Yeh7N3qJvyRtai9/wCOvsev+I5muJ5WMMNvCMRw4747e9WdOsbnUry41KxQYSMwSB2+Vsegrjo7qTTli/sq5mSGQiZY5vuH2J7V03g+6tHuzJqjpa3B3GO2WXAPuD3Ndkqbpx93boe7SrxlBwjo+xm6hoFvcOt7PLcS2yKxdIxyrDtVTRdOvP7PlZIJFhuJgglHXn+Guw0LRLBjcwfabyUzl5IzuAWNgP1rP06++zW8NtA8wiiYiWWYYyfXFHtHZpHSovmt/VjqfCGn6nqV7HYNHHFpsCEZZPuH0zXGfFHSY7PVrUCIzNEN8wBxs9B9K9I0PULv+w4l0+7jmc3ab9/BYZrP+K+mD/hJIry2tw808S5ihOVY+hrijXcK3vaIyjeVRp+Z5x8PLWbVvEENjYqGkkfLBUyoXP8AKvrwKNK0uK3iACxrgY4rh/hX4RtvDdhc3t3t/tS6O9ihx5Sj+Eelbuq3rXJIUqV68elfCcS5v7epyU9kZ1X9YmlH4UVLqUXEmGC7QeATWX4uguJvC1ytiGldV+eED/WJ3FWk3sQrAAN1DGtfTi3nq6huPlI7Yr5KhVdOqp9mbTVonx9r13Hc64bL7O0ds+0EPx5I77TWzef2ZPpE9poM9xdTZPJXAAA6/hXXftM+BBYGHX9Jjl+zTEJMirlY29fYGvPPBFoLK5kjvvtDJIisrRn5Wz2r9qy7GQxeGjViefCKjK62Ox8K6Zb22k2dxdyIdRIzEzOOB2rbubS9n8SJF5sc/l2+BtPy/l61z9tKLGadEWC8tgAqBhloc+nuK6No96A6RC0OqIu4OxzkepHpW8273OrRu5Jplnb33hDVbaECO9WTZ5uNqKPr0rsPgbNpWgaNPDPdAXMTkTHqp981w1haaldafeWtxqCRW+7MwH+rkY9s1Wgt9St9GudP04x2oL75G2clulc1akq0JU29GyZx5k433PSvGN2mta0R4dubSOB023ErJneSecepxXBeGPElr4a1HVdCWCa+iDsHeNSNob/9dW7Gz1ey0GaO2W1N/AC5knwvHqBXP6Df32jW8iXlxbfa7li8jIcsfTNFGhFU3T3S/q5hUpqnHleqN+28D2/ibQ5hFMsEvneZYpMcO7YyUHckD8qsS/EzxholuPD8eiRS3ar5Inw24ds47mvVPg9p1/aeFxcaquye6cyhCuCo7Z+tbOqLpVrfPc3FxbR3ON2GYbh9BXnVMwi60qNWHPFPT1PJrXlJ1Frc+R9QTxBpt+yX+lmR5WDuuw5xnrXSWTK8yy6BLb6WyLunhmOHc+i161rniHw7e6jcR/b4pJpFAZiBgfSuG1Pwx4Wkv5pW1OSK4XkuuCJP/r17VPGKrFe0i4v0b/AzUal7KLRpSwm9sBLrd3BbRmPruyzfT1NUrnQbK7tU0q3DLHdANb3UnDE991Z1n4Qg1uKF4LuaQWjBowxwSOuMVsatofiaWQXhSSezB2bLU/PHjvis3yJ2U7fh6GirVKLTZZ09G8LAW2+Hy7WM9Bk7sVMPB2teJvDUmuxvK2o3QMyiQ7SRjgAdq4Cw07V73XprWfzFYyBk80EMfr717O3xQg0OzhsNU0e+h1JU2LEsfysR0IPpXNi1XpW9glKT39C3Xg7O+p5zZT32osLTap/s+IrMsgwwY1L4r0G80/QI7/XZEkQoRaQIeWbGRn+dbvw18KPr2s6rrWsecLi6m8xlVsL/ALtZP7UV5eWM2mW9mpWAwOFx09/xrSnVTxccPDfd/d0Mp4ic422PFPDUFlqN/d3N95jXMCmT5T8hIrrtO04mGLVraOKK4nO3gdOa4jwhHAkRmnuisZG1zj1rbjj+0awYReubSM/fB4PHavVxF3NpM9vA0bQUi3qWk3Ut6EtxckxHzZgT8rAc5HrTbi4hvoI47eCRliy8igZA9q0/C17d6N4uWynuVuLe5TarynKqDWiljB4d1a5/emMSqWRhyrgelc7nbR/I9HVW/A86UzveJbshij8wADHGM969Fkk1CSa2gtLiKMwoF8uMYU59azNB0b/hJ9SuHkl8uYLuHTaSOaZbancWWrTxzoCicAkYJxRUfO7LdBNc3uroPlguY4Tayz4jEuZCByTn0rZ1R57XV7NbaMR7Yw6kLwxqv+/uLOSdF2qRnMnX8KdpMmozCQG483yk+WTHCg+tZvuyLOO42DVJBeXcwEjXMpwpTjJ9/QV6t8J/BVve6TfXWqyNO1y20qDwo9jXicv9ozw30zxqs8IOwpzvFbvgf4j654OtEtUhS8FyQ3lSZyprDGUatSk1RdpaGGIpSnBcjPSdW8GWP9svoV1K0enJF5qsXxnNL8Odc8M+Do7i3e6CmVxGrjkkDpmn6VZX/imC71W8DR3t0uC4GEjjA6LXnvi/Sbi10ryNC0WW7kMixxzqNw3Z65rCnBYiDoVp9r+vc+Zm5QqO71PoTVbG68RlIZGEOjnDkqSJJfb2FeGXFq/iD49wWfhd822jYM8yn5V6ZH9K9Ng8L+L5/AbWl34jay1VoCAbdPljOOFz1rjfCK6d8G/Bxkuc3/iLUzvkCncWPYHvjmvPw9oU6kKUlJv3Ul57t38iqatVUmttfXse0SWjMFBc+5p1taMjD0A6189al8TfHWpxCexj06ygUkshyWx2p178RPG8Wh+et5ZRueA2zgV4ceFq3MpTkvvPXftuW3KfQnln+7RXy/8A8Jv8Q/8AoMw/9+6K9D/Vt/zL8f8AIx9lW/lYzV9Xklu0s9SnkWGJQu5DwQff0r1XwT4h0nSPsyWcwkt1TyznhsevuK8fHiHRr/SmAEEU0k24GVgzbe4Wt3Q9Ia80VtZNzEIhJ5NrtYKJF6nPvX1mKoQqU+Spotjy207dLH0NH4gtb6xvZLB1llgQll79M9K8ttvEk02oG2u7SS7mEgdychVGf0qh4L1vV9N1YuNNSa3uHEcjJ1RO9a3iywtdNkub9dSMNr5JO0uMv7AV5FHCU8NUlTet9n/wwqkubRnUa34sisNNF9dXVrBZoThIm3PKR2HoK+bfiV8VNT8UsdOtAtnpCnHlQdc9txrB8VeIpdVRY7WaQWyNsG7196XU9PtJ9Nslt1U3jp5kgRsAgf1r18Ll1HC++1eXTyOzC4RyauY9jYymAXMRYRF8SOTwT7Z71of2JFPewyreIqOvmB85IPoRXVXcEF9axRTCO2VIw7JCcsvvj1qK40nQdDgt5rNNSvJZGG0PHhX9RXTKs2exToRTSSOZ0/RdQu7g/ZkjltoFO9kHBA55rfuhHqWnwaVY28UCCTzpipx8o64q/D/o0d9PcyLppVv+PZHyZl9DXM3Ylnu4riUCKyf5F2cYX0NTdyOiNFSd/uLjwyXmsXFxBNDdWFvGI87sbh2Aqfw9cTQNe3l9arcpGQptjyoH94EUmj+HrJ1mvEuki8kndAT/AKwDngVnaTqFpb6zJD59xbWkg2yCM5Lg9aL3ViJYdST7r+vvPRNA+y3uoWP9hXA1MxvuWznYIw9QD3xXo7/DW68Tz+dqkUek2gPyQx/NJ+J6YrxKxig8O+JIbOwkn+xXRDRXE0WJEY9Nhr1Xwv8AFrVrW8Wy1eBbmNPkDAYkPuTXmY2GIspYff8AH/I45169J3jqu/X/AC/U7/Sfhvp2iaO1tYyTzSqd6NK3cdOKw4PDZhvjd30kklwp4A4x7V6D4c8Raf4gt2ksJcsvDxtwyn6VW16yeRgYs4xyR1FfH4zE1oXVZu5nSxM5v4tzB81YrYW6tncckA8g+tVNzTMOCCBkcVfisX64JOMlscAVz/ibxz4Y8HZGq36zXq8C2gIdz9a+RdGrjKvLSV2ejCSpo6Gw05rqZgvATCsCOhqzqviDw94YdF1fU4IJW6KzjcfwrxHXPir4h8aWNzZ+DbQafaqCHkZsSsO4B7V51pwvneK61HTp75oJPneTJ2tX1eWcJOS5sS7eRhUnKad38j6V/wCFp+Atbsr+1m1BWtUjIl82MqCPbPU/SvGPHPgeDRdBfxH4Mu5NS0ebk7fmeIHrx6Vzd7aW7a4oujHFFIDKhA4A9D7irOhnXJILpNK1SPyIAYhCXARhjrivsMHlsMFrRlZdU9jn5Jw96EjE0W6hTVVu7JYZYZkHyGQAq+erCvSbfxLomn38N1cWFxBe3K+VJJEQyA9ya8li8L3N1qrR3EASaQ/KIvlBOetdRofhy7sp5p7OVpJ4s5t5Ru5HcV6lSnCe7NJVHH+ImvQ6bXtcY5t9Mija3aYAyrnrnqaLvXYrTUZY47l4bhAFaQLuG/saxbBdfv4ZbLT7dVdsySNGuefYVf8ADnw/8Qaks16xI1DIDwsuDt9cVi4Qpq82lYl42lHRPUwrxzqHie3utavJJo9m2RY24P8AhW5bWGnwK0+oyR21ikm5QzASyDOQoz2NehaD4DsvDuiahq/iFD5KKSI3xlm/pzXnI06LV57nUNVjV5Ix5sUKcKFHYe/FKnXp1LqL0Wn/AAxh7WeIk1DSPf8AyOx1H4rarqlrdh3j0/TlXaNgw7D2NcLqev28HknS45Z3mG4zTndtPsag0bUbu8u7h59OiW0ZSsFu44HHJrWg8P2Gm6bC+pXBaYqHEMQ3Ko7YPepjSpUNIxt6HZTpRpK6RV8JyRyw6lJNaTPJMQDNIuNp/wBge1XHvpNOeS3RonETbYptoJB7E56/SrNgdPjvInvWme3jXd5ecKT2A9ao+I9DklkZbI4in/fAt8pX2FU2pStLZjk1zWZo2Pi+e5vIo7pI49RtwS5hOI51HRl/qO1dppXiRoJmnS9+z/aE4jRg2T9O1ecPYWC6XIZo3haM7knLbWQgffBP8uhFchovjML4pgnntohasDGwjXbubHyvg9OcHHYE15tapSo2p1eu3/B/zMZSirKSPoTTvHE0jyRy2ccs0Tj9669fxrYvvGukBbZvENvbyXeSUVMHA/GvLrjxPILBrGS1MUs7HdIeoPvVC10iW5tWvoZIZWtxmUu3JA54rR4Kk9ZK3ozGphISW1j6J8J+K/D+rW23SriGPDbDGSF+b29a8/8A2mdHbUPDlncxEB4GbPqQRXht7NqWm2Pm2RVIrl8rIBjYfb6V6NDa+IfGPgCKLUL5rhogTDIePN9jU08tjha8cTCfu36nm1lKn7jXY8b8P6dbR2YF0yEbtxCNkj612a6MLhIn0aABHPzSSHgf4Vz+m6YLe7vINQiuI7kJ5YyuMccfX8K0vDV7deHYZlu4JZllUiNGHAPavYrNuTaZ7+Cqp01ysu/YLK11WCXUR9o2sE8tDgg56/StTxTo0izPfPcY0dUCjByV9awY9FlvGL6hfRwzXTAqit9wGt7StPawlltdVuEfSZ/lWRW3E1zydrNM7JPTfY5q/E2mXMFxZb0sJceV2LD1zVe6laLUGup4tsX3lXOSffFWtWt3SQKl79p06F8wxY5Ueh96uXNjYanpr6hLci3mTCNF02j1ArVSStcpPTsaUer2ltok6PD9oa4Tj/Y+lQ+ERcTxyWnlmKAYZmKEHB9+lczDZeW6SRTfaLcP97/9XauistSntFklQHbEMqhX5X981nKFk1HqU0uV26lnUW1C2ke008hYj8hlkXqPrSx2NxdeUllGDex8SzsOM0zVvGEmpRRQvDEsch3bQMHP9auWmrR6VsvNRt5HikO2OOFvTuai0rLTU4MTU5F5npHhTxna2ulvpV24ecJtIQYBHeuvm8a+HdK8KyX1vcW7C2QgWyOPM3j+Hb1zXm2nA+I9JmvNOsVgmXKIdnDZ9/avM/iDo8Phu1hit5ftWsz83V1kbVb0AFcLy+hiKnLJtO+qPnrSlP3Vqz0K5+Ol5rcP2Cy0hLS4kGHM0nCisR9T33k8sxFxcSLlmU8DjoPasf4ZeC7bU5QdQcpLMu55C3Ud62fE+m2mn6rDaaCwZFyHfO7r6V1Knh6U3Soxt/Xc93BYWNKXNO7kcjJa376pNdudsCniMA8+2K6i0gk1K0MdztiKHhVB4rWsl07S7T/SMu8o57kGn2+yw064u3VZRJ/q8enrj1pyqX0sehKXMrNGZ/Ysf91qKk/tyT/niPzop80jH+v61Pl6zvJLaRSpBUHlTyDX0T8NNVsvEfgG9sNRbZLFOJLZEYcHHYfWvm8jkiuj8Fa7Nomr208TfLHIHIPfBqMNOUv3M3p09UfNzi5pW3Wx9O6V4fu7Txhp+nWd/NC9xGXnjZ8xsO4x71k/tBau13qkGkWNuPLsVG8oOh7810GiXVvrF1aarpqj7VcJkP5mSjVwGvIG8Q3dvdyTLJIDGr44Zjx8xq6UG66qS3ivx7/oFCHPVtLoc7pun7IjDMvmQXQLNLuGRgcBfrWjFp1tpVlDJq1oGmuiEijU/OiDjJ9Kq2ulJBcxrqO8anE2xEB+QKf4ia0pNR0zw/crbBpNZ1U/ugSMrhuNo9a7Jyu9D3qUeXSJeeXStGe/NnpxneW2PnXcj7kQMPug+tZ0fiG9Fp9qmt5INORPKt18vq31qK8s9YWMWE8ixWgPmFSvzbuykVYh17V9Ttp9Nv4FM8K5ijVMBcd2FRy/P5m0Ut9/n/wDm7i1k1bXJmtoTDKw+Xzmzz3re1CNrWxNhIyBkx80i8se3FY9tJd3U13qVxbsjqMRAIRlh/dqS+vr3XtTAuQoPl7UO3Dfj71o7/I7Ix5mr7fqPs/O0+8gvbh1aBRggjHmcdPpSstkrz3xCfbB/qo0OUAPc0250q7cC0W6AdUDheQo+praM1vZeHZLbT4IptTcGJ3bk89wPWplJXHK11Zb/kWtG1WRHtLDVIzJqHllrV2+4h7CtS222dlLdSfZbq+nDGTaRiJ/asrRtRu5JtOgu7S2ivIYmV5Sv7zHbAqDUTqNhoAd4VeyaRmkdUJKmsGru2x51amr6r+tTtdHvNT8Pf2VqyyLKDKFlC/xJnke5r2zxV4j03QfDM2t6lIUs449+MfMxPQAepr5g0jU511G2g1C4eW3hxJAq/w5Per37Res3V/JZWYnVYLRU2RBsDcRyx9a8nMcsWNqQhLzu/I8aCUKjiziviV8YfEXii6kt7Ytpel7spBDkOw9WPeuGt47qXUoZ5i11cS4Yh8kn6+1XIEs5bi33FmZXCscYD5Pauzto7Sx1OW1gIjeRMiU84H90V6eGwFDCw5acUj0KdNzlc2/A02n2+gSSzNLHqVrMfIt0H7twe7Gi01yyGoTWup+alm0mJDA+VkPYZ9KqabbT2s8U9tNK1qW/eJtyfxroNU0zS4izQxFPNTzonB4D5zgitJKKbv1Or2aty/cc1ruuy6jJKsehW4tbUhFXBDBO2frXRaFo+myeGmaK0aOW5cBjEckH0rPtZv7Z1W7vEhcSxIEkRRwwArsNFjFqIrQzRW0bp57ITyMdTn1FKpLljZaCkoxVjKkguNP0z7PHFb3McEwcbz+9UDkqPX6V0WkeJtH1nSbprENZ6vAjHy8cuccVyeoywnVm1C3vpEjhbaH258w+uKh0/UYYX1C8SeGxt5DzO3MrN7ColT51ruKdNVFcprrqWt7bTRS3Fvqk77dkXOxs9/rX0d8Ndd/ta3kW/VV1ZAN/wAuCy9q+dNR0e03R32n6iSsTo7SMuCWz3roLLxDNY6tb6zaXhe6t2AlhDZDJ3/OsMbhY4mnyx3/AK/A5MVRTXNCOx6l8drhho1nbSMy2ckm6cr3A/nXgssgaOKKWOTyoyT8nDOOoBr1b4reJdL1jSdM1OOZhAEb5R97ef4cV4jqmptJM1+JJTbsACrpht309KWWUpU6CjJWeptgl7l1szcttbhW2ubG2gmt7eFSfm6t361oWF/YXfhqUXe0yRr+6MbZOPSuJ03WbRJJW1GCV4ZjuL9OfWtSAWOj34FzMZI5SHjPqK7JQ6He6afXU3ZdWkfT7LzirBSAsajDZ/2hWq7S2l0935YvFVQHAbKxe2O9crqmoC41cXYQJGmDvK4YAdOO9aSm3v57l9Pvlh34MplIG4+ntWTicdS2xsTWLahCj27xsjIfN3tgr6ACuF1/w9pV5PLLDE+monBkPKlvp0/lW1b3t0srwrIks8bBhjgP6Vb1mQT6bFa3KI1zMTJcRJhjHn+VZzoQqLlqK6MuVN2Z3/gL4dXGt+FLW6vJY4p5F4uFyTKBwGOfUYp2reE00Sf7FchF3oZN275ZAK6LwB8QNH0rw3baZrFwtrNZRhBnkMvauD+K/i1fFN6txo8Ti2sY2RJH+UyM3oK4cO8VKu6cl7i6/l6nO3O9nsYt+19rl3Na6dbp9htl2qgHB9TXonwp+2MbfSryNfsgUsi45GK4/wADwnR9NgvdQniimnGGGcfLnmvSvhe9vf8AibVru2LvboipCccKD1FdWOny0Jq2iX47HnVpe0qWWp0viLwTpes6S1u8CJdKp8q4UYZW9c14j4q8N6zo8C22rWTzQw/6u7gUsuPf0r6ZprqrqVcBlPBB718/hczq0NJe8v62N4w9m7w0PibUtImitWuYppJnLjM6c7AT0NXNIn/s2+jnkV7x4iP3RHysO5NfSWs/DTSrmK/ew3281yCxXPyBsdh2ryy98DaxpYDaVGSU4Z5V4J9BX0NHMaOIjZP7z1KGKg1yzdmcNqMNhOlxqNukitK4YwKeIzWPrcg1Z45oIJImjQIcIQPxrtNN8F61FqU0Kw5ecZfCnAPerbadqeiQ3dtBCJZHX97hc7RiupVop+67nT7XlWjuYGl/2XpvhQS6nPHmQ4hVPvA+49KoRzP4nh+x7zAbQZUquAR7mqWqR22opDbXERtpo3zjbgNz0x6VevNWurW+W10KFPOKgOSMrj1NXa2vUznWk7sv6PYpDFObaGCSe1wWlb09BVC3s7nVNX0+y06N7m9un+cN9yEE4zUln4f1i48u70yO6uTI25yiHYfbpXtXw48A/Y7qPxFq7G2vid5tkPyqB0zXnY3NKWDTk5XfReZw1F7R6vQi+KGuH4feDNN0TSWj/ti9BhiwOnYt+teQ+H9AtzbKmvSSTMF3tuOTmqfxe8Yzap8RdQkECyQW58i2kJPyjuR+NdF4b0157G0jdzNcSYZmbPzD0rXCU3Rw6b3lq35v/IrC0bR9s/6X9alvQ9OvtRt5obAi1h2na5yD/wDWqTwHYRx67PBcyCU7sOzdM+1eiXFnbWmnLawQxxCMDdGzbS1Yi6MtwzXdrClsMElkPGfeoVfmT6XPQhi07p9Snqmm2smqSi4UBI/urnlvrWRqd1Ba2wie2YWw6FvTviiCW6udTlhuGJKN98fdOPejWNZstQ1rTLB3EavIsfI+9kgU03F2eoPmi1fY5/8AtDQv+etzRXu3/CuvD3/PF/zork/tSj5mH12n2/E+AJFJckirekwebfQqSAHYLn0zVCSUsauaSzfaowvXP5V6dKpTlVtE8ikvfXqfVvw50iGzlt9K0938yFg1y2c5X0HvWNr/AJa3V7aakrPCwY/ux8+7PygH612vwrjntp8KoFzLaBjJKeB0ry/W7xpfEV0l1vbE7BwvUAdxTpycq012S/UdK7xDbHWtoEYXn2lzcxr5ZsyNzMx6ZFVNX0iS2vfssKxpNFEZsKMSK3Wq2mTm2dUExh1Fp98U33sDsrVs6fLe614juppoFe+JCtKxxtA/u+tdDvF3PdjGabbehk+NLfy9Jtbu11CR7qYq0qBsspHrVC3/ALavLiFY2AuJYyySrxuHoxrqH0a01e9ktku4Le9ikDvzg+/1qO7tksNButM+2Qzyyy4QKcstJTSVuprFpJLdmTcyazLNaWJgLrDhvkXnGecGovENolxrEElpO7uoAycDkdfwrUtLTUYZLSQeZDeQrsVVyAVHWm+NDaTXEEFnGUu2AWXyUzuY/wANNS10NI1EppLs9jKkNwLyaM3L7ZWGGlXIPtV6x0h4dft5bJjI1xhSx5RTnqfpSBBoTwWOtyeaFUyeWBlkJ7ZplnK80DeVetCkgJTy1O8AevpQ22rocpSaOp1dk08XkuoROZ7QbI5LflpWPQ59KxZvE7RrZ6IXEkU7BnyucOT3PpS+DbW/uL1LHU0aCwQMz3bnG4YyASe9P0DQHvzex2UJlWVmG0/6wqOjD8az92N+bocFVRinzPVf18irrNzPp0iSaf5LSyTJl1GchT0X0rG+KNlHdeK5FSdphdYleQ8mMnqDW5B4a1eDxNoNhfIwDXKDIUlQmeppvxMt5rXWbh0SKUlwobOTjpzWsZxU0k+jPFguarp/X9WOc8IeGba/1AiWaOe0sojcEQOMnB6Mx4H06mte2h1DWpUvpU09Y0+7btuDJ+IHIrM0e+s9CuZrKazmlkvsD0CseOn1q7ZTpYzzW7LJbamjABHPyqpPJPvSlzNvU92hHVs7K2lt9H1GyczsI3wZCpyM9xWRfr9r8Ss9yjnQo23+fGpyF9MdqzdQ80GSa2Y3IhB3svzbQepre0zxHYWunfZZZ7pru8i2AiPKBcdAPWsuVx1WrN5wcVeOreho2FzYWrFLO2ZkvXzaFG6Hplqq6xYQO8dpcSyW0TElZZFxgjqM0yCQ3dlbPpyQyajaMcKy4dfqKs6N4iuV0bVLTXLdJpZIXKPcLhRx2PrWbTWq3Oe8oNnDW0ktmL2OV5JrKXKRygEBVHUj3re8PeFb3xVZxyWMMi29qcQhhtEhP8RrOkYi302zS4KxsoAhb7uCecH1r6P8F6romn6QsVsnlCIYLEfxYqcZiJ0IXpxuzTEVZUo3irtnhsw1DwzdCLVY0miR9piHB5759KxdcurSw1p2mljR54clV6KCehNdr8WLZ7/dqFjcxzyyMP3RPzEeo964XWLaLVNQtbmWF4zFEIzER80h71tRfPFSl8ynK9NSas2SyX+NMGmKEjiS4WZJG5GD1zWFcTtda9HHNKN2Rgqvy4z6e9SafBFPrs9lbROInjI+foGHQVXvLG70fXle6VkY/OiMp5Hcit3ZadWc2Fla6XRnf2cOnzwTiaCJYGXBVyMH1IrhtRttrWqxjzVlk2wgj7uD0NaPibxPYRaZHYafIJvPAkaQDBQ+lcvBPvjmvr5mJVCsKMO9YU4Pc6ISa1NqdjdajJK4jW9jZQI3bKlR3HvUflXUtjf6jPEvyNlgD8jD0HrVNMQ6aiRKrXAw0xk/QA+lOjvJQiR3DRtZoh+Rfu5P861t2OaSf2TphHHaLZX+nl7yKWHLo/UHPTiqmozStrCz2x+zIYwJI8dOPWum8OeINP0zw21vFp7zXEwwHkXCp6YNS2tgmp73Fi9wVUO5iydtYc/K25I5nKWzRS8OWNy9vM0dml0OplfnJP8AOupt9BYahHc6sA0SLuhtx95n69PSvS/C+i6RpPh631LLSW3l/PGxGwH1A9a4T4peK9G8PGL+zIfM1y8BaIFvlgU92HauSninXquFOL7X/rY86vVlJ8qNaHwIdflhv764SKFBvS2U/Nn6V6B4POnaZZPbQW7We1sN5gwWNeG/BXWYdO8XTT+KNbSS8ugNit90HHY13/xa8Z2KWKwaVOlxdjltnIUfUd65MZRq1ayw0m3HutEv8zNUaqd7anfyeJrOCQi6SaGMnCysnyt+NUYPH+gXOpvY210ZpkGWKLlR+NeDW/xSmvVbRdTjYwFP3Y2n5j6VW0bTRe3wfT4ri3luCY3x8uwetJZPTin7S6/I6lh6y0kz3/WPHel2EJZZfMbnCKMs30Fcs/xOe58uG208r+8CuZRjaM15fqf23R9USSIrK0K7EKjJGO5rCtZrzbNqN4ZyZJPlP8APvXRSyqhFXtcf1VzV7nuGq/EKHStPe8itmMhYoG8s/NiuAsPjDZy3M5k0W4a8YnfuUhRXPvc3+pR+Y9/H9njICIW4JqlrlpqFpqskqWxuWkCssYB2gevvXVQwWHjeLjq/Mwnhpw2bPRfCfjbwt4h1WSw13REtZCAY5SuVx7mvTtA8NeFIvNm0i1spnb7zKQ5FR+C/Cel2uhQSTW8FxPcRBpHKDHI6D2rNsdEXwz48RdCizZXyE3Uec+SexX0FeBjatOtzww8pRstr6O35Ci5Racup0N5dpZ4ht0WJFHCqMflVFrySezvNvJ8pse3B6VL4jDwzAx8BuDjrVDTZGWUAgYYYwe/r+Ffn8pSjV5pHvQhGVPQ+PfCdxb3vim80/VFLRzynBPLbs17Z4LVtO1WaORhJ5JHlITnj3rxj4oaZc+Cfidd7F2K0nnRN6q3PFepeGdfttX+yXcTGG7YfMB0z6n2r9gclWpKcdmvzOXCTbhyvpodZd2TeI9Ye6nLWhiH7xoySoHpzV2+it7Hw9fLbvOVkztZO5xWbZ6/f29zeWsMMciHguckEmqut+I/NjtbO6tyj9mg5rmVOd1Hojp9lKyS2OH0T7cZrlp5GihU4bPpVTVy85t4ra1lkjMm5JQp+Rh0IPY16zFp9hLpckdmS7FC0ijBYcfyrF0mZJtPjWxCOLZj5gY8//q+tW6123YuVW7dkZX/CZ+LP+f8Am/75oqT7fL/z6w/990Vn7OH8q/A5OWPY+XrfTriaZY44nLscAAV638MvhVqOrXQmmIigjbLN3yK6vQfDll5sM6RMjRjzG8z7ze/NfQfgS60xLE2yBI5nOWB43VeIqRwVPmoxu/yM5U44f3lqzz/SLWDRL2L7a1w2pSEBN44degrgPFHlaV4pvJHXE28tuPCEHsa9r8fWQvRapYQkSGZWNx12IDyR714n+0JKLbxhAVANq8Svz0Y85NaZfV9vNX3kn+Bw+0Uq14i+GZ7O9t5pXKw30zErI4yqL/jVydU8P6vPPISXmi3I0Z3MQP6E15zoV75uprHFPFbwHnfJxu/2RXqek3cd3rnmXsKTwsghiCnKqD3J7V2VoODfY9r20bXe1ihrMFlqtjDqt1BcaeLlNmyJfnZv7zegqCLQLGXRlWPU1tLiMg+fIfmcdeK7BbeO31fU55DBdW6KGijP3YgBmuD1oxa9qMN/phLrvCt8uIkA5+asYSb06BGvKWidkjc1bxA+taWhgt3VY2MQn2/KzY7ntWHp9vJ/a01isjnW3gLxtCcxjjPX1rQvoLjVdItpbG8t7OzSTEltG2VbHVjVJ4JdStba+0kIWyUluHcKqf8A1quKSVloaRUYxstCDRtZlHi20uNTlNy9umJCFHGOo9zW4PEOkzLqlvDbRRXFxJhNww4XvxXKLq8mkamLjdp7lh5IXbvJbvnFatvNDfa9519aozsAplij27fcGnOCerNJKPxbWXf9DSurK1k0OOW2kuL1Ipd7RAfKH7ZqnrWq3FpHb/u0S+klUBouAqen0qhPfxSXn2Kwvp7VFkB2HlX57mrL+HZLm6mub28ilj3bjJG25f8AdB9aqnBXvPY8nFV1a3U9E8JaxPrfxKtI4oo3jgjCSMe+OciuF+NkptfGVxFCo8i1mWQRqOWyetelfA6PQ31O+NrvS+tEEaLNgMUI6j1FeYfFTStQsviTq9vHGbiC5XzEkY/Kqt7+orzqDX16UFpZHJR5YxTXQ42z1BNVvbjUNTDRXVsuI1Xpu6hs1qT6ha3ljd3jpKbohf3uw7uOuani0CW38GsYXg81j5jTMw3bcenpVO1urHSrS2SF5LjzFPnKTnfn09q9S6ex7uGaT0PQvBksl5o0ctvBDEkxKkBDkgetU/FBGg6vZ3jCO5imYJHGOBAc96o+E9fvNGt/shjNpayZdQ653A+nvWl4t8nULNFsG/cS7QuWBcSZ/u1ycrVTXY0acKlpPR3JNPnNl4vDt5VobgqkxQZYK3erHxFFykV5p8w3WseJVkXqV7c1m2enXytILm5RtRV1LhxyijsTW9qFxBqb+fPfLMkceMADYxA6VD0mpLU5nZSTR5v+9GkIDEZrRG/cKx+YNjsPSuv8Myy6TpdyurSiCFUDtCx+Y/SklMqaHPPFGAqNkSMmFVsds1X0HUrTxJd2lpq0QitoAC84/wCWxHbmtpS5ovTQ6HP3LNaFa6thqFm+oT+bGu/Zbxj+Ef7Vc5qSzHV4H2s0NrGDGxGA7ehNd1ry6bf39xF4ful81lCDzFwqAdSTXI6mbiGVYQzeRBjpz5pHUVdKXMEqvNG7RD4f1c3mvxXQt/s+GAxtwc+1eifEbw+1zdWisZJLhxuWcDI2nsfb3rzjQE+06vAi7T50o3YXBUk9K+qb3w5aazYRMPMt7mKLy0cDAPHcdxXLmNeOGnBvbU8KnX5avMtj5O12ws7XURDqNmbaVEKRCFQd/wDtGse2ubfVZFh1BvL52Jj+E5rtfHHh9tN1WeHX4rl7ogpC4z5Z98964i10yC2vkjvvLSZBuDK3DY6cetddOalG9z1o1lUj7ruXr+Sxg3w3EjMXBjLqOE44b61vfDTwVb+M/FUelJLJBZ2cQmuZGGHkJPAArjJFe71KN9yyTlg5iQZG2um8NeK7vwl40bWtOaGSORBHNGW/h9PY1NZT9m1SfvW/EKk2oWjueueOfh5aeH7KPUYJZbm0U7XtJyOnqDWb4J8YjR9GvLexslmeUmPZnJTPYmqXjr4lyeMdAk0+xs5VLNuZweAPT2rnLKI6Bosepz3UaK5+ZFb77dBXFQoTnS5MTq7nBKbcbPc6bxXqz+E9CEN/qAla6+a3sVfdtbuWHpXkF1p092LrV9UusvcSbdhbmX2Gan13WLDVdXa4lSUXK87mOQCO2KTdPr+r2L/Z5JIwceWMjbz1Ar0qMHTj+Zvh8KoWlJe8X7VIpbaG/wBTaaOKEhLaNVwQc9zWn4s1SCy0po4b64juJwEc+X97HbNZuvW8P9pRae140axOH8hhj5qcLiHUtVZbuwmkhjHKR8AEe/pRy3s2dnIm7op6FuaaKe9k+0Sglhg9D6V0UevXtgqTktayMWUc5/CsO+kd4ri6msxEu7MIhOSPQEUlpNeNZW8c8TySTHdjYQMdyPeqlHm1ZEod0dXp95rFtH/aUlvFKGUgtIetOu5Z7jTfKaeNrPOZEPGT/s1tp4dTxHY6fpmjTGOYkZZn5QHqa729+CWmjSlFrqN79vhTKSO4Klh7eledWxlCjJKbs35HLKooO7PC7Cyt7iQKkkttDE+5zIcceten3dytholjdQNbOicIwbLMPTFedaTaEm7+3lWdXaOR92MYOARTZ9Q0myiKWt3PdXKKSAoyqeldNSLqO3Yc4c7Vj1jSPEuqy+D57jSNVitRExiEU65ZW7Yqr4O8VaxB8QtPtb8ea18gSWUD7xHTFeffDmyudV12GKW5MNjeZYu/AHb869+8OfDu00nWrLUFuJJ/s6tguc5Y+lcGMeHwynGaV5J9P19Tx50+Wo4rudlqVukyruUFv4c1mx6YyShkHQ1q6hqFpp8RkvJ44kH944rnJfH+gpM8YuGZ1BPC9a+IllM8S+aEWdscaqXuXPNv2mfh7J4l8Lxaxp6l9Q0tGJRRkyx9T+IxXhXwz19ltTYpFGbiLlWbg19fWHjfSNTsmlBYQHKyb+MDpXzz8V/hpp8l7P4i8A6nBNuJkuLNZRkeuz9eK+vyVzo0/qldNW2f6P8AQxpYqMKjmtnudH4b1u2/syYTSwGSQ7SuQCDVbUEuI3P2ZrZ5MYHzDKivD7a+COxld4JM7mjlyG+tfSHwc8E6T4m8Mf2veTTTmclVIbBX1r08XCODi6s9vQ9X63CL5ou7ZD4Wi0yx0u6vL64drmRCGAkH5iuPtPEuh6BdqYGkZblv3o65Hcf/AK67+X4EW97qZW51e8i0uI5SOJsM/sT6V1dv8G/B9vYtbxWDbypAmZ8uMjrmvOlj8JBu8m79jP61C7lZtM8m/wCEu8I+r/lRVr/hRf8A0/N+VFdftcJ/z8Of+1MN/eOh1O1vdRaKS2swvk4Xbjgr9RWj4Zs4U1eO9vEeFE+Vh6YpdfubvQ5Y1kuoRp6Z3Ro3zB/f61yut+M7zUbRntrWOJIWA2RgkN9RWcYTqxtH4X1MHinUio2O48cXlssOmx258wtKAI044J615x+03oYS20W63DzAnl7V+7n1rtvhxp03ivV/7b1FD9mtSFh4Kgt6Y9BVn9ovQZtU8KwXFrCXe2k3HaMlR61z4fERw+Kp0k9r3+ZnGk4y10Z8m6FepbXK+ZAH8mT5t/RR616Za+NNTu7Z7C10uFUDj54lwNnfn1xXmdxa3UUv71d7yMFKMvBHrXYQ6drOnTQ2FtEr21wR5bRjIYn3r6mtCE1zMuNX2btJXPUbCPRpZIZLe6dUaMjyEbo2O9SaZDocGlahpDk26SHIhzjcx65NS+DPhzqV5bNJHLbQxEbfNQ5+YdxWV4h8Ga34Z1Jri8zfQIN6TKvDH+6fevE56UqjpKept7WFr3Zn+JNHtreOG0t4QISmJGj+8M9RVM+GmhhS28NQtM2PMKyE4JFdx8JYtM1iGXU9TuTHfy3HlC2PWEjoSOw969N8Y2UUlnYRxSRxHz1XchA4rGrjvY1VRa17/wBbilmEvhjrbv8A5HhngX4UXF6kmq+J2GnjJEaRfM7HrnFdlH8OL+406ZXM7CaXPOFOz3HXNe0QW1ssUYjRGVPunrVfVNZ0/S4Xk1C6itwvZ3AJ+leW83rzn+7XyMak6lV81SR8/eL/AAV/Y8dpDawl0yFZgn7xge1dVo2nafpPg+SbWomsdPU7ba3ZeWYDhm+ppuq/Eux0/U/7O0mCOZYkactdHbx13AnrXFXnxQbWpQurQ210xJWMRZACn1HrXrJ4mvBRmrLv1+4zjhK9VXUdi74P0+313VdW1XdEb5Im8seZsDcdhW/e+Gb3UPAT3V3cxz3om8wlf4Y/TJqj4T8B6XqOqSXdnPcIsoH7tB/qz3+le4ppsKaT9ijQJHs2YH071zY7HRoVI8j6r5IyUG3ZdP6sfJWs6HNKt3NbXwZIl8sxHkbe4xUXhzSJfEOow2ztBp8MEe9Vbo/pXofxR8JSeHGOs6MBBHKvkzQyycHPUrXn9jeB5TLeyyLHCPKCp0+terTrKrT56b0Z7eCr80Guv9dC74005dFtibG9eeRvUZVT7GsbRILhrqzu9YglQzfMkofpjn86s6lcrqNvHYWVs4Uy5N0/Kj6+1ax0+WCeJ7vUYyltHuigiPEh/wAapNxjZ7noudoavX+rEr6lqGoW/nCL7NaGbZNOB+8kU9yakvdZt7G7trWxsAbMty0xA831NZs7R6TBH9p1Fm0+VDuXHKMe30p1re6frEyacyK9tbKZVlQ/MQPQ+lRyre2hju720Ol1S6s7i3nxO1tbRJhYCcox7kD+RrnLUW8elG30u2la7DfK7nKkGt7U9GS50dLywMKzxnITcOR61QvDLoWk2zO9vMztvSGP5mQHqT6VMGrWQ1KMY6PUsatPp2leFbaysIli1WR8zspz9cVx2oGOKys0WQq8QLPzy70/WLq2vLZb22Lx3Jk4Mq43Zp/hnQdR8ZaoLC0ijUZDXE5OBEg6k10U4KnHnm9Fq7nDicRGMWk9Wdp8HfDhuvENnPqLQrZoPOABySwORk19LSyRxRs8jqiKMlmOABXjGq6hpPhjQksrayOIh5ZfGBJ75715jqfjSbVZEsbp5orWLhVDfKa8bF4WeZVPaXsl/VyMJl1SpHmeiPpCz1jQfFV5c6dFHFerCu9yygrg8cVS1r4YeEdXtWgudHgTPSSIbXH0NeO+GdW/4R1JdW8OuZJ1ULJFcfdkGensa2dU+PN1JYG20rQ3/teQFFLndGrHjPHXFck8vxNKdsM3b1sXXy1qf7uN13OH1f4Tva+Ibu38PatbyiGQxyLPIFdPrWR4b+EevalrNxBbC1aKI/OzzDn396b4Y0+8h8Sy3uuzIs4bzJEkbBcnqa9LOk6pZhr3TFPlXR3hlJyo9q9qVSrTXLzK9t2v+CbzwU4q3tPv/wAzX8KfBlrViNYu1S3x9y1OM+xJ9q8T+I9xa3Gv3Fjp8axaRby+RAP4iehY19JeH9SudO+G1/qF5IZZFVyQTkqOR+dfMV6hRpL+SF2svtOWYjOcnriscBOtUqzdWV7Oy6I5cPS5ar5tWjR1HT4dFtNOW3jty042ySffcYPfHSmPrKWd9cT2C7ZETbC0Q+UN7iq8CC+067WynJjRiRv4fHpVOynhh065n0wSlFI+0CYfcz3HrXpJaano/DuPtFe51a6ur1BK8i7mkkPzg99oNdp4etY9Qt1CwyGKR9o8ofOfrXDy3kV9JbtFJKZhkldp+avYPBlxHYQWTW8R8yPBZJM5BrOvJxjsaaKF7GYdF0+yknsjA6swypl7fWpNetbcaHHJYzpa3Vud/wAzDD+uPaul8R6nZSZuNRSH7W/K7Tjb/jXjevrcTX21WdrbJZQo6+3tWFFSqtN6Gapyqe+9LD/Duu6rp/ia2vLGBUZWEitJkbwOtexeIvj3pTaDLBpdldTavJGUMW3CxEjGc5rwa83OhlW/dXuF8uKJONq+lRWdudO8n7fEYzH8kePvO2e4rSvg6OIlGdRXaOarQVRmvczefZQT+TL9pkUh0bI3k9OK17DwPe6DYLrdzNaLDKAfIY/PzUeq3q2kFvAFjkvJcuz9StbGjMNXsvsN9MzSTEbMjof6CqlKSV1ouoSbjG6J7Wwk1GeBLURww27hvMThsE816P47+Ldp4e00Rae6/aFTC7xuJP4V4j4n8RLo9w+haJMHlj+Wefrlv7orL0G2N1N599GJ5EcBBIeAexNOpgadblnX2Wy9Tw/erTbj1Nm78WatrrrcXFwzxP8AMRJk7D7VY0jRku7qa+1N7newyiZ27his2DSdQfxNcyXDrboo3KBwrj1Feh+IV1KytNOv4YQ8hULErdOv6CnUqqFoU9LnbDAqCSe7M1dbm+wGz07RpSTkeXIud9VU0aDU7Peok0e/jO7b91WNdbeX08dkknlwJqMYLtgZIz/SsE6hqWp3EL3/AJbw7sN/ex34rGFZ7xVhPBp3tuQ/2R4f1Z5YrxJLm5dNrTqPucYzVj4c3ureCNOv7HR9Ttrq1yWVLj/lkR1rpfM0vRID/ZjCaS5UgIwHB6c1waeGdQkvPtMcXlcl/wDe+lVGcK8HCp8L6M5pUJq57X4Q8U+JbqCP7TYW+oITkyWz4IH416EJJZLbckZSQj7r9q+b9L8R6p4VVtQtJVIBCyWzJ94V7t4K8U2XirSEvLNgJMDzIifmQ+hFfO5pgnSftYQXL3X6kUr35W3/AF5mJ/wjWv8A/QWSiu03D2orj+vVey+5E/2dRPloW2ralqMklrZzXrnAkUscFv8AGvRfAXw81MXDXXiHFrZsMi1QjJPqfSvXIoLaySRrWCOPJ3MEXGT61nX1+2w7RkE455FLH8Q1OXkpxsehToKWyLdlHa6fbpa2iCOJOgFXGjE8ciS4eNxgoR271hWHmSSKxBC56HtXQRjC+9fPYSvUq1G5M0rU1DRHnniH4VaPqEjz6fGttcMpUgjKnP8AKvPdb+Ft1p6whJrjEQyjK4IDe3evoWYbonXcVJUjK9R9K+VPjB4k1TSNXjiivp7lkbeokfhSOlfb5RiMTXl7NT0Xc4akdbR3PU/Avjqx0PTzpXiKMadPB0Y8iT3z60z4ieNbe8tLNtJu4EhimEjvKQM47Y9K8QW/uvElqmt65seaTEcUcPBGOparSaDBqmowjVrlLa3d90MOfmc/SvSlltCFb20vi6rdXKoUnVXLeyN3xP4n0iZftGlyQ210GAuXtvuyHsf/AK9JceNb290ZNNtrKG8ExyLnfjy/b+tZ2t+F7C2E8lmEjlZNvlY28+tczq/h7+yorYB5XlnKtG0fKr6//qrpjGnJJdtj1aGX0LJbvzOkn+LniTw7Fc6XZzWxSEeWjlCzZPoa4K+8Tar4j1ZJdUnuLm442oOBkdMiupzZ20lnDbaOLi6B8+VrgfNn+6KXyf7Qmlh062W11zJkcKvEajnmnGFOD5oxSb6nRTw1OGsY2t/XyILnTbjU9TjfVYJLi4MeFVfl8oDpn2qnPN/xM0t754I44WDkIAcY960NT0/xPLZwyz+es0r7VkGcMB6e1c9At5e6TfNb2sBEbbZ7g8n6AVomn1OiguWPvWPVPh34puNI1ya4sbhLnTCBJcFz83uPwFfS9lcxXlrFcQMGikUMpBzkGvhuxma2sU00TD/SZA080Sn/AFfoa+mfgh4ittRsrzS7MP5FmQYy3YHtXg5zg04e2juvyPKxsFGamuv9XN/xv4Pj8TSW8VxJJ5BfLjd93HpXO658ItNOmvDozOkzkZ85sgeuPSvVKy9T1iDTrhRdkxQbdxlP3R7ZryKGNxEUoU3ouhwO1P3rnzx4z+Euq6Tpct1HcvMiYyI34IHYiuClsNY1OK3kDRpbRNteOZ9rp6nn2r6tj8ZeGdV1EaaNTt2lAEoBkAVgPfv9K8I+Ol9oZ8QvDosqYnQLeNbkFWOenHfHU17+X4yvWkqVWOu97HbSx2nJL7zmrgW2mWdxDfzW81vKnCht7t9MdKrajbR+H9Etb+xsGWKZcO5YEtnjFVFTSX0m5j020naTzACWQlseo/wqQWqWlu2lKlzcRTgMHKMSreg44r0+XXU3+tU4xumQxX7TRw25inS44MalvlZe5Jq7e6vFOwUIEnROdi8HHbPetXRvC9zkR28d2pdcAvAxOPUccVraf4He7nlaGC7uJE+XCwMAG+uKv2lGGsmcGIxntX7uiOGi+06oIIliK7cKF7sc8AV7LpWnf8Il4RazkwmtXr5kI/hTstdD4F+Gy6DdQ6pq7K8tvkxwoMjPXcfeuL8RXD61r15dX11Db+W5whPOPauGrjI4ufs6b91at932Ncvw3tp88to/izM1ixn1DV4LR71HhK4YDohz0FSL4K0yzu3OrTyIUG4qmCGA9a6HwnpulX1/BbxSPIobcJSMZra+IEVnE+y3VfLRSrsTksah4hqaoo9yVa0lTicw1r4c1pha6TP9lHlkFZDgMe1Y9p4Pu9PDNFcwRy4OxmI5981n3AgM7RxRbGBwSvVP/r1eW3uGsAxkk/dj72TzWyi4qyenmO0ou6ZizaXHPqhS9uJZZk4Dnuf8K7i18U3+lXNhaPPGLSIgZI6/WvPbrVdrbJY45y58sb1z1qz4wvLO50uCFklivYvnZsfeJq50udqM1oXKPPaMjvfHOrmOx16ysrnz4rpN7qnOOOTj6V414e1NdLn33lvJd6ZdLtRT1U9M4rSs76WwljvFnzjEckRPDKeDmqC20FvqotbneYDl4wMY3Z4Fa0aMacHE8+rRVGrfo1+Rf03UdO0eW4u4Y5WiudyeU45Q46kVSsrY20EolUyRTj7o6OPf3qOJIdRnuRco8d1FIAqJyPx961rnVMxRJKsiwwrtD7PlQ+9U9DZq+5l6GbOHX7SRrZohC42g8d+hFe1vdPc3nn6XaRyZG522/wAjXjdhcJp99PNqsJlZ1LwMR8rCvXPAlw11pNtJGBDGxJJ9uwNc+K0XMKc3GKa6GK2nW8+pM+oNI285weNpp0EVhCt8DbTSgjajPxuOK7LRtNhvdXuWu5YhGpwCTj65rm/GssVs8sGnRrcmFtx7r+Nc8avPLkRDqqo+U8ntI0n167ZBEklqv7uI/wB729TUV6l9eXkN9q5SObf8kecHP0rV8P8Ahq/13W7ySK08qbG8yPwFPpU2tWcjtOfK3XWngGSRjkZr0Odc1rhJpSsM0G2gm1e9ur9nEmP3JbgHjtWj4muLnQdDfUEby5LgeXGoHT1IqPw/aT3+o2AMTTrK/mykL91Qe3tVr4p3EWpNAgTbGj+XGg6EdzRTTdVJ7HmY/Ea+yj/XcsfAn4T6Z4vtJ9a1xr42qvtii3bDIe7E/Wl+KPgaDSPFdpovhqdwsqiRo5nzt9s1Z+GHj3V/DU19aSotxY7N8MTAg8Dkg+ldhpPizQfENvda1qSIuqsCiQAZ29q8+tUxUcTKpJ3h0SNMNRnTfNbQ8/uol0m1s47q/F4xbawQ58r2/Gu18Q6rZR+D4prclrhegJ6Y9q841iyRNfhZf+PcfNPk8D/A10dhpEviPUZY9O2LpOBt3nGT6itqkU7Sk9tT0J0lZO9mZVtcXiRpqV2nmLIB7jA7Gtp9btLiUeTapEAgY9wfpWjqVgdHhfRbxkjtZVyrA/njNUvDvhq1u9QSGNitsf4nOOf61LnBrmZlzJq7LPh6LStZuJ2dsXoX5Iw2Bu7Ul7c3enloLrHmtwWXnA6YqPXdHSz1+3stIUrPGQxnQZGfesqe2urrxCQzGe4RgzBf4gKIpN819AjBSd76M1vE2nWtjpttcGb7TFIm5gDkp9azfDE9xpWoJqegXIX5syRM3GB1BFad/qWn69BfJawMHiTZMmcBT61yPhbTJ5IsJNGYwdp56jsPerpt8jjP7mY1MDGrB33PZ/8AhbOn/wDPP/x4f40V5r/ZH/TCP8hRXJ9Qwn8v4nD9VqfzH1DIm4cHFZlzp+/OwDPGM/56Vr0Yr4ith1U1LhUcNina23lDqTVyiorokW0uG2nacH3xVUKEaSsiZzb1Z5R4t8XXWn6xdRWi3E1yZNoAXKJH6/WvA9Ztr/xb4jeCeGRwR8zhSCOete8+CtQhm8QMdTjJdX8hSB1JPGfWrHxHjtNOupjawkSsmSijAIweK+0w9ZYWoqMY6tbkYempTba1PE4NF1WxjlstJAmmhX5s8g/j2qzp628k9sutfZ7eeFTLBJE43Fx/CfbNalp4jeyublZ7aWCKWMBUCZJP19KivtLEJtV0+ytrkXjAkTt8yg8HbXoOcnpI9d0fZO+3/DanO+LNavbyW2mj3P5rBHbYelWby51tDbw2kYuIYXD2wZOc9+O4ro/Ech8OL9gitEur1kxGHGFizxwax7XVtW0TV4hPbW8FzMpKXCHcg+lCd4rlXobUavPG8Iqy/q5QvJ9dtPFlzqOp6dLcTSIUCpGcLnocdqu/DrVrSw1m5tdQj+zS3QKzytyxB7CoI57+zt1n1PXVWedvMCFucduPSoYvDs2oW89zLcRorDPng4ct2G2qdnHlkbPk5bTsttvwO0+JHji00yytYNK2zGNPk3HlPcCvNdK1a3t47VtRuPILsZQyDO4n+8KuWPgHUL9tsr+ZuzuOCCgHc10cvwpudU0hGsLOUGNNrSlSAxHcVmvY0I8vMO1KnDlUrHC629z/AGhfzwLJd2LMIkQrjI7MBXrX7N9wXv8A7QZWjectGYAOGAHU/SvCtUims5zpUEk7TxuSZOR07Yr1r4R6vbeC7Y6lqdvc3F9KpjhgQZP+8farxdPnw0oxV21oeHjm7qKWp9USOsaF5GCooySTgCuQ8QfETw3o+nrdXN4s8Tv5YWEbyT9PSvFPEvxlvdQ0i5cxRxbJRGkRQncfeuo8KaJp3jrw0LvVY4NMjSUO4gIUuwHvXzccrVCPtMTt5Fww1rSq6RE18eEPFeinWdOtZYZknVCqkISD1OPoa5vU734c2GnyaZYTXc19cvsaQgN5bepPpWRdaxrPh5ruxhtYpYUm8zCjAZR15+lZOgHRtSutQvLmzlaeRfkS3Ut5bHvx2r3KdBxXxOy21/M3hgIPWV2uljqdL8C2VxDJLp+vwpswHMhChz6ZrrfCnw6uZbxbtriCW1MmJBHJkhe+PevLIryaK2igtbW5tPKkDyvKDiT8K9L8PfEG4soysvkxxHkuvRvUj3oxCxTg/ZSuzysVR9lU0Xu/ieq2nhextHco8+4nIy+SF9BW1G6Ku2MAAHnFYltqlte2tpdWspnt5F9Oc+prRhByycLbIpIYetfKVfaS/iPU5ufX3SDxjqB0vw3f3agbkjIXPqeBXzVbWs+r3U12QJZnP3SeBX0v4j02PWPDl5ZzZVZIzgr1BAyK+atN159Ktp9NhhaWSaQhpSMMnbivXya3s5KO9/wPpsrkvZSaWuhqadqf2dhDLAkMyNt3IcdK0buNJJ5XmkkkRV3MRyM/Ws+1s4btZrdrqL7coJBY9R/jXTaB4emhspDd3URtnTCpvBbPpXqTqRhqzpnKKd7nFpDDeQFdO+SUktI7YOMVBBdzpE6PNuCHBSPnj1rft/C+oR36vEyWsL5DPIcDHY/WoPD/AIXvb/V7m20uaKQKMyN2qnVgk23oHPGz12IdITSoNOlubm2Nxco/7pSuQDXNa7rEZ1dmnt/MiYD5dv3fbNekT6npOh6ONKmtBNdscSSj+GuW8QRaTpurWywBZWcbyQ2SR6UUp3k7p+RUJ80yrL4faaz86KFFtJEI2twQccZFcrc2dxqmlpeQxyAaa4+2bAWIGeGPtXXPrdpfie2uneHJxHEh5Y9q7z4F6B9lv9fE6h7eWNY3VuQ+c5z+FKriHh6TqS6GOJvKg5PRrY8Xjtxd7Z7JspLJuDA/Mfw/lUJjvrG1BO0Rtl5kkGC3pxXu+s/B6wtb43ejyGK3HzeS0mNh9jXkfivwjqttdrLHA92Fc4ZJMhhnpVYfGUsR8DOShjFJ8rdmUY9Rs9V0uS3fT5/lHDsNqr6EfjUOh6tqemRxQ2j+Y4GZISeh9asanHf6JpEX2ZljkuXKOjqW8sVntHNZTQ3BnjuIWH75iNpHuPpXSkmvI6FNWt0Jl8T6rPepGyxRpO2xhuxgHvXbwaUlvp7mwuvtMW4bt7g5rkPEOmRXelvfaLD/AKXG+ZkUdB2NUfCPiSfS7WTTbqLiRcblPzDnn6VEoc0bw+4l1bx9w0rzWbiwlvTZ+aBKOHUZXPv6ViQXN9JcRwTxlxeNtzHz5vbJFapgvJITb2Biazlk+dT98ivZfg38M47GFNW1qMmTfvtoG/gHqayr4ilhabqT/wCHOSviVHSO7JPCPhi28GeH/tF87nVL4cqxzsT0A7cV5R4zWPUr9haFVit1Mjdua94+Mcccejx3ckhXys8ZxmvnGztl1SWV7m6FtZSnZvJ27vYZrDLZurTeJk9X/X5HkUoOdez7nQ+FIFu9Cu7pyTeqh8kt93NaHhrQ7azs55WuVS4nj3hm5If2qh4QludOu54YogdPjUq24Z3cdjWxp2mKdHiuraZVPnfMHbJAB7VrUbV1c+iu43s7AbHQ7/RXtrue4ivFyZGAwH9PzqTw4kmo3i29vdRafawjEfrIP6VU1KWCHzLOWVYjIcLJjkVUnhkGnzmAs1xEvyFASOB1qbXW+4LVNpl/XeZpW1Fy91C+YhnIIFPm1ojSUIs/MXBLIgO4fhWFHpt5rNjZanbyl7lDtkiz9z61PpUdxKLhxcRlg2SoGS30quSKVuw3TtpvYq+EtUlt/EkTBHme4YFRIcHj37Vt+LNQfT9Ze5ZoYWlBz5bZFYL3U9vcTOLeRpNmQdpz+Nc1ePdaraGW8DrDDkHd1B/wrRU1KXMzWNJOSfQ6a71jSNNt7m105XdbyPMr55Ln0rs/Dej2dxYad9jmWC4Zc7exPvXkWj3FrpkNzKJRcSyYKd29q6Pwb4oNlcb7uKRnPIXbx+FKrSlZ8h0Tovl/dvX+tD2f+x7/AP56RfnRXB/8LLm/54Tf9+zRXF9XxHkeZ7Ct/L+B9LUUVHOXELmEBpAp2g9zXyC1PMHMyggEgE9MmmzRJMoWQZAOazVL3tgs95EYJI23KvcY9ataVcS3VosswQFumw5GK1cHFX7GSmpPla3K40WxjuzdJEsb7g3y8DI718+/ETxvNe3d1c3AtIWsJjbtBG+XZc8H619FavZLqGnT2zEqXU7WBxhux/Ovj/4geGtQ8N+Lhe61BItrK+6W4C7gzZ617eSqFWbdR3ktrnbhJRhN36mva67c6sb2/uogZ5AIraAjHGPvYrnPC1yj+KDNO/nSW4O0F88DqRTba5tpLi4lheIJDl1aSXa7DHTH9KseDtU0NNRSRLWW3V0KStsyd3bB96+i5VFOyPQqTSpuCRueMdSt9T0GOVTLGpkVREine/uTU9to41G4jW3UIhhP7tpM+Uv9/wBqrXPjGy1W3m0+5gmtbHcdk6DD57Gue0SC8jgmWzjuJpbhin2jOCQR0JqFB8ttiYRlCPY6TWNFCraTTXunxxaYRE9wzgtM2eBWZ458TQL4gtrVIElW3jG4xZG5+vNZemaNLYXPna1tFpHPhom5Bb29TU+k+Hh4p8SqtvFP9pllULBEM7FB6se1PlUdZPRG0JRTvJ3sdrYa7ostrNdW99eee4RWgZsYIOTn2r2TRPH2jaxp1rBZlke6BiRVIGD0yK+fPiJ4U1fwjb3LXGj2qWCtmOZH3GTPGDXLeDPtFz4lt721aLTEtR/y0OxA3pzXJUwVHFwU09FszgxPK48/NsfXsfhTR7SLbp9haSX3GZZVBb3JNeXfFDRpNG1XTZNPxcTxo0kgbnbn29M1N4L8bSaPDqsOqM82qsxkWQAuhGKyvGHxf0q7b7F9kfE8YEjqP3gPTAriw+HxVCvr70fz/wCAebS560+a12ef28kcWlF9RiIKXX2mSPHyl/YelRHxNqlnpqR3Vs0cN5KZYpVG3aM+lJq8k82nw3DM01rcT7BCVy4j9Se30rb8UT6do1jaRX9s093LGPIkD5QL6Y7GvY00TV7nvQik11uchE5ubW6W2vJyxkyWlfgnvXovg/UXhsI/sGmtDGkWWdR9/A9awk0a30vw1ayme2aC4cySRL80ik9B7fWrWgeIYJ76PSbM3cOnW5+0HAwWYdifSlUtOLstDWo1ONkjmxqlzpLy3lwy3uoSyExRSNlY/fFOsbqRWMWtlWichwIzgg+3tXReKn0zUVvNR0m6Au1ix9nkUHA9Frn9PhtrnRBb3tuzzrG0gc4HPoauEla9tSa9OnUp3a6/cepfDTxNNp+oGykuYH05/lUE8D6HpXs9nO1wsoVkeBTgKP4hXyLoV9f6jYssUEKfZiFS0XiRh3J9q+n/AIfai99ptvbXYEd5bx9F5BWvEzfDpL20Vr1/zPncVhZUZ+p2UY/dAFcDGMV8sfEzT18N/ECWLY6wu4uV2nAKE9K+qC21QW/EiuL+JPge08Y6cWRhFqUcZWCb177T7GvLyzFrDVff+F6Ho4DExoTtN6M+br25tpb4XNhO0mRuYZ5U+ntVv7XqNvBJc3ZlS3UAqpP3h2IrLvNA1bwbqkyXun7pgP487WPse9V/7fn164H2yWONwPLCHgAV9dpJXjqu59BKKaVrNdzduPFN/fXcEUswKgDLA8YrsPA3iRtI07U7qJkW4dSEzxng4wK4/U10TS4/LnuwbgKGHlY6+9Q3LpfadZDS+isS5j+8ee9ZSpwqQ5WtDCVKEo8qW428u0vUnnuJs3jZL/Nwze/pWbpdxFNqQuJZSzwHhBzxVy4066u7eGO2RcctKe4+vpUmieH7hXk0nTLRri9nYBZichQe9bXjGJ1Knyq/Y2PDHhS88WNPdaQWmvFkCmU/LHCM9z3Nd/4j8b2fw5sbfwvoCi+19hmaQjKox53MfXmtDxRq1r8KvAdto2lPEdVkiIRj3c9XP4mvJfAmjald3V5qeoXdjFNNmV5ZpMtL64rzFbFp1av8NPRd/N+XkeDWrSx0nFaU4/j5A1/4k8a3LRXOvSpLC+ZYs4Tb9KgFhqKre3enancmGH920Gc5OOCK2r37Cl3E9oViAQAsgyGPqa6S2tb7WtEWWGKKMN+5mkxgt/tV2Or7Ne7ohPD0YL3Y2RwmmazqZWO1lCXF25+XcmRgetWbieDUcw+ItKNsyOEHlcCT/wCvXQWs0WkalDpGmwwXLWD7mup+HYnnj1rE8VXT3d1Pc6nMHEcmRBbdVpqfNLRW/M0VGEn7qsiAeHbK9ee1sr29syinmRcZGO9XtB+F9teXkTSa7bxQyDJmBBZh6emawBrM+oeVaQq4e5cLljg46DNdxp1gmmWluW27baQNKWPHJ7UVJThGylZmFfD1b8sXZHq3gz4ceHvDsCtao17NwfPnYOfw9K7jpXjsniW40i/kudKbz4GwzQE8MPVa6zwf8Q9L8RLGmTbXDtsCuRgt6A18xjMLiZ/vZNyX5fI89r2Pxq1+ofF/TBqPgq9Owu0CmQAe3evmvQ4NMurKGHWGdljk3wRKc7jX2JeW8d3azW8wzHKpRh7EYr5v1nwrF4Xv57LU4/NRpN1rMo+bHY135NiV7KVFvVaoKa5K6ff8y5JPa3WlWU2jWUrbXzLbqOnrWLqMN1bPqFzpMbizmGR5gOM+lbHhSwutN03UVsLgyySZbeRnA98dKHluJNG+yzuYjySGPX6GvQT5XZao9aMmiHw/oi+I7KCKck3qptB7g1QF5Noeotp5j3XsfDb+QR7VckuLzSZ4LxFVI5QVZ1bgcdRWOkM9xbXGrXEcjuzcSP1FWk223t+prHWWuwafdySw3tkh8hpn5Ze5q7o3h+80tlnmuE2Ic4HOaydNmtZLtcztHJ97ZIMDNWtSvZIrkQC5JJ545H4Vo072R1+z5rKPU66y+yXYkunkjjjkG11Hp6iud8R2KNCbUSKIPvBivLH0rQ0qOK0EK3i5AIbbnO6un1SOG7sIXFsjORyRzg1zuXJPyMU3QqJLY8i0XQNPinupL8MxK5VB/Cfat6GFJNJXa6GWLldvJqa/kWJbhoIWSU5BA4KY9P61wdql/YAXymSKDeQY89B7V1K9TVs64JyvJux3WYf+eUf/AH1RWN/b+m/3v50UuWXYOf8Au/ifXhqK4uoLaFpriVIol6s5wBWb4h8QWGhQF76ZVYglVzyx9K+a/iT4s1jVNbR5sxaeMOImOFZfWvlMDl08U7vRdz5ulSnWlywPW/GHxV0GzhmtrO5e4lcbC0S5Vc+9cBJ8ZdRg1CLTbKFIYBGAjbM5rx++1Ax3t0HjjMNwdxjOduO2PSr9h9pntJJIVhMOPkV2yy+2K+mpZXQpR5Wr+p3QyyPxSOvvvi94mgUvcTIm9ggC88dzxXU6BF4q8X6PJfvfQXti6sUguI92OOp9K8ntILexRJWng8+Hd5kZTH4CvQfBvj+z0DTSloJBLcZBRxlWHqB6VdagoQvQgr+hpPDRil7KCv6f195zzW2nWouLTWfDAaaXpdW5OD7r6/QVVh02eyge28LXAkheTcRdR4II7A9q6W28e6TcQ3Vze2YmuUk3RSMPlibtgVVsfEGpLqD6kLUyWW7f5aL94+n/ANatE563X4jqUpbqNreel/I5Lx1peoyrb3d3pc2m3eMSAofKOP4s10ej3xg8CSCxuFlZpgiRuwDsT3rrfGfxAS8kisbu38mKaADyZR9xjwDg9q4jT9C/su7mF/pqusi58y3blV9cU6XPUh76s+xxvFcsUq0bfj/X3kPjLR7+wmtJLieRxcqHMOciFx1PFbvw8u5vh7r0GpXlv9piv4/vqCXyx6AV3/ws0bQddYDZcTra/Mq3YwTyMHFepDwrpBv472S0WS4iGEZudv0rzMXmVKknh6sW+/Q5pV5TbUNvzPIPiT4in8U6NNZXWlkWpYGEYJbd2J/wrjdX8Of8I3YabbalDE73ziZsn7iD+Gvp7UbGGS2lZYIzKqllO3JzXl/jbQLnWtDn1HUVxcRri3AXnb6EetZ4DMIaQguWN+/3HNPmuovY858UWb6UtldaJe28stxkSA/MIlxU/hn4fC/0hfEOotbyeS5JAwPM4/pXL6pF4n1SxgNjYFYbM/vnQc7c/wAQFdhreoXem+G4bKe5tLXTo08x0hky8oPtXpVHOyjGWt/wPYpRcKUacN3uRaBYW9heXSX0ttJbsdyRM4ZueM/hWbr8eh6nY3EP2V1Fk+8yE5YL6AVzNlpd3Y293renyxzRg4EknICt7+tbd8NHtdHSaPV4pNWlwVgiIdgfQ47VbjaV7nSqXLNNydzLv/FemWNtDBokM8crEDzblc7R3/GpJGke7lFvIjPJblWcDrnsKveLtKt10qG61dv9PvbbcbSFfngYD5SV6gVy3g+HX2jD6XYNfQu3lnCElc9fpWkeVx5kWlDlbT+86JfAtzpBs5LgM97Oc+WvIxVmF7G/vJ2luWtFjYltke7c46A1TtrrX7KWOONL57pvkRpsltoPIA9Km0m+02/urrTzDNBPdEKV6Bn7YJ6c0nzWvJ39DWPPL4+nYuJDCNNXV9N1m3bV0c+ajAZKHtivT/CesxRSaRBosHmXsvyy4HG09T7fWvDPFPha58D6tBBf3MUl6zpKsCNuyuf4vbivaPgnqtrE2qXOoxrE4bak+MKF9B6VyYxRdB1F7y6fP9Dy81Sk00736ns0CLbq298knJyelcp4p8YQ6RhbCFry5OfkToMdc1y3jTxymr29xa+GZgWiG55i21XIHKVx2ieMLe1tZvtFk8ctyN28DJX1rxsLlsmvaVVd9v8AM4IYaU1otF94zxH8UdR1Owni1TSdOa1J2qWzuVq811GWyutQa7sdLktDbEGTdyueuRntXW6jpmm6tBDbxvKiq4lBzu3nPTNWdUsrS8sniCtDbwkeZuB8xvr7V79JUqKtCNjvp050laMmvmeVyQrrV8bgXIEs/KhlIGPwro9E0DWreNrjTLu2xjayCTnH09as3k8NlbmLRJYGuVYkb16e1ZO7UYR5kq7b0DzZWJ+VsD+H3ro5uZaaGn1nEw2afqj2L4ffDbxLDCstxPBbQXC5dmbe5H4V6z4V8G6X4YeW4tfMkuXXDzStk4Hp6V5R8J/iLLDAttfztPGEB8nO50+le5Lcw32nPJbvvjdD9089P518vmk8UpuNR+6+xyV8dVq3jPTyWx8r+Pdaudc+I7XLwia2z5cC43Kyjgc9jUdr4bvLzW/9FkWcldgiQfLHntTkjkGsXEMTAoXBRduSozziuj8F6nJo+qzNb2rsACxMgIYj/GvoHenT5aa2R6mFg6dJKCu0v6ZTukvNGSWz1O3PlxrlU2fK49jWtZ+INN04Wy2quGlTaTu+UHsOaZ428SwX1vLm7EUccZfy2xnP1rh9H0qfX/sUkpjgtkG+JSfnkOc4FZwhzw5qmhbp88bz0OtSC512z1Bre3FjLbZaaRz8zf7oriL6S0j2vdvIl04wtxj5XHuPWugbxROLvyJFVAjmJmP3gP5Gi9srbWBaW87KkDNxJuA59a0heD12Ipt099jm7AS3NzaX1mfLuLcbhn7rfWuj8S6zP9oht7xbfExBdoyMKe2a1H8O6xptjerZLbPbsAE3/MSvcjHSqv8AZGm3u0wQyzeRGHuXxgMR6U3UjJ36D9spO9r2HmbTNCaEXUtxcXd18qBGyEX1FN0+20iy8UW+lw3M6WdyQ3mS/I0UmeMH61d1LwbJqV3DrxdrezgjURwHhtnfHvVLx3Nql3qtpZ2cU8GlSlBDdFSHYcZyazjJSdovXr/Xkc1eMaqtJ7/h5HvPgnXVvRPpdxO0l9Z8MzrgyKejD1qj8VdAOq6TFdwKTcWZL8DJK98VwGlFLL4kaQlhqDS4iCys5+99a93IDKQRkHg187io/Uq8asOuv+Z4lNPlcOq2Pm1k1LSLWeaGRZIpuWAIBIx6VR1l/PtbHcknk/xb+oHevSfHnha0t76OZ5GhspMjC9AfSuJs/KlSeyaFmZgVRmP6ivapVo1YqcT16VVVFzdS9qWj2Fx4WRIpvLx+8jLNkEY6VzcGsX8WmvDbQpdWyAxyRgZIz3FVXh1W31Ca1vlEkMR+6TwRV3QNeTTy6xwABcqVfkkVsotR79TRJqOuvU524jewvkvLyFWDnKr0yPTHau18FWVpqE76lqSbRGN0Y7MKyvEV5Ya9/o9lEGnXDBSPufSrto9za2FhHqDp5EbYZEPT6VU25Q7M7I1PcutGa18tpJ5k92xRXJ2KvOPwqXSZ47Wx3FmKpxk8cetY+qm8vrt7nTI0FlGNyq3UY9Kw5b59X0u8i1Kd7JYzvTyh94ipULq1xuKnBK//AADW1eZI0nmREmjlyAT0z9a5GPUC2lyQXMcAljY8A9v61Ue+kuNJtrdXkMpb90W6NzVmy0mWOGb7TaGRpDjdnoe1dEYqC1NY2gvedzP+0Rf88v8Axw0V0H9jP/z1P6UUvaIj6y+xNc3d54s1Wc3V4oKDo/8Ae9DXPzT3LQzW0aRMynZvlO4t9B6Vp6dHJeRX63pTz4/3gCggk+lZTwJr95bQaarrIMJJJIduwd+K0ilHToLD4eMLp7L8PM5/UoUim/fzxySo33UOQfxrQ0o6lrt81skqWqYyGPHTtmvUNK+GOnG1Sezn+13iSANFKdq/Wuu0vS9Ns4Du0+I3aZLyL0X2+tY1MZDaOrLniqbXuK7Xl+nY+dtZ0PVLW58m8hkm7ho1Jqpo1vPeSgST+QIAfmBxuHpX0Re3DalqSRzRyi3QYUDjBrzT4jQW1pcJFaRhEUDZgYO739a1pVnN2asylUdRqLWtjBxbCFXiUpGs6qiKu5m9STWhqWozRPM0yyW5lOyAKed3qapW00caxTS2039njCmVVwQfSrV9o86WEWw/aZZWysbksyIejnFaO19RKPv2f9f11JXvPPjtw7re3WdjTSLkRr3G719q7LwhYXGuXMdprVzv06Yb7a4gYNsYfwk9K5fTrFYbi1020uUmHmDeCcDPfFdz4IsbSGS7srfzDKjAsmNqxehBrnrytF8rsePjIw5NF/X6Ed7f6t4R8WQS2duHsrb7ydG2d6958P6xa67pcV9ZNmJ+x6g9wa828ZeH4NT8Ni8lBhuA4Rn3YMh6AD6mn/Dp5/C96mm6huVLojbg7lDe1eNjacMXQVSPxx/G2549Ooo6nrFebeNbPW4GaHR5ZXVmMh3JkKp7Z9K9JrP1yzlvNOnitpWimZGVSO/HSvGwlf2NRN7eZ0VI8yv2PnS5svK8SLLaatDb2MgY3qGYBt/cH2NdR8OPCmn+KruTUtXiOIMpFADxt96y774RWEjzXDXUsbTEKYpWwVf1+lRahp2oeAtOW0ttTmE5YFTGedn19K+nnNVoezoztI7o4lONoS956FXVNE0fQPHWoeHy7nSbwq6IT8qv/dPtXLxwQaV49T+xLCI3wY+ShG5QOm413lsuh+IvLkivLcyKn795pAJD6ge9cJ41tNP0W8haykvLcSqPmcbmBzxyO1dFFt+5K97WZ3060avu3d7ap9+5c0nSdQ1XXdS1DWbcy3kOGdg20OP8Kq+M7u7sdba/0oXNpFJEBAqH5VPc1qRavZLaEfbGUKi9RkyOf73tU8fhbUj4dt7zW9TiRZ7gJHAD85X19hVc6jJOWnSxUZRc1z2tskR6Lrd2HN3aOtxJbWrJ5lwfn3HqAK4X+yJNVuJbz7W6XMZ8xon4K++a62XQ7prq607R9RtfsgImd5ZAGjb+6D6V0ei6Zca5NcaPfaXbxvGBGblGyxBPXPSnzxp3kv6RFXEQoQk4v/MxfA/hC48Wa8Lm/Y3QthiW6c4Xb7e9X/iPqFlo9gLTRoYmWBsCMHPnHPXHevUfEtvaaDo1r4b0VdtzMN2fbpuP415F4y8K654NlgubxI7wTygpLHz8+eFI7CuahiVXmpt2T+Fd/M8qkniKvNUei6HPCJ2u4ZBCGaNN0ttACFQ/TrmrB1OAaYZrBG8tiYpJpGAMZPbFPkgl06WS/wBRu0srudXMarz26fWszTrKUaXJALRYWmAlE8gJ3v2Artsmrs9inBTeh1Oj6k2kJHZD5YHIniuJufnHZj2qaTxJ5l7c3SqUNzhAqxloz2/yax719XGnqJbZHkWP97GRyB64p+ha4gn3acphuA4DwzJ8qj1rNwTvK2o5UG03Y0rfSbdmng+xqrochjwGzyT9KoX+k3baenmG2WKF9mUOWYH0q7NfSTPcS3E6pcLGXgEY+Vmx6VmaHDJJpNtd30M9k0U2JCwIHXqKzd1qzjlB7tmJ4emm0jVrm7hvbczEhBvGD9MV7/8ACPW5ru9vbK4JcsA+cEYOO3tXznfadbPfXbqJsO4eDd94n39ea9W8LeJ9Qh1KylYpHNGkYmGzAK//AKqxxtP21NxW7X/DGFekpRT6o9P8F+H7Cx1m/kmMb6gHyEYDKD1FYvxeGmaZbCa1WNNSlONsYBY/hR8Umn0S4XWNOG2WRf8AWdQK8cvPEUV9fSzakJmmuQVjk6kP2wa48Jh51prFc2nb9Awr5qnM5bf1Y5fxGbyTTo77UoPKiZsJj0HrW3ox1bxRbWF1ZWiJ9llAJXKjbnp9Ks2GmSyaHdWd3dySLIPM2SxkhdvbPatPw94gNvoF409mIbZ2wREcEYH3lr2ZSfLaKPYq1m17i2G65oqRajcxXtwsMsqb4YlA24xzzWb4fsI7H97eOHV0ysancwYUSz2V8i3E2pFtPA8tDNgMrE966bQfCtvHDLf6eZbiZYT8obIJI7VDlyRtJnJKTUdxml3l5/YN4kxWKec4Djqims4eKFttIt7cFNtodnmAYEhJqjpn2u0uZoLq9dhM3NtIu0qPrV228N2Gs3yQ3crNZxZL+Sfm9s1LjCOsg5qavzI6HVtXOq+H4ktr5YPs+Bvxk89sd6ueEtYutUVtO1mMywxgKh2kE59K5iez0+7e7JM4srbCQgDDs3uO9eqaNdrp/hVJbawkuLxYyAzL0rkrWhC0Vd39LHHiq0adNpLU47x3a6dYeI9Kj0pkieACR5N3U8EDNe66Lc/bNJtbjOfMjBJr5xj0GyuNTje6uZrq6nkyUjPMZJ9K+jNBs2sNHtLWQ5aJAp5zXBnEYxpU43u13PKoX5rsk1PT7fUrR7e7jDxt69j614X4o8zQNQnhu4gTH/qcDqK9/rn/ABb4ettZs3aWPdPGpKEdfpXn4DFKjLln8LOrmdN8y+Z4oIBrFtHe2CSNqCZE0J5J98VN4d06LWLa7m1DT5I/soO9Qu38amE4ttZLRwXKTEBPLhQl8j2pL/U9W1C+e30hJIFTm4+0IULj2z1r6CSlay08zrp11PSDNTTPBPhnxBo39ofaJLGaEFSwcLj8680uYFi1NrdLmaeJM7cjP413WpRNo62Btp/tFjdf65EXdtP0FQw6HCJbjWJILwmM8SiImPHp9KKU3BtyldPY6adXlbu7o5nRPHMth5tleQpLC2V6YIHfNLp2kTaneyyWTMyEZCxjg+1eiabo2j6zFDctbxlG5bp8xrRn0qbRC4s0jggx8qkc/nRLEwUmoq0mE8TBO8Vqcpb+FdIjs431NWScNgqvVPfFc/qDWtlq39mi9ElmzcOOvPrXYaGLue81KTUrVSkYyHI5x61n29hp1/E88CQRTwkbGkA59OacZtSfM7kRrKL5qjK2NF/5+5v++aKf5Nz/ANOn/fVFacvmL+0MP/N+RxlxbyXAim06dkJzujblw/v7UzwwkOjeJUXUgghnP7wlv4yf6VevoRaahItq+wErHM7N90scZApviPQ107ULOwnK38JO6OTd0bP3Sewrpcvsvqeq3Ga9m+q+f9eR6U/iXQ9JTfDLG6R/fG7LN7j1rj9P8S3Oq+fHp+0RSz7pHJ+Y+gFcvrOjo1zBbW6CGFjvbymyUb0PtXJanfXnhDUPO0+cNkYSRTkE55zXP7KlRpyqSe3fyIVClTpOd7u19T3OXWLJ7q4nuJVj2R58oHHA/qa8r1/Uk1zxKL5FRbe3UF4gMfKPT3q7pmpXPiGG+lvE8ixmk8zKDPJGV/DFJpFptj8mTyba3gcTFzwzt7nvW1GMYLmFRapJy62t6L/Mr391A9rb6bb21x5Szee8mzJA/ukVo6df+VNJbSyO1hccYgG6QH3PYVp3Ntnzru2mMqSsUJHB5GDx6VT8LWt5oZ+ztGnkXD/uC33gSepqm00c86it7v8AX3k1tbWq6nFapEtrb7g/nyDDHHqe1dJa3NvbXTWNoCIiPPkZeWYD39KuapZ2WoWdxBLZypexMGWJDy/+0faqn2KDQ7hZWvY0muQsckbMNyL6D0Fczmp77nHNqau7/wBdT0WGKz1LQtNe+ZmtsiVD0yw6DFc9YWIvvE1pJYXE0hWcNKn3lVQc9e2anl8U3Fgmm6QtnHLJJIIomJwAvQNn1rrbW1k0608yKLa7H5ljGQeOua8pynh07/avbU8JqzdjpIjOZpPMMflfwBSc/jU9c9Z3d0XJuCqgHAGDWu93Fb2++eRcgZwDyfoK8WpScXY66dVPRjNQ02C/QCdclTlT6VxutWkWl6jI8ltby2ZX5kfliPYVsv4w00DaJdrnqrfeU+46iuW1HxN9u81J1s5ULbAmcMR6g16GDo14u0l7pnUtL4dzEsfAngDU7v7Qq/ZricHbEkgXaagg8JaNaxy2eoRahcW8Mm5JpBk59AfSmWOsWUN1dPomnebfhsBrkHauOuK6eb4oWGlrbQ65CEeQgFovmUGvSqfWIP3LyXa+qN1VxEbJt/qYdj8ObJtMc21oojuJfNee4G2SIDt9KuaH8PptRglt9avp7u0OTDOnyMnoFPpXV6L8Q/DOuT/ZY76JJWOAkrBd30rsVxtG3GO2K86vjsTTvGas33NPb1Zv3pfhqeVxfCHRLC0uHE0+XXdKXOd2Oc49aw9K1zSz4msNCt7C4trHzd8ksv3pm7Z9q9J8eata6XpbrcuAJx5fLYIB7iuO0HwnI3iiPUr64hGmRxhoCD80h6/kK68NXlOjKpiZPrb+upx1ZuUuWTJNT8P3WrePZ9S02ZI5YUCiORvlIHciuT+LVx4kEudVngtyqf6PFCcq7Z4JrYufGrWvjW5fSrKO8lZvJWTdhcdOor0XUvDVn4h0pE16OOa4BEm9P+WbjptPoKJVpYSdOVZLlsrdzrw0lFJyR8qaBYS6xfbLm486/mYMts3I59K9FsLU6RYtFLH9snVtqnGWhx2rlLK7fS/FVt5y2xVJWAki5I55/HFeg2t2mpX1yukkGAOHkcj58+gPevXrSenY9tvVfy2uWbSytNbtjcAs14xCvk4z/sgd68w8X2aaf4rA1GIxLEQESE4Lf71ewzW1jaaQ7XcjWVwHMqsAMjHNeU+INXsLzW4zJFLds0gZ3dT90VlhZNybWxWH+N9v6+RZs0eS8iuVhSJpx5UcbfdC/wB4Vs3WoiKKTaqS2pcAg8/MOlZ/hmxAnuL9JJvLuZSLLzV+4PQV0eqaGr6dHZAPDd7dzLEM5+tVUceazOLENN2Z5tqVjcSXML3BZbQkuko5EXPC1e1GO5i8S2ot76J7bygzgNwx64NbGuW8XlWmlWEr/ZYvnuJNvGR2HvXP3Glh7SeVy0cMJDo5HU9gaqOtjK+l2fSWjGHxZ4GjSdAPOhKEMM7W6V4J418F3OjSeUqtlMyYP3fqDXu3wqWWPwRpguF2sybjxjqayvid4t0fRSlnqOmTaldTAhI44yQB7ntXjYLE1MPiZ0aceaLb0PPp05zklT1kfOOl+Jta0/7RaNfW7ROdxEynKr3x716p4G+G17rXhj7adRgit79GKRCPdhDnn2zXGavBosEFu+oeHrqATNmMQNvMeeu7047V2/hP4i/8I3pkOkWdv9vhXi3+bDID/Cwr2Ma6kqd8KrSv5HocmLircvrY4HxL4R1DwT5i3WlSXsNvJlJY1JiYHuai8N+L/wCzSi6i88czyDyjApKIv+1XrvifxVret+Hp9Li0uCO7uU2vlidqnuB611/gWCwsfB1rY3qwJNFDi5jfHJ7kiuWeNnTop1oXlfo/x6mbxFVNqsjyy+ayuNUXUb6WFzIoVTHg7VIxlq0LDQoY7PUJvDr+ZdMAkwJ/h7YrT1nR9A1Mz3Vi62yJkGJF+aQCqPhiHWHuxfWGlzQ2ZwkY2HkA9TVc/NC6drdH+RhPG3jywNLTfhxqrWiy3VxbRyqQyx8np69s1bS7u2ubpYX8sxoFwRgOw7V6Ib5kt1MkEnnEfcVSef8ACsvw9ptwYHk1aCNJWlMiqpz1PevIjjpuMpVkvL+upy1m6zSTucl8MvC8w1K81vUo/LeV/wB3GBgHH8VeoUgAAwBgUtefisTLE1OeRvTgoKwUUV89/tG/EXxh4U1eHStJ8nT9Ouod8V7GN00nZ1yeEIJ7DOCDnnA5yz262tNMttenaOSEanPH5hiLjf5YIBYL1xkjJ9SKo+OdL0/UtGkW+kELqP3cinDA+grz79mrwzcWfhO48R6vLLNq2uN5nnTMWkEK5CZJ5+Y5b3BX0rQ8aeF7ptVfUtQ1C5mt05gCniI+4ruwS9rWTlOzX9WOateEeWK07jrPRpreziSF08sxsuZB970rq7DUY7Pw1HFqyxxyLGY2QEYYdMj615zpviLUBNb2duHupJH8pVA4yehz2rR8ZaPq8d1pN7rf2eTTo5kF0YCQQuRnOe1erXoc81Cq0uq7mHtaiW5S8F/2bA0lrFdbbqCXfDGT8pFdvHb3HiXzZJwsaodoGehqD4kXOi/8IrLI8ls08abrXYwLBx0wK4zw/deKrTw/NqdgsMkM/Misfu+4pWeJh7aPuyvZX/Qp1pqT1vbsVPG07WMi20VzItzykuOmPerPgTwxca5dE3UBgsLZxhv+ew61mWtrL4kv7WHe7XUzZmGOPxNe7aTYRabp8NpAMRxrgVrjsV9VpKnH43/X/DF01KppNmb/AGFpv/PtH+VFamBRXge2qfzM6fZw7HyzfaPcCwW6mAZJgEjIbkv6mtDwrBexSXUGo20csAYvHAjZc4HD5P8AkUujyPFokl1JKwt5m8vcT/q29Me9at9YTzSxyWskX2mWH5ijfcx646V9lN/ZZ9FKpzx5br1+4rRTO2mtczWGyOdsBkOWUjrmvH/ireB9dSyhRIobdAxiT+FmGSCe/GPzr3Lwfbs9reQEHZy0uccYHOM186+KdM1eG7n1HVLG4hiuZm2ysNyZOSFDjgnA9e1eRmtZqm6cVu/wOHFzteKXU7X4TtBJbTTtK/2i3IiaHGQ6nlW9iPmH0r0yK1t7y0nkmtjFZDlg6/NG3uK8x+Dej65a+I4Lh9InbT7uE8zDy0fjcjDdjIzjkZ4NewW+nG1tZpteki8yScvJHExOwdhz2960wNdyoxjK91oRTqXiu/8AWxJd6NptyLO4Fy/2eZAruo2lAP8AGofD2mPdSzMk6xwWw/cvKPmIH8Rz2qK3vUAurPUgyQSZ2yqeQp6Ct3TLiawli+z2c5torYqSyD94PQ10Tc4xaT1InzQTRkRWGpaTfm5M8dzPdSCN23ACMHvWRLoC6t4xbTbi4PmFw8roMgL6ZrqPsk13vtbd42mmbzN+MNGvoa7LwvplvpF0z28DTG4ULLNjnPoPasquJ9jFy+1YwrVuRW6s57VNMjuNTtLfTYwz2RHkg9wOvNel6bDLHp8Ud1tMoX5sdKit9JtoL03McYDYwFA4Hv8AWua+J/ixvDWlolnC1xfz5CRKMkjHJrx6lWWMlCjTOSlRa9SHxxr9voxS385YpJflWQnkZ9K8w1Lxbb+GGnhjin1HUJWExnZ+FB/z0rk1hTXr+S8vr1rm+QNuhziODHQc1rSaHYaZYvDDci5u2g86YFckA9gfavoKGEp0IqD1fU9KhlcW/ff5kRXcs+taddyGCRg7q4PnM3fAHUVZn8Q6QLm2gtkmj+QOXdcsWz39DVPV9YawsY/7M1K2S2iwyJKnzf7v1p+hnS7jHiHTpJLu7mfZPpcgHzk/xqPSulrS8v69T0PqMYK7+X9dzbvIp5tPt743Nq+mCUGXyp1DE+lctqMhju/ttvp7yQTrt81n3FT6DtitDxDBDqELRWWkWlj5UvlGJ1K7sdal8OzW+mJHBLpkV7GufJ2Pwre9TDSN9/69SY4dRi5Nf199jAh8L2ep2K3PlPa3aniWOTgMOQCOoNdf8NviXcaBPHYazcedpZIG+RstB2HPpUPiW2udNtYrxLKznIzJIitkAeh964rT9T0C4W5shA0KXYMkrkcq45wPaqlCGIg41FeP5HPisI61LnhrbbyPcfGUuleIJF1TzFuLFItqeWc7j1x/9aqejavraeGb27lslkggJit4wpLRgjGcegrhPhZFDY6zZ2l5MzaHeyh4VPB3jp+FfTghjWNkVFCt1AFeRjqkcCo0bcy6X7f59zwVTc7pvVHyHeT6hZSQ3Nq0E+nyShJnkzujOedoHf3Ndr4f+JGuXdpqWlzm1gto0ZUmYfvCpHb/ABqne2sWieJNdghWKXTDK0MsUg5YnuPeuc0+zS2uhLLFIlsSUeHq5T+8BXsVKdOtHmkr7NHbhpKSceW9ilq0QmvbGCznV7qXLmX7wB7Z963rLVNU0PT3tba382J2AmnZCpD961fB/hbTY4ni0lZp7so1xm6XGQOw967jxhJ4a0n4XajrElvEbhYCEjkYbjOflUY7/MQfoDXLisbTor3k2j1HiYQVpK6OH07xFHf2V7eXFrLdJC4jwXypHc++Ky764k1meN7a1C2LAlpEGDj2rlfhUser6ZLFPC1wdOYytEj4aVW5GR3wQf0r2EyaPd2cOm2tuqy7f9HWI/LnvkilRxEZwjUgt/wI9romuv4EehXj6etqkjg2642RSJtkCnv9a3NTbdc3Uk0gUsAiSJ1APes3xDplnqsdpd3t1HA1spi9i3QVV1AW1nZQ2CRzpuIMly+SFJ6c1mkptSW/U5ZWb03K7adHpclvACTJdhySx3LwO/vXJWuojWbvVLKwkle3cKhYx52yZwMVu+JWntpbCLTIhPaE8Rhstk1fv9di8Pm6uUtbW2dUDxpj/WSgdPwNdMLpXtdszalKSjDWT2PWdKaDw7otvaTb2lih3uW9utebWWqXuua1fKbqB4El3odvK57CqWgRap4j0G61/V7xr2+nQokEeRHbL/tCsuLxLBoNlc2NtbKI3YAyImS/PUVw4fC8jk95vfyPWwmB9lGSjrNaeh1Vr4YtbDVry68RTK3mkMhjxg/hWVovhTR5fHFtqyNIpYkKMYUt2zWpoV817p9zPcvGbIc/vfv/AO771f0oR6wl09vJ9nKJuVW6j0IqnKcVLmfl5G0Zyi22+lvI1prxPDMV3Mum+ZcqGLTHkewHtXn/AIk13UJtJ0vUWvog7yktbwDJC+je1VrbX9avdI1qxKF3tWMaysM5Hep7XV9P0LSbAR6Zv1R4yJJmGVeqp4f2b5mryv8Ap57GtLD8j5pK7/r7je8DeI9L+1pLPYHdNlWmRcjHqRXsURRo1MRUxkfKV6Yr5n8Daxa6zq18Z1e11CI/LHH9xx3r1T4W6/BNdXehxNKRbDegk5Kg9RmuLNMHe9SPTc4MfglFurTXqej0UUV4B5IUUUUAY/ibXY9EtYtsTXWoXLeVZ2cZw9xJgnA9FAGWY8KASaxrfwNYalp15/wmEFvq+oakFN27qdiYHyxw90RcnBBBJJYnJreh0W1j1641d/MmvZYxCjStkQRjGUjH8IJGT3Jxk4AA06AI7WCK1tobe2jWKCJBHGijAVQMAD2Ap0qLLGyOAyMMEHuKdRQG55F4i0C/8MamL/R7YSWsbGRO+3vg1meIfiK+t6PJYz2X2ViP3pJ/lXt0iLIhVwGU8EGvKvH/AMPZLm9W80eIOj5EsW7BHoRXvYPGUa8orEr3ls/8ziqUnHbY880zR7O7smv2uEMkXA3HGFrpNC1XX77RF0vS7UNaspBlGMg+mPQ+orQs/h1cXMcEKxtbwtgzAnANeqaDo1pomnx2lkm2NR1PU11Y7MaUVZe876LsKFLn06GB8PfCn9g2bXF2CdQnA8wk52+wrsaKK+crVpV5upPdnZCKirIh2/SimfN6UVNij5Y0zUUS7hD2yzWzMBIhPI56gVvSxWz+JIbrSA4kP34WGE6+tZHi3wze+HtXYBZCyHIOMjHY5703SNcuJH2rcJFchdu9uNw9MV97KMasfaUne5pQxkqHuz22OxmW6bVbo6YjQzJEWdUGUcdq5b4v6VrHiHQrOC20hkvFuFfy48KCgRwW5x3IrTj12908oLdS6Kuwvs3Zz6V0chl1bT0d5JFniyZA5wcDn5RXnV6LnHklonpfqdkqsJpbWfXqZvhHTNSsdL0C2uj5V3BborpL1iAQDj1OeKs2ERurm+hku7e4eRi1wDyQB/CB6GnyXa6hN9v06YL5KeTibhSap6jMItGl/tMWipGeDDLt2D0OOtEItKxXMttF+aNHU9VjttJtrTT4bOVFYLLkc7fQVDZ+JGnnJ04rc3kpELR4+VV7Vy/ie3W5uoodPHk2flgHDcZ9c9xVrQ4Lt7yOy0lWjeNgxkxnec/rWyw8XC7/ABMcRVo04e7rJ/1qelabbXNi72dqkd1fTEGZ8EhAeMZr0WFNkarxkDtWboFolrDJudXu3Iafa2cNj9K1a+Vxdf2srLp17nm0o/ae7A8V8/8AxN1YyapeXFrdDziNqvs3BE54Hua921O4W2064mYnaiEkr24r561a0neO6XUEij89maOQHhiRw1ehk0FzSm/Q9DBU1OqnLZHP6ebW6gtba9sRbyTjb5qg5dzxuI9a6DwpDpRvZdNu4rq7NoGSWXBGD604W+l2VtaxW9w7X1koW4ll5TLdwf5VztjYi2W5mu7+8jvPNIiaMcMG7mvf0qRdro99JVYNRdu339Oo7x7Nol1qVtELZra3EXlpGOu4n7xqhb6S/hLVYZ7CZrkypsSUDIVm4wMd66uwge9061hEUBurWQhri4ABkQ9cimJpWtWWr3dwYFkYIXht4G4UD+IU4zUVyfmHtbR9nuktn1CS0vtK1C20rWbieS3uU843M642ue2TUDaJIdPvn0USuyABoWO4Ej+Jan1db28a3nuGnvGlZYzbsc+UB3PpVm0Rl8UXjafqUMNqEDMucFe3ArO8lHfX8DndRx107vtuYdvItnp39g3Dq8t/zJJL8hjapza6Rp9s/naZ5rxxlZLrON/H8J71PDbaPqWtq+oPdbkVgGlGVyOQSeoFSyXFm9ysVuf+JWikz7jkA/7Aq29evmazlZcqb11fQxdO0LUNVtY9YsPM3WGZUVhjKrznFfQngnXpvEPg9b5wouQrI20fxAV5HFq6waSn2K8kEMUxjCAAFQf7w9K6X4T3t3ZTapa3atFaEPLE2MIT7VxZlTdeg5NK8Xp3t1R8pirwrSdtDkLHQrDXfEL2mr6gYUjk82cOwUAg5613HinQ9MtNQ0eTTzuhYl2nWQNx9fSvK73U1HiSKUxmZ2l/fxKv3l716KmmXd0ialpUYk0p4jGIZOChx1X6etb4qEoSjNysrbdP67E4eVpWZdtrazvbORP7QnEsD4G0Abl/u15L+0jq8UUGkaDaJHCCDeTxqckHlVz/AOPHH0rsLSC60uwGk20c7yRlpjcMcBG64964fx74Tt/Eljq3iiTV7hr+CLLRtECjhE6L0wOPfk15uOo1HTfI7o7Zwe62PPPhrqsmmeKIEjUOt5/oxRm2gliNvPbnA/E17z9jgtZElljS1triJtpSXHz98e1eL/D3wK/iW3F/JcvBaR3PksyYBBAViQT3ww7V9BtFb3OjarPIYALODybWOROdoHLY7k1OWudOl76917fPQ3otxVnsyjZ27G3udPe1laaaLNsH+6NvU59aqW2v337h2jiltpF8gpIMmNxxuxVDVvFUlj4R0if+0MzxS7DCFyQuehxzVG30298R6/Hcef8AYpZSJGhjH3VHqPU160Kd7ue2v4Cry9lFtmzqrW93LbItxHavbzqstwBhSDjIX1NUItN8O3PiOEa7c3zWguMxRdRIc8E+xq8mnm98S21u+lvc6CAVDoPmlk/vD0xT9WaVZI9HsdIEs0Eh2yOSXVeuc9zQ5fYi7aeWh24DCumuefxSXlojZ8dGXw6iQ+GbqKPTJRuuIUYM4/CubnC+KLiKXSY28uwAeRsZLnuMfhVS7gafxEsal4PtyqrPN7dRW/ba02n6rd6RoMMc5nwrSIP9WoHJqIwdOCS1l3/zO5J04q2s/wA/Uw73VLi8vLW0VEiVJBmJcjmsPXvE15b6ymm2jN9qQ7WMXQ+1aPiW6vnl8nRbdpbsjE86jOfTp0rqfhv4Gt7dm8Ta+u6WM7tg+bHqcVpOpCjDnn8l3Z0ynTp01KS0/NmT4VljF1dgXD8p5swUc7gOlbOsyafeeGre72PBdBwsbkgBtx71a8VT6Nezm88MXXlXJzHMoXCuD61iT/ZLjRxpkzn7Rb/vEI6N361jF+0tOzRzRkqqjNaXZtL4NaG82Wn2aExsrtdq/wAxJ7VrfCaX+0fEfiDVZbeOCG2xa+YON7L95q8Z/tOS3svssV7cXeovLkxFshUBr1fwzq6x6JdxaQ8LadHDmcSEAyOR83NRi6NT2Ti3e+n5X+8xxam4OMndv+v+Aegv400h3vY4ruP/AEeMsXLDGfSvO4/ibrKuot7UXMLN8suw7CPc1T8ZLodx4VsV0aFA9wrB3BzsOO5+tbnw18KXE/w+tYNRmjSF8uQOSBk964o4fDUKbnNbu2pxxwmHpU/a1LvprodzH4qsjpUV1IcytgGFCCwP0rJ1TWta8qe6eOKx09FLK7k729K5Twenh17vUZLu+b/Rn2oXcDp3HrXUxa/oPiHWY7OSVZokG1VfG12/rXPLDwozfLBtLV6fkYSw8YT0Ta/Qg0jXfE9xax31vbWuoae+MlTtcDvgd67PT9Utr4lI3CzqMvCxw6/UVy8ttDp2oSpp15cQWwOZIkXKA+n0rH13V4L/AFbTfsMUi6uGOZYuMgdj61E8PGu7xjZd+3r/AMAylQ9o/wB0j06isfQdcg1RpoOUu7c7ZY3G0g+uK2K8ucJQfLLc52mnZhRRRUiCiiigBkMsc0SSQuskbDKspyCPY0+jp0pskiRIXkYKijJLHAFAttyLA/vUVnf25ov/AEEbP/v8v+NFb+yqfyv7gvHuXtQ0+11CAxXsCTIeMMM4rybx/wDDC3RRf6LHKxXhoVP3f9r6DvXsdFXhcZVw0uaD+Q+lnsfNOiW13ayzteIwh6FcHG7+lbkNzeCTzmSLaUKMMcEd/wAa9kl8P6fK8jSRsxckkFuPp9KbJ4a0qRER7VSqDAFezLOqc9ZROV4fU8Rur1rhQirtjDbgFXAY1Qla9mv08u2KuD8rFcMte8N4U0gkH7MOOeDVu20Swt33pArPnIL8kVX9tUor3YD9h5nkWleE9W1yOSadDv4AeQ4DCvT/AAx4YtNDhXYPMuNu0yNyQPQe1dB9KK8rFZjVxC5do9jWFNR2I7eCK2gSG3jWOJBhVUYAFSEZGKKQ8155pscn4wtYtI8C3lvpyC3hVNvyjoD1JrwrTrl9Qv31eMtJHbJ5ccO3Kufcf0r6N8TQC40C9jkUshjO4DuMc14Rounq8wcQynTUuEaM4xubPWvocnlFUZLzPVy/kUJSe5Vl0TUbzT73ULq42xOVla3QfP8AL/EV9K6m30yLUJIPsAZ7NVRpGIwJD7Z6Gut1awtjekNa3JndQEnQEYXuD7VxkNzewSXFk8dxcpZTeYn2YZ3p6HHpXZCvKtG8dDqVWVZXWlvyLnjOxsbCwuYm+Sa4UllX7xx0x7iuY0Szv7TWXbU53uLJbfzH2N8yLjjn1p7+IZPEJttPt9KupNRjuPOQNGSVXPIJ9KktrG2kmvr+2iFvJC37yOSfh29h/StqalCHLN6lRi6cHGpv/X3Gdq+tW09tFZ6K0jFm3s6jOR6HHemWWmW8lrHdfZZDeAF1hH8QH8RpfsOpWCWX2VIhp8snmXMqnGCfT6CpI9LmsftKwXJmjmkzIInyAh7A+lbaJWix1Uo6Qf47iwy2E8Zv41e31ENie26KV9QPen6zottq2tIujaG1sspSVZpH4JHUKKvX+lSTXcO7R5XGFhglwRx3Y+1asmlt/bVneTapGXj2wpa25wsZJ+9n19aydRJpp6/12/U5niPZq97aP+tDQ1a20aPw8lpJbCGUzKZpCu0gA9at2Yv9U8UyWzxMNPNiRbDG0Zxwa6DxNaWFyqW5mtyLdfOk8wjJxzUHgXWTr+qSzuigwoVUrwAPpXme2bouoltffpfax8zJ+1nqeHQLJo3icyPbILiNyjhxkDntXvenaRd3fhaC2aZcsQ+4cAqeorM+IPgtL121HTbVXumOZAvXP94e9Saf4ubTdAFtdWkralDGVSJFJDYHBJ7VrisTLGUoToL3k9SpQSl7xl+KNJ1CzWS2Msc+mTsqwrGhLoe4Y1yeqXX2Dw1ren/Ziou7KaygDcYeSMqOPTJqx4SvPGoimliTFs8plHmqfl7kDPTitK60O9uDd6/qVtPcXMjZhgVgUUeuO1aqCinSqyTXk9WzVYmUVZr8Ty/4b+GdYg0ibSriNRbPO08ro2cfIoA/Q112naTqepwzadd3NtZyuwKOrZcRjsDWkPB2o6raLJbS3cTSuGuU3hAPp+FdxYW+heHmP9p39s11EnKmQcL705VaeHp+zpO7WyW5osdNK0Ukcp4Y+Hum/wBtXFtNazvHtD+cy5Xd9a73SPB9joDX99beZcXcsRAMnOAAcAVxOo/Ey5TU5Y9NUS26plY403EDsferum/FOJbV11oR2k5UiMOCpJx6GuTEU8dVV+jtdXJ/eS96pFs47Q/E97e2FuumwNCLdnzHF80hyfmIFUr0ra3NlLo+qXCSNcDz45v9aFz39K8+8K+PL/wzq0n9mRwks7I0zpkDJ6j869F8DW+myrqOoapc/wBr6g8TStFGwPQHg169Sl7FuVtPz/r1PrXGmm5r4fzOi3WWn3E+o3sizx8m2iPOGPcf41gaPFD4X8O6v4nkOy8u3Km3zklWOMgevNMEz61a6XfeITFpuhRqzK0f3yQehz1rPfxHpy6vGkttJPp0LfuiwOX9zWcabd479/RdP8xxpPWD30v10vt8yx4Y1O00yFZLITxpdlVLyLltpPJrV1bxPfaRdXOjWLRPbysAZWbkVb06TU73R5by3a0FxPNmCN8EKo7YrjvGEy3RtNIu9I8u6M3mvPb5AY5601GNSfvL+u4uRVKl5r+v+Ab/AImexttAaW2ZBMpzKQuOcdqxNAk/s3wtPf3FrLc6pfp9mtLfqQx4DEfjXXan4cZdDtbO5ubaR7hd28t/qsdjWV4Yv9Tn8QLe6Za27W2n4hLyghT6kGiMk6b5df62DnjGlJp3/A1vCHw5TwzoEkeuQCXUb1DumBz5Q9AfWuRvrA2eoQ+HYFeWyuG8zzSPmXPXBr1HXtau9YjSaNdqwg7I4TuL56k1mxW39q+HbiSzKvq9vhjz9xeuMD2rno1qkVz1nq39z6HLhqtRN1avXS35GfoPhO0SaPSPtzLEz4ZZOrj2r0vU9FjOgHTNHufKa2GFG7OPY1wmnaAfEHi+yvluPLls1EjbT1+tbVodU0TxFrTSNFLBcOGMj9elcmJ5qk1yz1SvbzM8UpVJpc2q1sed3Hg17a8vLXUZjawIpeWZOd30PrWZomlpZXVleW90409pNoaVcOcH+degSa7apfy24eO5W4JUiTlR7VjeIhqF5Z2OmfY7eNICZVPQMK74Vaj0lszuhXm/iW/3WPQ1vrSaG4sEn8uRoS+9vl7Vk+FjD/wjS3jKsmqBysUo7sDwM+lZGoeHX1PwG95cK/2mNDsMZ5C965UfbNK8M20NjdBY5GDLvBzuB4rjp4eM4tQlrfX5HHHDqakoy1ukdnpqTSeKrrUdQuEtNRiAMsSnC4x1/KvVbO5ivLaOe3cPE4yCDXzbqVrdz3FxrOsXYFxOBEQG9q9A+GvirTdEsINF1a8SGUnMMkhAVwT0z61jj8HKdNTjq10X4nPjsLJRVRW00dj1iikVg6hkIZTyCDwaWvAPKCiiigCK7uI7W1muJmCxxIXYnsAM1886j8RpfG+uSaZbZislbCqv3j7muq+PviO7j0xNB0dh512CJ2B5C9MCvJvD2nDSLOO409o47lcBy31r6PK8HGNP201q9vI9XLsGqidaorrp5vudz/wgx/56SfnRS/2/rX/P1b/lRXdet3R38tbyPoCiiivjj5sKKKKACiimMI2ZWbaShyCe3agB9FJvX+8Pzo3r/eH50ALRTM4LEuCD0HpQjfKN5Xd3weKAFZQysrDKngg+leWa5oN5pi3MNlM9qiOr2pxuSTnofevVNw9RVHVbKDUrdYpZGXawdSrY5rrwmIdCWuz3NqFX2ctdjyzwz4p1BheXLxyS+U/lmGXpk8cVLPqcGm2+qXNtZPbajApeT+7txxj1NbOr6Qbpbi2hRtPWLmMyMCk8nY1h6fepHd3N5qMsd1LEFjmwuRgfwqO9e3F06l5RXy/LyPSi4STaWnZfh5GHpjX1/pkN217Z6dBErXM1wrfvWXH3ce9ZTQWd5oi30UUkgJwrMcMXzwQvpVpbDXb/AFVSttBZ2ImEiLLGUG0nofb2roJItL0/UlgmITUAwdZwcwgds+ldnPyPTV+R1JKDutW9bLt5/wBfIyLfRpoLDfDJLJc3Iw0cyH7vQhR61c0zw3PbF5ZLNxYq+6GAP98jkZ9K7eNby+025kS4heaMF4ZIsZcY7CuY0m3vLzU7z+y5LiG5mjzsnfKL6n2PtXOsRKalqlbf+tDjdVyTNmKLXru6ku5JEFvHCVNvuyQMclTU2g6dpeteH5IXt/sqQSfupkPz7vU1sG+ZIZIIhA4WLyic8sx649qgtLeHQrEEzI1wUyLdCOtee6snGy0elrf1+Z5GIq2jZHC+KtQW/smtJrR01KB8GYDAkj9TXe/DXRRpmjfaHwZrnDZHZOwrH8P6CdT1a4udRcm2BBVQdvPpXocflxoqJtVVGAAelGYYqKprD0/V/wCRhRh1JCcda5DUL/8AtHUriz0SzjluI+Jbl1+RW9M9zWN8SfF62scumWMo804WR1bnnqo98Vo+EdukrY2lvZ3Ultcx+Y9zt3KH9zWFLCyo0vbSWr2X+f8AkKc+Z26HW2VstrZiJju4+cnue9c34V1nQ559S06xZRJHcOrRn+P3HqK0PEdw9zbmw0+Q/a5Ou3oF75PbiuQ0iw0Dwbqct19qCwngq7gsr+uPSlQoqdOTk3zPZL+vuHKV5JROw0vQLLS0nkkdnMuS5lbgZryz4gaHoFkXvL69njaI7bdEOfOJ6KfWtXxzrV/rs9tHprPFoyNukkCZZyPUdhXF+M7aXWYLUy72nLl4HQ7guB8u4dq9TA0KqkqlSe+6OzD4dxqRb0X4kPhhGgs7/XQYoIYwI7lUGZAD90DHTHWl1K5TWLe0tddijkLMQrhMbg3A5p/ha0n0jSdQJM8d3f4hl3qWCnPXFa+uWLx3+k6akgu51jyZB1b0Ptiu9ySqXfy+SPYioQnaO/c55tIutNjm0+Kzgt7dELlZI8mX0wa4mLT7uydrm2STTJWYPGxz5M2O2a9avYtVu762F3e26TwsUSKHOcY5JqzcWNpdaM+m3sgkEC+dH5xwxY9F9KuOIcUr63GpOLT6vt/Wp4/4lutZ1i+ha9aJUhxm1g5QZ613HhrRY7W3WXUZY5lkGIhkDYPeodQ8LXGmXr38dqbUzbWhj4KOw9fpVaC3GqXDWN/Fd2LHkXCg+WfUnsK2cozhaD0NqmK5YKL0Xdf1obvhuVZ7/WxJLC0dtEUtnjbIywOAfxrO8RWur23hvw9qFxaPG9sSXeMFi/P8XtXWeFPCcnhvTdRtX05dTguQDFdWrBzn6VyfxC1fxVFdxWuk6bqK6TbnLeZbOAfVenSuSFRTq+41b/gf8Hqa0qsKlReyaltr5W1/MfJDY63Dq2oXV3NbzzIJLNEBAY45GK2vB3naT4aE1jGuoX9zIA8PUAA9cCovB3hzUPFkd1OYH0ywRcwhxt3uRyAPTNPsbW9Fp9ojcadO2bcBTjkcUTlCV6V9rafoTV5Zt076K2n6aGvqN3dyeII4La4it55YiH2JkA+nsa0/DXh+PwJoWqapNdNPeaiMFXbAyc4x+daHgHw3aaFpeoXl/OLrUGy00sjA7cDgD0rzjS4r/wAUajOusakY7aK4yiO2MLnjiuNNV+anF2hG19N/Q50vbJ0ouyVrvv6He6TYf2O9jcm7EN2Bm4HGWBrnPGGtINV1COGZphNH+RxxTNb05m8StcQX5ezEflqgOTwKyIEfU75bXUF/dBCYZUHf3Nb0qSv7WTvp/wAH8DenS5pe0k7nN/D62k17V3trp0DqxUMT/Wu31aSTw/qVxpEku7CboZG559M1zXhLw8Iri5kt5S11HNtfqFXP8QrrrmPTr+wjubydp9XjfY0KkFsVvWknU3uu3n39C6zXtbN+6WdNu/EFpDbKJo5NPl3JJFt6N3Fcfrd+Li+it9Sk8q3kLLCEHKEetVDf30OpS/8AH1JbI2I17RirtrpcetXd8HjYsqbowwxlh3H40QpKm3KVvkVCjyvmkrX7FbW7a4GgSW14wVmYmGUdaoyaQ/2CC11Sa2dZU3JMvIBx69q0J7m91LTYftiM9zaKVMI+834Vf8K/DrxFr6rJqTRaXpjDAQ580qfY9KqVWNKPNUkl/XQ0dWNGPNNpG98KfGOo6cV0nVlNzYhtsEsQ3Mg9D7V7XHIJOisP94YrmfB3gvR/CtvssA0kh6yytub/AOtXTlhjqK+VzCtSq1HOkv8Ag/I+bxc6U6l6SshdwzQKiyPWnowx1FeVTquTszmaPlPxzJd3nxY1WxDyKyyiNc/dAI4x6Vur8O2j0e5mnunaaP5nCN0OOOK9O+JfgqHVm/tvTQqatbp1zxIo7EdzxXK6V/b89mke+zlZjlju547Gvs6GM9pSi6btayZ7+Gr/AOzxVO2mjPO/7D1L+/JRXsX2m7/581/75oro+uT7L7y/b+R//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with the French American British (FAB) L3 variant of acute lymphoblastic leukemia. The blasts have vacuolated cytoplasm (small arrows) and their nuclei have large prominent nucleoli (large arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23830=[""].join("\n");
var outline_f23_17_23830=null;
var title_f23_17_23831="Angiosarcoma of the breast";
var content_f23_17_23831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 658px\">",
"   <div class=\"ttl\">",
"    Mammogram, CT scan, and MRI angiosarcoma of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 638px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 55-year-old patient has angiosarcoma of the left breast secondary to radiation therapy for breast carcinoma eight years prior. She presented with breast enlargement and bluish discoloration of the skin which was clinically initially felt to correspond to an \"expanding hematoma\". The mammogram of the left breast (A) reveals multiple nodular masses (white arrows) in the outer part of the breast with overall increased trabecular background markings and skin thickening (thick white arrow). The CT scan through the mid chest (B) shows a skin nodule (yellow arrow), breast nodules (white arrows), and thickened skin (thick white arrow) of the left breast. There are increased trabecular background markings throughout the left breast. The T1 weighted fat suppressed MRI post contrast images show three suspiciously enhancing masses (white arrows in C) and thickened and enhancing skin (thick yellow arrow, D). The T1 weighted MRI image in axial projection (E) shows nodular foci of skin thickening (blue arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Priscilla J Slanetz, MD, MPH, FACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23831=[""].join("\n");
var outline_f23_17_23831=null;
var title_f23_17_23832="Prescribing epinephrine for anaphylaxis self-treatment";
var content_f23_17_23832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prescribing epinephrine for anaphylaxis self-treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23832/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23832/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23832/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23832/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23832/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23832/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/17/23832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    is the drug of choice in the treatment of anaphylaxis, and is available in many parts of the world in the form of epinephrine autoinjectors for self-treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/1\">",
"     1",
"    </a>",
"    ]. However, when prescribing these devices, clinicians must teach patients how and when to use them and dispel fears about adverse effects. Autoinjectors may be lifesaving for patients, but only if patients are willing and able to use these devices effectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    is a sympathomimetic agent with multiple actions that can reverse the symptoms of anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Beneficial effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    acts as an agonist at alpha-1 receptors to mediate vasoconstriction, increased peripheral vascular resistance, and decreased mucosal edema. Agonist effects at beta-2 receptors result in bronchodilation and decreased mediator release from mast cells and basophils (",
"    <a class=\"graphic graphic_table graphicRef65684 \" href=\"UTD.htm?32/4/32844\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even when injected properly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    is often associated with minor and transient adverse effects such as tremor, dizziness, palpitations, anxiety, restlessness, and headache [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, serious adverse effects, such as myocardial ischemia, are rare after injection of a 0.3 mg dose in an adult or a 0.15 mg dose in a child. Such effects occur more commonly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    overdose, especially after intravenous administration. Reluctance to administer epinephrine due to fear of adverse cardiac effects should be countered by the awareness that myocardial ischemia and dysrhythmias can also occur in children and adults with anaphylaxis who have not received epinephrine treatment and in whom no cardiovascular disease can be found after the episode [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Unintentional injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of unintentional injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    from autoinjectors is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], with more than 15,000 such events being reported voluntarily to the American Association of Poison Control Centers from 1994 to 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/7\">",
"     7",
"    </a>",
"    ]. A systematic review of 69 unintentional injections found that 91 percent involved a finger or thumb [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/6\">",
"     6",
"    </a>",
"    ]. In another large retrospective series of 365 unintentional injections specifically to the hand, all patients had complete resolution of symptoms, without the need for admission or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/8\">",
"     8",
"    </a>",
"    ]. In this series, warm water soaks alone were used in 32 percent and no drug therapy was administered in 77 percent. In 23 percent, various vasodilatory therapies were given (including topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    paste or local injection(s) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    ). Most patients had resolution of symptoms within two hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute contraindications to the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    for anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/9\">",
"     9",
"    </a>",
"    ]. Therefore, all patients who have experienced anaphylaxis should have access to epinephrine for self-treatment, including patients who may be at greater risk for serious adverse effects, such as older individuals with cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DEVICES AND DOSING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Available autoinjectors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following preloaded",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjectors are available in North America:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Auvi-Q (Allerject in Canada): containing 0.3 mg per dose (provides audible directions to guide user)",
"     </li>",
"     <li>",
"      Auvi-Q (Allerject in Canada): containing 0.15 mg per dose (provides audible directions to guide user)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      EpiPen: containing 0.3 mg per dose",
"     </li>",
"     <li>",
"      EpiPen Jr: containing 0.15 mg per dose",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending on the country, other brands of autoinjectors, generic autoinjectors, and prefilled sealed syringes containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    are available. It is important that prefilled syringes be sealed, since epinephrine in unsealed syringes degrades rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in the design and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    self-injection products now available need to be considered in context of patient skills and preferences. We suggest designating the specific name and description of the product intended to be dispensed on the prescription order and providing patient education that is specific to that product.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of only two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    in autoinjectable form presents difficulties in delivering an appropriate dose to many children. The recommended dose of epinephrine for children is 0.01 mg per kg, up to 0.3 mg. Therefore, the premeasured autoinjectors contain the recommended dose for a 15 kg (33 lbs) or a 30 kg (66 lbs) individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dosing in small children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prescribing information for EpiPen Jr states that the 0.15 mg injector is appropriate for children weighing &lt;30 kg (66 pounds). The Twinject package insert recommends the 0.15 mg dose for children 15 to 30 kg (33 to 66 lbs). Using these manufacturers' guidelines, children weighing 25 kg would receive the 0.15 mg dose, although the optimal dose for a child of that weight is 0.25 mg. Furthermore, little information is provided about the administration of 0.15 mg to a child weighing less than 15 kg, other than the caveat that dosing decisions are the responsibility of the prescribing clinician.",
"   </p>",
"   <p>",
"    The following studies have addressed the issue of dosing in children:",
"   </p>",
"   <p>",
"    In a randomized trial of children (aged four to eight years and weighing 15 to 30 kg) who were at risk for anaphylaxis, participants received either 0.15 mg or 0.3 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    intramuscularly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/11\">",
"     11",
"    </a>",
"    ]. The higher dose resulted in significantly higher systolic blood pressures compared to the lower dose, but was also associated with transient nausea, palpitations, and headache.",
"   </p>",
"   <p>",
"    To provide additional guidance to the clinician, a Clinical Report from the American Academy of Pediatrics reviewed the risks and benefits of selecting the 0.15 mg or the 0.3 mg fixed doses for children of different weights [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The following were considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a 10 kg child, the 0.15 mg injector delivers a 1.5-fold overdose",
"     </li>",
"     <li>",
"      For a 20 kg child, the 0.15 mg injector delivers a 1.3-fold underdose, and the 0.3 mg injector delivers a 1.5-fold overdose",
"     </li>",
"     <li>",
"      For a 25 kg child, the 0.15 mg injector delivers a 1.7-fold underdose, and the 0.3 mg injector delivers a 1.2-fold overdose",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The report concluded that it is reasonable to prescribe the 0.15 mg dose for children between 10 and 25 kg (22 to 55 lbs) and the 0.3 mg dose for those over 25 kg (55 lbs). Dosing might be individualized to select the higher of the two fixed doses at lower weights for children with severe past reactions.",
"   </p>",
"   <p>",
"    The optimal means of delivering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    to infants in the community setting, particularly those weighing less than 10 kg, is unresolved. Although the use of the 0.15 mg fixed-dose autoinjector in children under 15 kg has not been specifically studied, surveys of pediatricians [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/14\">",
"     14",
"    </a>",
"    ] and parents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/15\">",
"     15",
"    </a>",
"    ] disclosed general comfort and preference for selecting the autoinjector over an alternative such as prescribing an ampule and syringe, at least for larger infants (ie, &ge;10 kg). A study of the ability of parents without medical training to utilize an ampule and syringe after receiving verbal and written instruction in a non-urgent setting disclosed this method to be error-prone and slow [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, for infants under 10 kg, the clinician has two prescribing options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prescribe the 0.15 mg autoinjector.",
"     </li>",
"     <li>",
"      For caregivers who are able to demonstrate proficiency, prescribe an ampule (1",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      also described as 1:1000) of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , provide a",
"      <span class=\"nowrap\">",
"       syringe/needle,",
"      </span>",
"      and give instructions on how to draw up and administer the exact dose indicated. Of note, epinephrine should not be drawn up by the clinician in advance and stored by the caregiver because when the medication medicine is stored in an unsealed syringe, it degrades rapidly on exposure to air [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;EpiPen 0.3 mg and Twinject 0.3 mg per dose are appropriate for adults. Very large or obese adults should have access to at least two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Number of injectors to dispense",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no consensus guidelines about how many autoinjectors should be dispensed for each patient. Most allergy specialists prescribe at least two for all patients, and some prescribe more. The following should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retrospective studies of anaphylaxis have found that a second dose was necessary in up to 35 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/16-22\">",
"       16-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a theoretical concern that overweight or obese teenagers and adults may be underdosed (on a per kg basis) when treated with the 0.3 mg autoinjector, although this has not been proven [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/3,23\">",
"       3,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The distance between the patient's",
"      <span class=\"nowrap\">",
"       home/work/school",
"      </span>",
"      and the nearest medical facility also impacts the number of doses that should be available to the patient. The World Health Organization (WHO) and Anaphylaxis Canada recommend the availability of one dose for every 10 to 20 minutes of travel time to a medical emergency facility [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Concerns about over-prescribing additional units and generating excessive cost have been raised. As an example, having multiple units available at school for each at risk child, when many units are already available in the school for other children, may not be necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     KEY TEACHING POINTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several important teaching points that should be emphasized when instructing patients in optimal use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjectors. These teaching points should be reviewed with patients at regular intervals. Patient information that reiterates these teaching points is also available. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Information for patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anaphylaxis is unpredictable",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should understand that anaphylaxis is highly unpredictable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. One exposure to an allergen may result in mild symptoms, while the next causes a life-threatening reaction, or visa-versa, for reasons that are not fully understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Epinephrine is the best treatment available",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be assured that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    is the most effective treatment available for anaphylaxis and that having an autoinjector will enable them to start treatment without delay. Fatal anaphylaxis is associated with lack of availability of epinephrine or failure to inject epinephrine promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This fact may be expressed to the patient as the following: &ldquo;in most cases of anaphylaxis that prove fatal, the person who died either did not have epinephrine available, or had it available but didn't use it. Thus, by having an epinephrine injector and knowing how to use it, the patient already has a significant advantage.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Carry the autoinjector at all times",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    autoinjectors must be carried at all times in order to be available when the drug is actually needed. Patients may make the mistake of having their autoinjectors on hand only in the setting where they spend most time (ie, home, school, or work). However, they may be at particular risk for anaphylaxis when out of their normal routines (eg, during exercise, while dining out, attending celebrations and banquets, or traveling). Thus, patients should devise a way for an autoinjector to be available at all times. This may mean storing autoinjectors in multiple different settings or carrying a small bag containing the autoinjector and other essential items that is taken everywhere, without exception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antihistamines or asthma inhalers are not sufficient treatment for anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients must understand that antihistamines and inhaled beta agonists can treat some symptoms of allergic reactions (urticaria and pruritus and bronchospasm, respectively), but they cannot reverse laryngeal edema or hypotension and are too slow-acting to be effective in rapidly-developing anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef65684 \" href=\"UTD.htm?32/4/32844\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antihistamines and asthma inhalers alone may appear to adequately control symptoms in anaphylaxis in some instances, but it is unclear if improvement is due to the medications or the patient's own corrective physiologic responses. Therefore, clinicians and patients must regard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    as the first and best treatment for anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     When to use it",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should use plain language to explain to patients when to self-administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    . In the setting of an allergic reaction, patients should use the epinephrine autoinjector",
"    <strong>",
"     immediately",
"    </strong>",
"    if they:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are having trouble breathing",
"     </li>",
"     <li>",
"      Feel tightness in the throat",
"     </li>",
"     <li>",
"      Feel lightheaded or think they might pass out",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If treating a child with an allergic reaction,",
"    <strong>",
"     also",
"    </strong>",
"    use the autoinjector if the child:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is not responding as expected or has altered consciousness during an allergic reaction",
"     </li>",
"     <li>",
"      Has food allergies and is vomiting repeatedly shortly after eating, especially if these symptoms are accompanied by flushing or hives",
"     </li>",
"     <li>",
"      Is coughing repeatedly during an allergic reaction (indicating bronchospasm)",
"     </li>",
"     <li>",
"      Had previous anaphylaxis and develops widespread hives after a suspected or known ingestion of the allergen",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     How to use it",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    should ideally be injected into the mid-outer part of the thigh, into the underlying muscle. Intramuscular injection is preferable to subcutaneous injection, as it results in more rapid systemic absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/26,30,31\">",
"     26,30,31",
"    </a>",
"    ]. Patients should be instructed to hold the device with a closed fist (ie, like a baton, with fingers away from either end) as accidental injection of the fingers or palm can occur if the autoinjector is inverted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be instructed to stay with other people if possible during an allergic reaction. There is no need to undress before using the autoinjector, as the needles are designed to penetrate clothing. However, we typically instruct patients to raise skirts or lower pants, if possible, to avoid an obstruction such as a buckle or contents of a pocket.",
"   </p>",
"   <p>",
"    The clinician should demonstrate how to use the specific autoinjector that is being prescribed, by using the specific training device for that autoinjector. Detailed written instructions are provided separately. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Information for patients'",
"    </a>",
"    below.) Manufacturers also provide DVDs and videos on their web sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Use it without delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should understand that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    is most effective when given within the first few minutes of an allergic reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Call for help and go to the emergency department",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    should be self-administered first, and then the patient should call for help and be transported to the nearest emergency department as soon as possible, in case the symptoms of anaphylaxis worsen or recur without further exposure to the trigger. It is important to make clear to patients that the reason for proceeding to the emergency department is the possibility of worsening or recurrent symptoms. Some patients misinterpret instructions to go to the emergency department as evidence that epinephrine is dangerous and that they must be examined whenever they have self-administered it. This, in turn, can cause them to avoid use of the autoinjector.",
"   </p>",
"   <p>",
"    If patients become lightheaded they should lie down with their legs elevated, if possible, in order to increase blood flow to vital organs. Similarly, if the patient loses consciousness in the caregiver's presence, the patient should be placed on their back with legs elevated.",
"   </p>",
"   <p>",
"    Patients should never be propped up during anaphylaxis. Rising to an upright position during severe anaphylaxis has been associated with sudden death due to the \"empty ventricle syndrome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients should be transported to an emergency medical facility in the supine position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     More than one dose may be needed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be advised that a second dose may be needed if symptoms do not appear to be stabilizing or improving, and this may be given 5 to 15 minutes after the first [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Practice with the training device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoinjectors are dispensed with a training device that is identical to the injector but does not contain a needle or medication.",
"    <span class=\"nowrap\">",
"     Patients/caregivers",
"    </span>",
"    should practice periodically with a training device. They should also use the trainer to teach others who may need to administer the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    if the patient is incapacitated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Teach others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be encouraged to inform and educate appropriate friends, family, colleagues, and food providers about their allergic condition. It may be essential that those around them are able to recognize an allergic reaction and react effectively, both by administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    and calling for assistance, if the patient is incapacitated.",
"   </p>",
"   <p>",
"    Patients and caregivers should use the training devices to teach others how to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3705?source=see_link\">",
"     \"Food allergy in schools and camps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Replace the autoinjectors yearly",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    autoinjectors have a limited shelf life and need to be replaced annually. Some patients renew their prescription on their birthday or at the start of the calendar year, in order to link renewal to an annual event. Patients sometimes express dismay over the cost involved in replacing multiple epinephrine autoinjectors yearly. It may help to suggest viewing the autoinjectors as a form of life insurance: they must have it, although they may never use it, and this outcome should be seen as a success.",
"   </p>",
"   <p>",
"    Patients should be informed that it is preferable to use an out-of-date autoinjector, if that is all that is available, rather than not injecting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    at all [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/33\">",
"     33",
"    </a>",
"    ]. Autoinjectors have a window to inspect for discoloration of contents, a sign that the medication needs to be replaced. However, expired autoinjectors in which the solution remains clear should also be replaced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Storage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoinjectors should not be refrigerated. Patients should be instructed to store the units in locations with neutral temperatures (fanny pack, purse, cabinets) rather than locations where the unit may overheat or freeze (glove compartment of a car, in an uninsulated bag on the beach).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     AREAS OF UNCERTAINTY FOR THE PRESCRIBING CLINICIAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several areas of uncertainty for prescribing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    and teaching patients about when it is appropriate to inject the medication. These situations require clinical judgment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Who is at risk for anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    is indicated for persons who have experienced anaphylaxis to an agent they may encounter again outside of the medical setting, and for patients with idiopathic anaphylaxis. However, there may be less obvious circumstances where prescribing epinephrine is also appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/12,34\">",
"     12,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It may be unclear from the clinical history whether anaphylaxis occurred and clinical judgment may be needed to decide whether it did occur.",
"     </li>",
"     <li>",
"      An individual may have experienced a mild reaction to an allergen that is known to cause severe reactions (eg, a",
"      <span class=\"nowrap\">",
"       peanut/tree",
"      </span>",
"      nut allergy). As an example, it would be reasonable to prescribe",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      for a child with severe eczema who was found to have peanut allergy and placed on a peanut-free diet, but who had displayed only flares of eczema after eating peanut and never had a more serious reaction. Such patients may be at risk for systemic symptoms if subsequently exposed to the culprit allergen [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An individual may have had an allergic reaction with clinical features that may indicate a higher risk of anaphylaxis on a future exposure, such as reactions to trace amounts of a food.",
"     </li>",
"     <li>",
"      There may be comorbid diseases or medications that increase the risk for a severe reaction, such as asthma or the use of beta-blockers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Oral allergy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a systemic reaction in a patient with oral allergy syndrome, and the relative indications for prescription of self-injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link&amp;anchor=H1929291#H1929291\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Indications for epinephrine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Instructing patients when to inject epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain symptom combinations, particularly with known or likely exposure to an allergen, are indications to inject",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , as reviewed above [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/26\">",
"     26",
"    </a>",
"    ]. However, there are circumstances where it may be appropriate to instruct patients to self-inject when such symptoms have NOT occurred or are mild:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If symptoms are mild but the patient is in a remote location",
"     </li>",
"     <li>",
"      If the symptoms are mild but the reaction appears to be progressing rapidly",
"     </li>",
"     <li>",
"      If the patient or caregiver is uncertain about the severity of the reaction, it is preferable to administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      rather than withhold it",
"     </li>",
"     <li>",
"      If there has been a known ingestion of a food, or an insect sting, that previously caused a severe reaction, even before any symptoms have developed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Knowledge about the nature of the exposure is also helpful in deciding whether to inject",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For example, if it is known that a food allergen was rubbed into the eye but definitely not ingested, then progression to anaphylaxis is unlikely and symptoms such as eyelid angioedema would not be a reason to inject",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      . However, if the allergen was definitely ingested, the victim had a history of severe anaphylaxis to the same trigger, and eyelid angioedema was noted, it would be reasonable to inject epinephrine.",
"     </li>",
"     <li>",
"      A child with asthma and an upper respiratory infection, who ate a presumably safe meal and then exercised and developed severe wheezing is not likely experiencing anaphylaxis but rather an asthma exacerbation and would warrant inhaled bronchodilator therapy. In contrast, a child with severe asthma and peanut allergy who ate a peanut cookie and developed severe wheezing would warrant injection with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4973413\">",
"    <span class=\"h2\">",
"     Responsibilities of older children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;As children at risk for anaphylaxis mature, they need to become responsible for recognizing and treating anaphylaxis. In an on-line survey of 88 pediatric allergists, participants were asked about the age at which children are able to begin assuming these responsibilities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/37\">",
"     37",
"    </a>",
"    ]. These allergists most frequently responded that children aged 9 to 11 years should be able to describe some symptoms of anaphylaxis, recognize the need for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , and demonstrate correct use of an autoinjector. By age 12 to 14 years, most allergists expected children to take some responsibility for self-administering epinephrine when needed. They individualized the timing based on assessment of patient readiness factors, including medical history, developmental level, and ability to demonstrate correct autoinjector technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=see_link\">",
"       \"Patient information: Epinephrine auto-injectors (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"       \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Academy of Allergy, Asthma, and Immunology has devised an \"Anaphylaxis Emergency Action Plan\" that can be personalized and provided to any patient who has experienced anaphylaxis (",
"    <a class=\"graphic graphic_form graphicRef60439 \" href=\"UTD.htm?2/42/2722\">",
"     form 1",
"    </a>",
"    ). This plan provides clear instructions for patients about how to treat an anaphylaxis episode and gives both the clinician and the patient an opportunity to personalize the instructions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with diagnosed anaphylaxis, three key steps include: prescription of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , patient education, and follow-up evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23832/abstract/26\">",
"     26",
"    </a>",
"    ]. Epinephrine should always be prescribed in the context of a comprehensive care plan, including instructions on allergen avoidance, as well as indications for injection of epinephrine, and instructions on activating additional emergency services (eg, calling 911).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When prescribing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjectors for anaphylaxis self-treatment, clinicians must also provide patient-specific advice about when and how to administer epinephrine, and dispel fears about its adverse effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       Epinephrine",
"      </a>",
"      is a sympathomimetic agent with multiple actions that can reverse the symptoms of anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef65684 \" href=\"UTD.htm?32/4/32844\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       Epinephrine",
"      </a>",
"      will cause transient and minor adverse effects in most patients, even when used properly. However, patients should be reassured that serious adverse effects, such as myocardial ischemia, are rare with the doses delivered by an autoinjector. Furthermore, untreated anaphylaxis itself is associated with myocardial ischemia and dysrhythmias. Thus, all patients with past anaphylaxis should have access to epinephrine for self-treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       Epinephrine",
"      </a>",
"      autoinjectors are available in doses of 0.15 mg and 0.3 mg. The higher dose is appropriate for children and adults weighing more than 30 kg (66 lbs). Large or obese individuals should have access to multiple doses. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Devices and dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dosing in children is more difficult, as the available doses either result in over- or underdosing for many. One expert panel has suggested prescribing the 0.15 mg dose for children between 10 and 25 kg (22 to 55 lbs) and the 0.3 mg dose for those over 25 kg (55 lbs). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several important teaching points that should be emphasized when instructing patients in optimal use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjectors, which address most patients' areas of concern and confusion. This information should be reviewed with patients at regular intervals. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Key teaching points'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical situations arise in which it is not clear if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      should be injected. As an example, it is reasonable to instruct a patient with severe anaphylaxis to food, who subsequently had a known ingestion of the culprit food, to inject epinephrine even before any symptoms have developed. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Areas of uncertainty for the prescribing clinician'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/1\">",
"      Simons FE, World Allergy Organization. Epinephrine auto-injectors: first-aid treatment still out of reach for many at risk of anaphylaxis in the community. Ann Allergy Asthma Immunol 2009; 102:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/2\">",
"      Simons FE. Anaphylaxis: evidence-based long-term risk reduction in the community. Immunol Allergy Clin North Am 2007; 27:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/3\">",
"      Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol 2010; 10:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/4\">",
"      Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 Suppl 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/5\">",
"      Kounis NG. Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? Int J Cardiol 2006; 110:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/6\">",
"      Simons FE, Lieberman PL, Read EJ Jr, Edwards ES. Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. Ann Allergy Asthma Immunol 2009; 102:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/7\">",
"      Simons FE, Edwards ES, Read EJ Jr, et al. Voluntarily reported unintentional injections from epinephrine auto-injectors. J Allergy Clin Immunol 2010; 125:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/8\">",
"      Muck AE, Bebarta VS, Borys DJ, Morgan DL. Six years of epinephrine digital injections: absence of significant local or systemic effects. Ann Emerg Med 2010; 56:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/9\">",
"      Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/10\">",
"      Rawas-Qalaji M, Simons FE, Collins D, Simons KJ. Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxis. Ann Allergy Asthma Immunol 2009; 102:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/11\">",
"      Edwards ES, Gunn R, Simons FER, et al. Epinephrine 0.3 mg bioavailability following a single injection with a novel epinephrine auto-injector, e-cue, in healthy adults, with reference to a single injection using EpiPen 0.3 mg. J Allergy Clin Immunol 2012; 129:AB179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/12\">",
"      Sicherer SH, Simons FE, Section on Allergy and Immunology, American Academy of Pediatrics. Self-injectable epinephrine for first-aid management of anaphylaxis. Pediatrics 2007; 119:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/13\">",
"      Simons FE. First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol 2004; 113:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/14\">",
"      Sicherer SH, Forman JA, Noone SA. Use assessment of self-administered epinephrine among food-allergic children and pediatricians. Pediatrics 2000; 105:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/15\">",
"      Simons FE, Chan ES, Gu X, Simons KJ. Epinephrine for the out-of-hospital (first-aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical? J Allergy Clin Immunol 2001; 108:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/16\">",
"      Korenblat P, Lundie MJ, Dankner RE, Day JH. A retrospective study of epinephrine administration for anaphylaxis: how many doses are needed? Allergy Asthma Proc 1999; 20:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/17\">",
"      Uguz A, Lack G, Pumphrey R, et al. Allergic reactions in the community: a questionnaire survey of members of the anaphylaxis campaign. Clin Exp Allergy 2005; 35:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/18\">",
"      J&auml;rvinen KM, Sicherer SH, Sampson HA, Nowak-Wegrzyn A. Use of multiple doses of epinephrine in food-induced anaphylaxis in children. J Allergy Clin Immunol 2008; 122:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/19\">",
"      Oren E, Banerji A, Clark S, Camargo CA Jr. Food-induced anaphylaxis and repeated epinephrine treatments. Ann Allergy Asthma Immunol 2007; 99:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/20\">",
"      Kelso JM. A second dose of epinephrine for anaphylaxis: how often needed and how to carry. J Allergy Clin Immunol 2006; 117:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/21\">",
"      Manivannan V, Campbell RL, Bellolio MF, et al. Factors associated with repeated use of epinephrine for the treatment of anaphylaxis. Ann Allergy Asthma Immunol 2009; 103:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/22\">",
"      Rudders SA, Banerji A, Corel B, et al. Multicenter study of repeat epinephrine treatments for food-related anaphylaxis. Pediatrics 2010; 125:e711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/23\">",
"      Rudders SA, Geyer BC, Banerji A, et al. Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis. J Allergy Clin Immunol 2012; 130:1216.",
"     </a>",
"    </li>",
"    <li>",
"     The website address for Anaphylaxis Canada is www.anaphylaxis.org (Accessed on February 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/25\">",
"      Norton L, Dunn Galvin A, Hourihane JO. Allergy rescue medication in schools: modeling a new approach. J Allergy Clin Immunol 2008; 122:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/26\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/27\">",
"      Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/28\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/29\">",
"      Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/30\">",
"      Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998; 101:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/31\">",
"      Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/32\">",
"      Pumphrey RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol 2003; 112:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/33\">",
"      Simons FE, Gu X, Simons KJ. Outdated EpiPen and EpiPen Jr autoinjectors: past their prime? J Allergy Clin Immunol 2000; 105:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/34\">",
"      Sicherer SH, Simons FE. Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community. J Allergy Clin Immunol 2005; 115:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/35\">",
"      Larramendi CH, Mart&iacute;n Esteban M, Pascual Marcos C, et al. Possible consequences of elimination diets in asymptomatic immediate hypersensitivity to fish. Allergy 1992; 47:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/36\">",
"      Anaphylaxis in schools and other childcare settings. AAAAI Board of Directors. American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1998; 102:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/37\">",
"      Simons E, Sicherer SH, Simons FE. Timing the transfer of responsibilities for anaphylaxis recognition and use of an epinephrine auto-injector from adults to children and teenagers: pediatric allergists' perspective. Ann Allergy Asthma Immunol 2012; 108:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23832/abstract/38\">",
"      Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 388 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23832=[""].join("\n");
var outline_f23_17_23832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Beneficial effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Unintentional injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DEVICES AND DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Available autoinjectors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dosing in small children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Number of injectors to dispense",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      KEY TEACHING POINTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anaphylaxis is unpredictable",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Epinephrine is the best treatment available",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Carry the autoinjector at all times",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antihistamines or asthma inhalers are not sufficient treatment for anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      When to use it",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      How to use it",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Use it without delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Call for help and go to the emergency department",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      More than one dose may be needed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Practice with the training device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Teach others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Replace the autoinjectors yearly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Storage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      AREAS OF UNCERTAINTY FOR THE PRESCRIBING CLINICIAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Who is at risk for anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Oral allergy syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Instructing patients when to inject epinephrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4973413\">",
"      Responsibilities of older children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/388\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/388|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?2/42/2722\" title=\"form 1\">",
"      Anaphylaxis action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/388|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/4/32844\" title=\"table 1\">",
"      Epinepherine actions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3705?source=related_link\">",
"      Food allergy in schools and camps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=related_link\">",
"      Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=related_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_17_23833="Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children";
var content_f23_17_23833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23833/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23833/contributors\">",
"     James B Bussel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23833/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23833/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/17/23833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune thrombocytopenia (ITP) of childhood is characterized by isolated, immune-mediated thrombocytopenia (peripheral blood platelet count",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/1\">",
"     1",
"    </a>",
"    ]. It is an acquired and most commonly benign disorder. ITP was previously known idiopathic thrombocytopenic purpura or autoimmune thrombocytopenic purpura.",
"   </p>",
"   <p>",
"    ITP in children typically improves spontaneously within three months. In a minority of children, the ITP persists for six or more months, and in a small fraction, ITP can be a very refractory, difficult to treat disease in children.",
"   </p>",
"   <p>",
"    ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, and is the main focus of this topic review. Immune-mediated thrombocytopenia with an underlying cause (secondary ITP), including ITP that is drug-induced, or associated with systemic lupus erythematosus or HIV, is outlined briefly. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.) The treatment and prognosis of ITP in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=see_link\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In immune thrombocytopenia (ITP), autoantibodies (usually IgG) are directed against platelet membrane antigens, such as the glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    complex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The antibody-coated platelets have a shortened half-life because of accelerated clearance by tissue macrophages, predominantly those in the spleen. In addition, the same antibodies may inhibit platelet production. The net effect is a decrease, often substantial, in the platelet count.",
"   </p>",
"   <p>",
"    In some patients with ITP, antibodies may not be demonstrable and an alternative mechanism of T-cell-mediated cytotoxicity may cause thrombocytopenia. These cytotoxic T cells probably act upon megakaryocytes in the bone marrow rather than circulating platelets. It is not known how often this occurs, nor whether cytotoxic T-cells play a role in the typical patient with ITP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune thrombocytopenia (ITP) is one of the most common causes of symptomatic thrombocytopenia in children. The annual incidence of ITP is estimated to be up to 6.4 cases per 100,000 children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/4\">",
"     4",
"    </a>",
"    ]. This figure is probably an underestimate because it is based primarily upon patients that develop symptomatic thrombocytopenia and are hospitalized.",
"   </p>",
"   <p>",
"    Children with ITP can present at any age, but there is a peak in incidence between two and five years and a smaller peak in adolescence. In a prospective population-based study from five Nordic countries (Sweden, Finland, Norway, Denmark, and Iceland) between 1998 and 2000, the annual incidence of ITP was 4.8 per 100,000 children younger than 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/5\">",
"     5",
"    </a>",
"    ]. Half of the patients were between 1 and 4 years of age and about 80 percent were younger than 8 years of age.",
"   </p>",
"   <p>",
"    In childhood ITP, there is a slight predominance of boys to girls, especially in infants. This was best illustrated in the largest case series of children with ITP from the registry of the Intercontinental Childhood ITP Study Group (ICIS group) that included more than 2000 infants and children with an age range between 3 months to 16 years. In infants between 3 and 12 months of age, the male to female ratio was to 1.7 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/6\">",
"     6",
"    </a>",
"    ]. The male predominance was minimal in older children, such that the overall male to female ratio in this pediatric cohort was 1.2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/7\">",
"     7",
"    </a>",
"    ]. By contrast, there is a female predominance of ITP in younger adults (eg, 18 to 45 years of age). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seasonal fluctuations have been reported, with a peak incidence in the spring and early summer, consistent with viral triggers, but the reported findings are not consistent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune thrombocytopenia (ITP) typically presents with the sudden appearance of a petechial rash, bruising",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding in an otherwise healthy child (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 1",
"    </a>",
"    ). Other than these symptoms of mucosal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cutaneous bleeding, the child usually looks and feels well. Thrombocytopenia is occasionally detected incidentally if a complete blood count (CBC) with platelets is performed for another reason (eg, for a camp physical).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;In about 60 percent of pediatric cases, there is a history of a prior infection within the past month [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. There is also a very small increased risk of developing ITP in the six weeks following a measles, mumps, and rubella (MMR) vaccination. MMR-associated ITP is rare, occurring in approximately 2.6 cases per 100,000 doses of vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H22#H22\">",
"     \"Standard immunizations for children and adolescents\", section on 'MMR vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other than the prior history of infection or MMR vaccine, the history generally does not reveal any significant findings. In particular, there are no systemic symptoms (eg, fever, anorexia, bone or joint pain, or weight loss) in children with ITP, nor any prior history of bleeding or significant disease. If any such symptoms are present, another cause of thrombocytopenia should be strongly considered, including secondary ITP and disorders with non-immune mechanisms. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A family history of thrombocytopenia in first degree relatives is identified in very few children with ITP; familial thrombocytopenia in these cases is more likely to be inherited non-immune thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/8\">",
"     8",
"    </a>",
"    ]. Drug-induced thrombocytopenia is rare in children, but should be considered in the differential diagnosis of ITP, by reviewing the history for possible exposure to relevant drugs (",
"    <a class=\"graphic graphic_table graphicRef73618 \" href=\"UTD.htm?36/3/36924\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients diagnosed with ITP have signs of cutaneous bleeding (also referred to as dry purpura) that include petechiae, purpura, and ecchymoses, as shown in panel A (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 1",
"    </a>",
"    ); approximately 60 percent of children with ITP have only cutaneous bleeding at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/5\">",
"     5",
"    </a>",
"    ]. Mucosal bleeding (also referred to as wet purpura) involves the nasal passages, buccal and gingival surfaces, and, less often, the gastrointestinal, genitourinary, or vaginal tracts, as shown in panel B (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 1",
"    </a>",
"    ); mucosal bleeding may be present in as many as 40 percent of children with ITP. The severity of presenting symptoms is generally commensurate with the degree of thrombocytopenia. As an example, mucosal bleeding is significantly more common when the platelet count is less than",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    compared to",
"    <span class=\"nowrap\">",
"     &ge;15,000/microL",
"    </span>",
"    (51 versus 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large registry study of children with newly diagnosed ITP, the following bleeding manifestations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cutaneous (petechiae, purpura or bruising) &ndash; 86 percent",
"     </li>",
"     <li>",
"      Oral &ndash; 19 percent",
"     </li>",
"     <li>",
"      Nasal &ndash; 20 percent",
"     </li>",
"     <li>",
"      No bleeding &ndash; 9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Menstrual, gastrointestinal or urinary bleeding was present in less than 3 percent. No patients were observed to have conjunctival or retinal hemorrhages.",
"   </p>",
"   <p>",
"    Other than mucocutaneous bleeding, patients usually appear well. On physical examination, there is no significant enlargement of lymph nodes, liver, or spleen, although the spleen may be slightly enlarged in 10 percent of cases. If one or more of these findings are present, another diagnosis should be strongly considered. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714177\">",
"    <span class=\"h3\">",
"     Serious hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious bleeding occurs in about 3 percent of children with ITP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the Intercontinental Childhood ITP Study Group (ICIS) registry including 863 patients, 2.9 percent had severe bleeding at diagnosis, defined as epistaxis, gastrointestinal bleeding,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intracranial hemorrhage (ICH) requiring hospital admission",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/9\">",
"       9",
"      </a>",
"      ]. Among patients with severe bleeding, 86 percent had platelet counts",
"      <span class=\"nowrap\">",
"       &le;20,000/microL.",
"      </span>",
"      Therapy with intravenous immunoglobulin or corticosteroids did not appear to affect the risk of subsequent bleeding after diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the Nordic registry of 501 patients, 15 patients (3 percent) had severe hemorrhage, consisting of profound epistaxis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal bleeding that required blood transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/5,10\">",
"       5,10",
"      </a>",
"      ]. The level of the platelet count was not predictive for the need of transfusions, as three of the 15 patients with severe hemorrhage had platelet counts between 16,000 and 24,000 microL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4714305\">",
"    <span class=\"h3\">",
"     Intracranial hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial hemorrhage (ICH) is the most serious consequence of thrombocytopenia. More than 90 percent of ICHs in children with ITP are supratentorial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of ICH in children with ITP is 0.1 to 0.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/5,6,8,10,12,13\">",
"     5,6,8,10,12,13",
"    </a>",
"    ]. This was illustrated in reviews of the ICIS registry, which reported 10 cases of ICH among 1784 patients (0.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/8\">",
"     8",
"    </a>",
"    ], and from the Nordic registry, which reported no case of ICH among 501 patients during the first six months after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/10\">",
"     10",
"    </a>",
"    ]. Of note, the ICIS registry may overestimate the risk for severe hemorrhage and ICH, because the registry consists of patients identified and registered by their physicians.",
"   </p>",
"   <p>",
"    Predictors and outcomes of ICH were evaluated in a retrospective review of 40 children with ITP and ICH in the United States, who were compared to 80 matched controls with ITP but without ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 10 patients, ICH was the presenting feature of ITP; in 8 additional patients ICH developed within seven days of diagnosis, and in 12 patients ICH developed in the setting of chronic ITP.",
"     </li>",
"     <li>",
"      Patients with ICH were more likely to have a history of head trauma (33 versus 1 percent), hematuria (22 versus 0 percent), and more extensive signs of bleeding beyond petechiae and ecchymoses (63 versus 44 percent), as compared to the matched controls.",
"     </li>",
"     <li>",
"      Platelet counts were less than",
"      <span class=\"nowrap\">",
"       20,000/microL",
"      </span>",
"      in 90 percent of the patients with ICH and 85 percent of controls, and less than",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      in 75 percent of patients with ICH and 59 percent of controls. Therefore, it appears that severe thrombocytopenia is permissive, but far from sufficient for ICH to occur.",
"     </li>",
"     <li>",
"      Children with ICH had a 25 percent mortality rate, and 33 percent of the survivors had neurologic complications at follow-up (median 11 months, range 5 days to 6 years). Outcomes were somewhat better for patients whose ICH was precipitated by head trauma or who presented with ICH, as compared to those who developed ICH after presenting with ITP.",
"     </li>",
"     <li>",
"      Although therapy was given to 28 of the 40 patients before the ICH and to all patients after ICH, it remains uncertain whether post hoc pharmacologic therapy or emergency splenectomy affected outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4713815\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia usually is the only abnormality detected. A platelet count of",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    is used to define thrombocytopenia in ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in most case series, the presenting platelet count is usually less than",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/7,10\">",
"     7,10",
"    </a>",
"    ], probably because patients with mild disease are less likely to have bleeding, and may never come to medical attention. About 80 percent of children with ITP have platelet counts less than",
"    <span class=\"nowrap\">",
"     20,000/microL,",
"    </span>",
"    and about 44 percent of children have platelet counts less than",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Platelet counts in children are generally somewhat lower than in adults with ITP.",
"   </p>",
"   <p>",
"    The white blood cell count and hemoglobin concentration are generally normal. Anemia is occasionally seen in children with significant bleeding (eg, epistaxis or vaginal), but should also prompt consideration of other causes of thrombocytopenia (eg, bone marrow suppression including leukemia). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A careful examination of the peripheral blood smear should detect no morphologic abnormalities in the white or red blood cells, although post-infectious cases may have activated &ldquo;atypical&rdquo; lymphocytes. Platelets that are decreased in number but large in size are consistent with ITP, particularly when symptoms have been present several days or longer. However, the finding of many very large platelets, small platelets, schistocytes, spherocytes, or polychromasia suggests the possibility of another cause of thrombocytopenia. Patients with these characteristics should be specifically evaluated for these other causes. Similarly, an elevated reticulocyte count (suggesting hemolysis) calls for further evaluation. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Disease course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary ITP is categorized into three phases, depending on the length of the disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newly diagnosed ITP &ndash; ITP within three months from diagnosis",
"     </li>",
"     <li>",
"      Persistent ITP &ndash; Ongoing ITP between 3 and 12 months from the initial diagnosis",
"     </li>",
"     <li>",
"      Chronic ITP &ndash; ITP lasting for more than 12 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 50 to 70 percent of children recover from ITP within three months of presentation, with or without treatment, in which recovery is defined as platelet count",
"    <span class=\"nowrap\">",
"     &gt;150,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. When pharmacologic intervention is used, it is directed toward the early control of symptoms, such as stopping severe hemorrhage or minimizing the risk of significant bleeding. Such therapy is not thought to affect the long-term outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=see_link\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The course of ITP is illustrated by an analysis from the Nordic registry [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/10\">",
"     10",
"    </a>",
"    ]. Six-month follow-up data were available for 409 patients. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A platelet count",
"      <span class=\"nowrap\">",
"       &gt;20,000/microL",
"      </span>",
"      at one month after presentation was achieved by 92 percent of the patients.",
"     </li>",
"     <li>",
"      Complete remission (platelet count",
"      <span class=\"nowrap\">",
"       &gt;150,000/microL)",
"      </span>",
"      was observed in 50 percent of the patients less than one month after presentation, 68 percent by three months, and 75 percent by six months.",
"     </li>",
"     <li>",
"      25 percent had platelet counts",
"      <span class=\"nowrap\">",
"       &lt;150,000/microL",
"      </span>",
"      six months after presentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presentation of newly diagnosed, persistent, and chronic ITP are similar. However, children who have chronic ITP are somewhat more likely at presentation to have an insidious onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/10,14\">",
"     10,14",
"    </a>",
"    ], be older [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/6,10,14\">",
"     6,10,14",
"    </a>",
"    ], and not have a history of a prior infection or vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/5,14-16\">",
"     5,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune thrombocytopenia (ITP) is characterized by isolated thrombocytopenia. It is a diagnosis of exclusion, so other causes of thrombocytopenia must be ruled out. The clinical presentation and results of the initial evaluation determine whether further evaluation is needed to exclude specific causes of thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16831379\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ITP is based upon the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      Otherwise normal complete blood count (CBC) with differential white count, and ideally with a reticulocyte count.",
"     </li>",
"     <li>",
"      No abnormalities on the peripheral blood smear after review by an experienced practitioner.",
"     </li>",
"     <li>",
"      No clinically apparent associated conditions that may cause thrombocytopenia, after a thorough history and physical examination. Findings that suggest a diagnosis other than ITP include enlargement of lymph nodes, liver, or spleen, systemic symptoms (eg, fever, anorexia, bone or joint pain, or weight loss), a long-standing history of atypical bleeding, or the presence of a clinically significant systemic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children with a typical presentation of ITP (sudden onset of a petechial rash or bruising in an otherwise well-appearing child between 1 and 10 years of age), a presumptive diagnosis of ITP may be established after the above steps. Children younger than 1 year or older than 10 years should be scrutinized particularly closely for any atypical features. The only true confirmation of the diagnosis of ITP, rather than the many items that exclude other diseases, is an unequivocal but transient response to ITP-specific treatments such as intravenous immunoglobulin (IVIG) and anti-Rho(D) immune globulin. However, not all patients require such treatments. Moreover, a response to therapy does not distinguish between primary and secondary ITP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=see_link\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16831408\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with lymphadenopathy, splenomegaly, systemic symptoms, or any abnormalities in the CBC or peripheral blood smear, further investigation is needed to exclude other causes of thrombocytopenia, including malignancy, persistent infection, immune deficiency, autoimmune disorders, drug-induced thrombocytopenia, or bone marrow failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under such circumstances, one or several of the following tests should be performed, depending on the reason for concern: (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymph node enlargement, organomegaly, bone or joint pain, fevers, neutropenia, leukocytosis, atypical lymphocytes, marked anemia or weight loss &ndash; Evaluate for malignancy, including bone marrow aspirate and biopsy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bone marrow examination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Anemia &ndash; If there is evidence of hemolysis (schistocytes, spherocytes or elevated reticulocytes), evaluate for an autoimmune hemolytic anemia with a direct antiglobulin test (DAT, formerly known as the Coombs test). In addition, the DAT should be performed in children for whom anti-D therapy is contemplated, to exclude the possibility of a major hemolytic response to anti-rho(D) immune globulin (anti-D). If the DAT is positive (confirming Evans syndrome), testing for autoimmune lymphoproliferative syndrome (ALPS) should be pursued, whether or not there is any lymphadenopathy or splenomegaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H28#H28\">",
"       \"Autoimmune hemolytic anemia in children\", section on 'Evans syndrome'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If there is hemolysis and a recent history of diarrhea and gastroenteritis, perform tests of renal function (blood urea nitrogen [BUN] and creatinine) to evaluate for hemolytic uremic syndrome (HUS). Especially in a young patient in whom onset at birth or soon after cannot be excluded, ADAMTS13 deficiency and other congenital causes of thrombotic thrombocytopenic purpura (TTP) should be considered. Similarly, genetic or acquired causes of TTP should be considered in adolescents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link&amp;anchor=H7#H7\">",
"       \"Atypical hemolytic uremic syndrome in children\", section on 'Genetic forms of HUS'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"       \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If the white blood cell (WBC) count is suppressed or non-microcytic anemia is present and there is thrombocytopenia, perform bone marrow aspirate and biopsy to evaluate for malignancy and inherited or acquired bone marrow failure syndromes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link\">",
"       \"Inherited aplastic anemia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link\">",
"       \"Acquired aplastic anemia in children and young adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excessive bleeding (more than expected for platelet count) &ndash; Perform coagulation studies including prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, and D-dimer to evaluate for disseminated intravascular coagulation (DIC). In addition, screen for Von Willebrand disease type 2B and check platelet function when the platelet count increases.",
"     </li>",
"     <li>",
"      Signs or symptoms of systemic illness or recurrent infection &ndash; Perform studies to evaluate for the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Systemic lupus (SLE), or other rheumatoid disorders",
"     </li>",
"     <li>",
"      HIV, hepatitis C, and cytomegalovirus (CMV), and possibly malaria",
"     </li>",
"     <li>",
"      Immune deficiency, especially for common variable immunodeficiency (CVID), Wiskott Aldrich, and DiGeorge syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21235124\">",
"    <span class=\"h3\">",
"     Role of antiplatelet antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for antibodies to specific platelet glycoproteins (such as glycoprotein",
"    <span class=\"nowrap\">",
"     Ib/IX)",
"    </span>",
"    is not recommended for patients with suspected ITP to either include or exclude the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/3,17,18\">",
"     3,17,18",
"    </a>",
"    ]. This is because the currently available tests do not distinguish primary ITP from secondary ITP. In the future, if studies suggest that these antibodies predict response to different treatments, then these recommendations may change. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Antiplatelet antibody testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow examination (aspirate and biopsy) is performed in selected patients with ITP to exclude other causes of thrombocytopenia, such as malignancy. In patients with ITP, the bone marrow should be cellular, and the erythroid and myeloid precursors should be normal in number and appearance. The megakaryocytes are typically normal or increased in number, and may appear large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for bone marrow aspiration and biopsy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical clinical or laboratory features at presentation that suggest malignancy or bone marrow failure, especially lymph node enlargement, splenomegaly, bone or joint pain, fevers, neutropenia, leukocytosis, atypical lymphocytes, marked anemia or weight loss.",
"     </li>",
"     <li>",
"      If a patient is treated with steroids, IVIG, or anti-D at appropriate doses but responds insufficiently or not at all to this treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=see_link\">",
"       \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      New findings that emerge during follow-up that are not consistent with ITP (eg, subsequent clinical findings of lymph node enlargement, organomegaly, bone or joint pain, fevers, or new laboratory findings of neutropenia, leukocytosis, or anemia without bleeding) or loss of response to typical ITP therapies that had previously been effective.",
"     </li>",
"     <li>",
"      Prior to planned splenectomy, if a bone marrow biopsy has never been performed before.",
"     </li>",
"     <li>",
"      In a patient with chronic ITP (&gt;12 months from diagnosis) who has never been treated or has never had a substantial if transient response to treatment.",
"     </li>",
"     <li>",
"      In a patient with ITP who has not responded to or received other treatment, and in whom treatment with a thrombopoietic agent is contemplated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone marrow examination is",
"    <strong>",
"     not",
"    </strong>",
"    necessary for children with a typical presentation of ITP. This perspective is supported by an international consensus report [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. The following observations provide support for this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study from a single tertiary center, all cases that required bone marrow aspiration were reviewed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among 332 children with typical hematologic features of ITP (ie, normal white blood cell count and hemoglobin), none had evidence of leukemic changes or bone marrow failure in bone marrow aspirate samples. One patient went on to develop aplastic anemia.",
"     </li>",
"     <li>",
"      Among 152 children with nonspecific \"atypical\" hematologic findings, more than 90 percent had the diagnosis of ITP supported by bone marrow examination. Only 11 patients (2.4 percent of all patients and 7.2 percent of atypical patients) had a diagnosis other than ITP, divided evenly between bone marrow failure or leukemia. Reassessment of the clinical records of these 11 patients revealed that all had clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory findings at presentation that suggested a diagnosis other than ITP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar findings were noted in another retrospective review of 127 children with presumed ITP in whom bone marrow sampling was performed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/21\">",
"       21",
"      </a>",
"      ]. Only five patients (3.9 percent) had a diagnosis other than ITP. As in the previous study, all presented with clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory findings that were atypical for ITP. Leukemia was not diagnosed in any patient.",
"     </li>",
"     <li>",
"      The centralized leukemia study registries have never registered a leukemia patient with isolated thrombocytopenia; the closest would be a patient with Down syndrome and isolated thrombocytopenia, but this patient also had marked splenomegaly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the preceding data, treatment with steroids is not automatically a specific indication for bone marrow aspirate and biopsy in a patient with typical features of ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/3,17\">",
"     3,17",
"    </a>",
"    ], although many centers perform a bone marrow examination for all patients before initiating steroid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of immune thrombocytopenia (ITP) is generally straightforward in healthy-appearing children with the classic presentation, consisting of the sudden onset of bruising and bleeding, and with thrombocytopenia as the only detected abnormality. For patients with other symptoms or hematologic abnormalities, diagnostic considerations include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/17,19,23\">",
"     17,19,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukemia &ndash; Most childhood leukemia is due to acute lymphoblastic leukemia (ALL). Children with ALL usually have other clinical and laboratory findings that distinguish ALL from ITP. These include systemic symptoms (eg, fever, bone and joint pain, or weight loss), hepatosplenomegaly, lymphadenopathy, leukocytosis, and significant anemia (hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"      Examination of the peripheral blood smear is a step to include or exclude ALL. ALL is characterized by blast cells on the peripheral blood smear, but these may be difficult to distinguish from atypical lymphocytes that may be present in a postviral case of ITP. The diagnosis and classification of leukemia are based upon specialized tests that are performed on cells derived from a bone marrow aspirate or lymph node biopsy specimens. If there are enough circulating blasts, the type of leukemia can be determined on peripheral blood flow cytometry. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Active infection &ndash; Ongoing viral infections, such as infectious mononucleosis (Epstein-Barr virus, EBV), cytomegalovirus (CMV), hepatitis C, and HIV-1, can cause thrombocytopenia. These disorders may be differentiated clinically from ITP by the presence of systemic signs and symptoms but specific testing may be required [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/24\">",
"       24",
"      </a>",
"      ]. Detection of the virus by polymerase chain reaction (PCR) testing is the only useful approach to confirming the diagnosis. H. pylori testing might be considered in a population at high risk for H. pylori disease, because there is some evidence that H. pylori infection is associated with chronic ITP in adults.",
"     </li>",
"     <li>",
"      Autoimmune hemolytic anemia &ndash; An autoimmune hemolytic anemia (AIHA) that occurs in combination with thrombocytopenia is known as Evans syndrome. A hemolytic process should be suspected if there are spherocytes and polychromasia on the peripheral smear, and there is an elevated reticulocyte count. Reticulocytopenic cases of autoimmune hemolytic anemia (AIHA) occur but fortunately are infrequent as are Coombs- negative cases. The diagnosis of AIHA is established by a positive direct antiglobulin test (DAT, formerly known as the Coombs test). If AIHA is diagnosed, testing for ALPS is required, as discussed immediately below. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H28#H28\">",
"       \"Autoimmune hemolytic anemia in children\", section on 'Evans syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic autoimmune disease &ndash; Autoimmune diseases such as systemic lupus erythematosus (SLE) and autoimmune lymphoproliferative syndrome (ALPS) can present with only immune-mediated thrombocytopenia, and the underlying diagnosis may be inapparent for a prolonged period. Autoimmune diseases are more commonly discovered in older, female children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most common initial symptoms of SLE are the gradual onset of fever, malaise, and general deterioration over several months, with or without a malar rash; joint stiffness consistent with mild arthritis may be the first sign. Laboratory findings include elevated antinuclear antibodies (ANA), and especially anti-DSDNA, but this laboratory finding is not always present when a child first presents with thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"       \"Systemic lupus erythematosus in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ALPS has been thought to typically present with chronic lymphadenopathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      splenomegaly. However, it is now recognized that children presenting with Evans syndrome (even without lymphadenopathy or splenomegaly) may have ALPS in approximately half of the cases [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/25\">",
"       25",
"      </a>",
"      ]. The signature laboratory abnormality is",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      double-negative T cells (DNT cells) detected by flow cytometric immunophenotyping; DNA-based testing for mutation of CD95 FAS will identify 85 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=see_link\">",
"       \"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunodeficiency syndromes &ndash; About 10 percent of adult patients with common variable immunodeficiency (CVID) have associated autoimmune hematologic disorders, including ITP or Evans syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/26\">",
"       26",
"      </a>",
"      ]. Thus, patients with ITP and recurrent infections should be evaluated for CVID by measuring serum immunoglobulin levels, although ITP patients with CVID often have no history of infections. For this reason, an international consensus report on ITP recommended measuring immunoglobulin levels in all ITP patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/17/23833/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link&amp;anchor=H10572433#H10572433\">",
"       \"Common variable immunodeficiency in children\", section on 'Diagnosis'",
"      </a>",
"      .) Wiskott Aldrich and DiGeorge syndrome also should be considered; the former in boys with eczema and milk allergy and the latter in patients with hypocalcemia and a right-sided aortic arch. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22729?source=see_link\">",
"       \"DiGeorge syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug exposure &ndash; Drug exposure appears to be an uncommon cause of thrombocytopenia in children. Drugs associated with thrombocytopenia include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      (this is a special case in that it is usually identified inpatient in ICU patients),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      , sulfonamides,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"       valproate",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef73618 \" href=\"UTD.htm?36/3/36924\">",
"       table 1",
"      </a>",
"      ). This possibility is explored by a history of exposure to such drugs, including whether the drugs are present in the household and might have been accidentally ingested by the child. Proving a causal association between drug exposure and ITP in an individual patient is very difficult. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"       \"Drug-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone marrow failure syndromes &ndash; In acquired bone marrow failure syndromes, such as aplastic anemia, a low platelet count is almost always associated with other significant changes in the peripheral blood, such as severe anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neutropenia and a low reticulocyte count. The diagnosis is established by bone marrow examination including a biopsy. In infants and young children, inherited disorders causes of impaired thrombopoiesis should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link&amp;anchor=H12#H12\">",
"       \"Acquired aplastic anemia in children and young adults\", section on 'Clinical presentation and diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link&amp;anchor=H17#H17\">",
"       \"Causes of thrombocytopenia in children\", section on 'Genetic causes of impaired thrombopoiesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemolytic uremic syndrome (HUS) &ndash; HUS is a microangiopathic disorder characterized by hemolytic anemia (with fragmented erythrocytes, also known as schistocytes), thrombocytopenia, and acute renal injury, which may progress to oliguria. Patients typically have a history of gastrointestinal symptoms (diarrhea, abdominal pain and vomiting) occurring about one week prior to the presentation of HUS with bloody stools. In HUS, the direct antiglobulin test (DAT [Coombs test]) is normal, distinguishing it from autoimmune hemolytic anemias. If HUS is suspected, renal function should be evaluated with measures of blood urea nitrogen (BUN), creatinine and urine output; stool cultures for enterohemorrhagic E. coli are supportive but not always necessary for the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Evaluation and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic disorder that causes platelet activation and consumption and resembles HUS. The presence of schistocytes on the peripheral smear, anemia, and neurologic abnormalities (confusion, somnolence, headache) are characteristic of TTP. Renal insufficiency also may be present, often with gross or microscopic blood in the urine. TTP is associated with absent or reduced ADAMS13 activity: it can be congenital, caused by an inherited gene defect, or an acquired auto-antibody-mediated disease like ITP, in which ADAMTS13 is targeted in almost all cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link&amp;anchor=H13964768#H13964768\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Congenital TTP'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"       \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (DIC) &ndash; The diagnosis of acute DIC is suggested by the history (eg, sepsis, trauma, malignancy), clinical presentation, moderate to severe thrombocytopenia",
"      <span class=\"nowrap\">",
"       (&lt;100,000/microL),",
"      </span>",
"      abnormal coagulation studies (prothrombin time [PT] and activated partial thromboplastin time [aPTT]), and the presence of microangiopathic changes on the peripheral blood smear (schistocytes). The diagnosis is confirmed by a variety of laboratory studies that should demonstrate evidence of both increased thrombin generation (eg, decreased fibrinogen) as well as increased fibrinolysis (eg, elevated fibrin degradation products and D-dimer). These patients are usually considerably sicker than one would expect from ITP, and often bleed out of proportion to their platelet counts.(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H20#H20\">",
"       \"Disseminated intravascular coagulation in infants and children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inherited disorders of thrombocytopenia &ndash; Several inherited thrombocytopenic disorders can be differentiated from ITP by other distinguishing features. Examples include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inherited aplastic anemias, thrombocytopenia generally associated with anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link\">",
"       \"Inherited aplastic anemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombocytopenia-absent radius syndrome, an autosomal recessive disorder characterized by severe thrombocytopenia and bilateral absent radii. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H28#H28\">",
"       \"Neonatal thrombocytopenia\", section on 'Thrombocytopenia-absent radius syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Von Willebrand disease type 2B is characterized by greater than expected bleeding for the degree of thrombocytopenia and very variable factor levels and platelet count. Stress typically makes it worse and certain types have platelet clumping on peripheral smear. Initial screening for Von Willebrand disease consists of measurement of plasma Von Willebrand Factor antigen (VWF:Ag) and VWF activity followed by Von Willebrand factor multimers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H9#H9\">",
"       \"Classification and pathophysiology of von Willebrand disease\", section on 'Type 2B'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wiskott-Aldrich syndrome, an X-linked congenital disorder characterized by thrombocytopenia (with small platelets), eczema, and frequent infections. The x-linked form (XLT) is often characterized primarily by the thrombocytopenia. In the neonate with XLT, platelets may not be small, and there may be blood in the stool from milk allergy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A rare group of disorders due to mutations of the MYH9 gene, which encodes the non-muscle myosin heavy chain A protein, are characterized by thrombocytopenia, giant platelets (",
"      <a class=\"graphic graphic_picture graphicRef72433 \" href=\"UTD.htm?17/31/17911\">",
"       picture 2",
"      </a>",
"      ), and Dohle-like inclusion bodies. These include Sebastian syndrome, May-Hegglin anomaly, Ebstein syndrome, and Fechtner syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link&amp;anchor=H20#H20\">",
"       \"Causes of thrombocytopenia in children\", section on 'Giant platelet disorders'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/17/29970?source=see_link\">",
"       \"Patient information: Immune thrombocytopenia (ITP) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Childhood immune thrombocytopenia (ITP, previously known as idiopathic thrombocytopenic purpura) generally presents with the sudden appearance of a petechial rash, bruising",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bleeding in an otherwise healthy child. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In about 60 percent of children with ITP, there is a history of a prior infection. Otherwise, the history does not reveal any significant findings. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The examination of the child with suspected ITP generally reveals signs of cutaneous bleeding (petechiae, purpura, and ecchymoses). About 40 percent of patients also have mucosal bleeding (involving the nasal passages, oral cavity, and genitourinary and gastrointestinal tracts). Patients with platelet counts below",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      are more likely to have mucosal bleeding. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious hemorrhage requiring blood transfusions occurs in about 3 percent of children with ITP. Intracranial hemorrhage is the most severe consequence of ITP and is rare, with a reported incidence of 0.1 to 0.8 percent. (See",
"      <a class=\"local\" href=\"#H4714177\">",
"       'Serious hemorrhage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4714305\">",
"       'Intracranial hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 70 percent of affected children have the newly-diagnosed form of ITP, defined as a complete remission (platelet count",
"      <span class=\"nowrap\">",
"       &gt;150,000/microL)",
"      </span>",
"      within three months of presentation. Children with chronic ITP (thrombocytopenia lasting more than 12 months after presentation) are more likely at presentation to have an insidious onset of symptoms, be older, and not have a history of a prior infection compared to those with acute ITP. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disease course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ITP is based upon the following: (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Isolated thrombocytopenia (platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL),",
"      </span>",
"      with otherwise normal blood counts and peripheral blood smear.",
"     </li>",
"     <li>",
"      No clinically apparent associated conditions that may cause thrombocytopenia. In particular, a disorder other than ITP is suggested if there is enlargement of lymph nodes, liver, or spleen, systemic symptoms (eg, fever, anorexia, bone or joint pain, or weight loss) or a prior history of atypical bleeding or significant disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial laboratory evaluation includes a complete blood count (CBC) and peripheral blood smear. Any findings that are inconsistent with ITP (eg, abnormal white blood cell count or blood smear) should lead to evaluation for another cause of thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A bone marrow examination is not required in children with a typical presentation and laboratory findings of ITP. Indications for bone marrow aspiration and biopsy include atypical clinical or laboratory features at presentation, new findings that emerge during follow-up that are not consistent with ITP, or failure to respond to treatment if treatment is given. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bone marrow examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with laboratory abnormalities other than thrombocytopenia or with clinical features that are not typical of ITP, other disorders that can cause thrombocytopenia should be excluded. These include malignancy, infection, autoimmune disorders, drug-induced thrombocytopenia, and bone marrow failure. The steps in the further evaluation depend on the reason for concern. (See",
"      <a class=\"local\" href=\"#H16831408\">",
"       'Further evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/1\">",
"      Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/2\">",
"      Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006; 133:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/3\">",
"      British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/4\">",
"      Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol 2010; 85:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/5\">",
"      Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr 2005; 94:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/6\">",
"      K&uuml;hne T, Buchanan GR, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 2003; 143:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/7\">",
"      K&uuml;hne T, Imbach P, Bolton-Maggs PH, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001; 358:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/8\">",
"      K&uuml;hne T, Berchtold W, Michaels LA, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 2011; 96:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/9\">",
"      Neunert CE, Buchanan GR, Imbach P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008; 112:4003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/10\">",
"      Rosth&oslash;j S, Hedlund-Treutiger I, Rajantie J, et al. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: A prospective Nordic study of an unselected cohort. J Pediatr 2003; 143:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/11\">",
"      Medeiros D, Buchanan GR. Current controversies in the management of idiopathic thrombocytopenic purpura during childhood. Pediatr Clin North Am 1996; 43:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/12\">",
"      Lilleyman JS. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology. Arch Dis Child 1994; 71:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/13\">",
"      Psaila B, Petrovic A, Page LK, et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009; 114:4777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/14\">",
"      Glanz J, France E, Xu S, et al. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pediatrics 2008; 121:e506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/15\">",
"      Bruin M, Bierings M, Uiterwaal C, et al. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Br J Haematol 2004; 127:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/16\">",
"      Ahmed S, Siddiqui AK, Shahid RK, et al. Prognostic variables in newly diagnosed childhood immune thrombocytopenia. Am J Hematol 2004; 77:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/17\">",
"      Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/18\">",
"      Chong BH. Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Crit Rev Oncol Hematol 1995; 20:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/19\">",
"      Kurtzberg J, Stockman JA 3rd. Idiopathic autoimmune thrombocytopenic purpura. Adv Pediatr 1994; 41:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/20\">",
"      Calpin C, Dick P, Poon A, Feldman W. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia? Arch Pediatr Adolesc Med 1998; 152:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/21\">",
"      Halperin DS, Doyle JJ. Is bone marrow examination justified in idiopathic thrombocytopenic purpura? Am J Dis Child 1988; 142:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/22\">",
"      Vesely S, Buchanan GR, Cohen A, et al. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J Pediatr Hematol Oncol 2000; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/23\">",
"      Sadowitz D, Souid AK, Terndrup TE. Idiopathic thrombocytopenic purpura in children: recognition and management. Pediatr Emerg Care 1996; 12:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/24\">",
"      DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol 2009; 146:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/25\">",
"      Seif AE, Manno CS, Sheen C, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood 2010; 115:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23833/abstract/26\">",
"      Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005; 25:57.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5930 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23833=[""].join("\n");
var outline_f23_17_23833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4714177\">",
"      - Serious hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4714305\">",
"      - Intracranial hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4713815\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Disease course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16831379\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16831408\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21235124\">",
"      - Role of antiplatelet antibody testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5930\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5930|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/8/10372\" title=\"picture 1\">",
"      Petechiae in immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/31/17911\" title=\"picture 2\">",
"      Giant platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5930|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/3/36924\" title=\"table 1\">",
"      Drugs associated with immune thrombocytopenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=related_link\">",
"      Causes of thrombocytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22729?source=related_link\">",
"      DiGeorge syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/17/29970?source=related_link\">",
"      Patient information: Immune thrombocytopenia (ITP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=related_link\">",
"      Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_17_23834="Suicidal behavior in children and adolescents: Epidemiology and risk factors";
var content_f23_17_23834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23834/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23834/contributors\">",
"     Stephanie Kennebeck, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23834/contributors\">",
"     Liza Bonin, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23834/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23834/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23834/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/17/23834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/17/23834/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/17/23834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suicidal behavior includes the spectrum from thoughts or ideas that revolve around suicide or death (suicidal ideation) through fatal completion of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Between these extremes are suicide threats and suicide attempts (potentially self-injurious action with a nonfatal outcome for which there is evidence that the individual intended to kill him- or herself) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/1\">",
"     1",
"    </a>",
"    ]. Children and adolescents who present for medical attention with suicidal behavior require a variable amount of medical, social, and psychiatric intervention depending upon the seriousness of their intent, their underlying risk factors, and their emotional support system.",
"   </p>",
"   <p>",
"    The epidemiology of and risk factors for childhood and adolescent suicide will be reviewed here. The evaluation and management of children and adolescents with suicidal ideation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link\">",
"     \"Evaluation and management of suicidal behavior in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suicide is an important public health problem for children and adolescents around the world [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. In the United States, suicide rates doubled in the 15- to 19-year age group and tripled in the 10- to 14-year age group between the 1960s and the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/9\">",
"     9",
"    </a>",
"    ]. The reasons for this trend are unclear, although it is not simply because of increased reporting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/10\">",
"     10",
"    </a>",
"    ]. Possible explanations include increased rates of alcohol and drug abuse, depression, family and social disorganization, and access to firearms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suicide is the third leading cause of death among all children and adolescents in the United States, including those aged 10 to 19 years (",
"    <a class=\"graphic graphic_table graphicRef67131 \" href=\"UTD.htm?26/29/27102\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Adolescent suicide rates declined somewhat between the late 1980s and 2003, but increased between 2003 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and again between 2008 and 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/13\">",
"     13",
"    </a>",
"    ]. In 2009, there were 1922 suicides reported for children younger than 19 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/13\">",
"     13",
"    </a>",
"    ]. Suicide accounted for 14 percent of deaths in adolescents aged 15 to 19 years, and 8 percent of deaths in children aged 10 to 14 years.",
"   </p>",
"   <p>",
"    Between 2003 and 2004, suicide rates increased among females aged 10 to 14 years (by 76 percent), females aged 15 to 19 years (by 32 percent), and males aged 15 to 19 years (by 9 percent) (",
"    <a class=\"graphic graphic_figure graphicRef79081 \" href=\"UTD.htm?41/8/42114\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/15\">",
"     15",
"    </a>",
"    ]. The reasons for this increase are not clear; possible explanations include the misclassification of unintentional asphyxia from adolescents playing \"the choking game\" (ie, intentionally restricting the supply of oxygenation to the brain, often with a ligature, to induce a brief euphoria) and changes in risk factors for suicide or suicide methods [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The potential impact of the United States Food and Drug Administration warning regarding the risk of suicidality and antidepressants on the rates of antidepressant prescriptions and suicide is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3864?source=see_link\">",
"     \"The &ldquo;choking game&rdquo; and other strangulation activities in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suicide attempts are common. Available data indicate that there are as many as 50 to 100 suicide attempts for every completed suicide in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Survey data from the United States in 2001, 2003, 2005, and 2007 found that approximately 7 to 9 percent of all adolescents attempted suicide in the 12 months before the survey [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/22-25\">",
"     22-25",
"    </a>",
"    ], and cross-sectional data from a self-report questionnaire administered to 15- and 16-year-old students attending 41 schools in England provided similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/26\">",
"     26",
"    </a>",
"    ]. A more recent nationally representative, retrospective survey of adolescents (N = 6483) in the United States found a lifetime prevalence of suicide attempt in 4 percent; among adolescents who attempted suicide, 67 percent had a lifetime history of treatment or some type of services prior to their attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/27\">",
"     27",
"    </a>",
"    ]. The reasons reported for suicide attempt vary by sex and age (",
"    <a class=\"graphic graphic_table graphicRef69888 \" href=\"UTD.htm?21/21/21853\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Suicidal ideation often precedes suicide attempts. A nationally representative survey in the United States found that among adolescents who suffered suicidal ideation, a subsequent attempt occurred in 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suicidal ideation occurs in prepubertal children, but suicide attempts and completions are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. After puberty, the rate of suicide among adolescents increases with increasing age (",
"    <a class=\"graphic graphic_figure graphicRef56318 \" href=\"UTD.htm?39/53/40798\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential explanations for the increased incidence of suicide attempts and completion with increasing age include increased access to firearms and potentially lethal drugs, increased rates of psychiatric illness, substance abuse, and other comorbidities, as well as changes in cognitive development. As adolescents develop their capacities for abstract and complex thinking, they are more capable of contemplating life circumstances, envisioning a hopeless future, generating suicide as a possible solution, and planning and executing a suicide attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Younger children who complete suicide are more likely to be of above-average intelligence, possibly exposing them to the developmental level of stress experienced by older children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, puberty may have a negative impact, particularly for girls, when there is a lack of synchrony between the timing of pubertal development and chronologic age. In a large cross-sectional study, girls who matured early were more likely to have a lifetime history of disruptive behavior disorder and suicide attempts than their peers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link&amp;anchor=H18#H18\">",
"     \"Normal puberty\", section on 'Psychological changes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of suicidal ideation is greater in high school girls than boys (21 to 31 percent versus 13 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/22,23,37\">",
"     22,23,37",
"    </a>",
"    ]. Female high school students are more likely than males to have a specific suicide plan (median of 16 versus 11 percent, with a range of 13 to 20 percent and 8 to 15 percent for females versus males, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, the rates of having a specific plan are similar between the genders in college students (approximately 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suicide attempts are also more common in adolescent girls than boys. As an example, one nationally representative survey in the United States found that the lifetime prevalence of suicide attempt was greater in adolescent females than males (6 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/27\">",
"     27",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    However, adolescent boys are more likely to complete suicide than girls (",
"    <a class=\"graphic graphic_table graphicRef59548 \" href=\"UTD.htm?31/9/31900\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56318 \" href=\"UTD.htm?39/53/40798\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/33,39\">",
"     33,39",
"    </a>",
"    ]. Most studies relate the differences in completion rates to the method chosen. Girls tend to choose less lethal means such as overdose or cutting, whereas boys tend to choose firearms and hanging (",
"    <a class=\"graphic graphic_table graphicRef76221 \" href=\"UTD.htm?27/48/28429\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Another lethal method of suicide that is more common in males (usually older adolescents and adults) is \"suicide by cop\", in which the suicidal individual engages in conspicuous and threatening behavior with a lethal or apparently lethal weapon in an attempt provoke law enforcement officers to shoot him to protect civilians or in self-defense [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. This method is also known as police-assisted suicide, victim-precipitated homicide, and law-enforcement-assisted suicide.",
"   </p>",
"   <p>",
"    Differences in the rate of adolescent depression between boys and girls may explain at least some of the difference in the rates of suicide attempts. As puberty progresses, most boys develop a more positive self-image and mood, but girls, particularly white girls, have a diminished sense of self-worth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/46\">",
"     46",
"    </a>",
"    ]. During adolescence, the prevalence of depression increases and becomes twice as high among girls as boys [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Race/ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rates of suicide and suicide attempts vary according to",
"    <span class=\"nowrap\">",
"     race/ethnicity",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef56318 \" href=\"UTD.htm?39/53/40798\">",
"     figure 2",
"    </a>",
"    ). Among adolescents, the suicide rate is highest for white males. However, between 1980 and 1996, the suicide rate increased most rapidly among black males ages 15 to 19 years (from 3.6 to 8.1 per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/51\">",
"     51",
"    </a>",
"    ]. On the other hand, in the 2007 YRBSS, Hispanic adolescents were more likely than black or white adolescents to report a suicide attempt in the previous 12 months (10 versus 8 versus 6 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much effort in psychiatric medicine has gone into identifying risk factors for suicide. Improved ability to identify individuals who are at risk for suicide attempts and completion may facilitate prevention and enable more appropriate allocation of resources. Unfortunately, factors that reliably differentiate between suicide ideators, attempters, and completers have not yet been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/52\">",
"     52",
"    </a>",
"    ]. Nonetheless, general categories of factors that affect an individual's vulnerability to suicide have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/8,53\">",
"     8,53",
"    </a>",
"    ]. These factors can be used to determine the level of intervention necessary for a particular patient [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/8,54,55\">",
"     8,54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link\">",
"     \"Evaluation and management of suicidal behavior in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for suicidal behavior in children and adolescents can be categorized as predisposing or precipitating factors. Predisposing factors increase an individual's risk for suicide and include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychiatric disorders",
"     </li>",
"     <li>",
"      Previous suicide attempt",
"     </li>",
"     <li>",
"      Family history of mood disorder",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      suicidal behavior",
"     </li>",
"     <li>",
"      History of physical or sexual abuse",
"     </li>",
"     <li>",
"      Exposure to violence",
"     </li>",
"     <li>",
"      Biologic factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Precipitating factors (also called \"proximal\" or \"potentiating\" factors) are unlikely to contribute to suicide risk in and of themselves. However, they play a vital role in interaction with predisposing factors. Precipitating factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Access to means",
"     </li>",
"     <li>",
"      Alcohol and drug use",
"     </li>",
"     <li>",
"      Exposure to suicide",
"     </li>",
"     <li>",
"      Social stress and isolation",
"     </li>",
"     <li>",
"      Emotional and cognitive factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Psychiatric disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of adolescents who attempt or commit suicide have a psychiatric disorder, with depressive disorder being the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/27\">",
"     27",
"    </a>",
"    ]. Other predisposing psychiatric disorders include oppositional defiant disorder, conduct disorder, bipolar disorder, anxiety disorder, eating disorder, personality disorder, and substance use disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/30,56\">",
"     30,56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Alcohol and drug use'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most children and adolescents who commit suicide have a mental illness, and suicide victims are more likely to meet criteria for a psychiatric disorder than matched community control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/34,43,57\">",
"     34,43,57",
"    </a>",
"    ]. In one retrospective \"psychiatric autopsy\" study of 119 subjects who committed suicide (mean age 17 years), at least one psychiatric diagnosis was present in 91 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/34\">",
"     34",
"    </a>",
"    ]. Depressive syndromes, conduct disorder, and substance use disorders were most common. However, the prevalence of psychiatric illness appears to be greater among older adolescent suicide victims than younger victims. A retrospective study in 140 suicide victims found that a psychiatric disorder was present in more subjects &ge;16 years of age, compared to subjects &lt;16 years of age (90 versus 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescents who attempt suicide also have high rates of psychiatric disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. In a case-control study, 129 adolescents and young adults (aged 13 to 24 years) who made serious suicide attempts were compared with 153 randomly selected controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/58\">",
"     58",
"    </a>",
"    ]. Adolescents who made suicide attempts had higher rates of affective disorders (70 versus 15 percent), substance use disorders (39 versus 7 percent), anxiety disorders (15 versus 6 percent), eating disorders (9 versus 5 percent), and antisocial disorders (35 versus 7 percent) than did controls.",
"   </p>",
"   <p>",
"    The risk of suicide depends upon the nature and severity of the psychiatric illness. As an example, suicidal behavior is increased in patients with psychotic features, such as command auditory hallucinations to commit self-harm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. A community based study found that among adolescents aged 11 to 13 years (N = 78), suicidal ideation or behavior were more common in adolescents with psychiatric disorders (eg, depressive disorder, anxiety disorder, or attention deficit hyperactivity disorder) plus psychotic symptoms, compared to adolescents with psychiatric disorders but no psychotic symptoms (OR 5.1, 95% CI 1.2-22.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/63\">",
"     63",
"    </a>",
"    ]. Similar results were found in adolescents aged 13 to 15 years (N = 72).",
"   </p>",
"   <p>",
"    Comorbid psychiatric diagnoses further increase the risk of suicidality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/56,64-68\">",
"     56,64-68",
"    </a>",
"    ], although the degree of increased risk depends in part upon the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/69\">",
"     69",
"    </a>",
"    ]. Among depressed youth, particularly among males, suicide risk increases with comorbid conduct disorder and substance use disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/68,70\">",
"     68,70",
"    </a>",
"    ]. In one case control study, the odds of a serious suicide attempt in subjects with two or more psychiatric disorders were 90 times greater than the odds in subjects with no disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antidepressant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between antidepressant therapy and suicide risk in children and adolescents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Previous attempts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals who have attempted suicide in the past are at greater risk for subsequent attempts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    completion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/67,71\">",
"     67,71",
"    </a>",
"    ]. This is particularly true if they have a history of multiple attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between one-quarter and two-thirds of children and adolescents who have attempted suicide make a subsequent attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/39,75,76\">",
"     39,75,76",
"    </a>",
"    ]. The risk of completed suicide in previous attempters appears to be greatest in the 6 to 12 months following the previous attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 3783 adolescents who attempted suicide, 40 percent reported a previous attempt; previous attempts were more common among those who indicated their reason for suicide was physical, sexual, or substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/39\">",
"     39",
"    </a>",
"    ]. In baseline and follow-up surveys of high school students, individuals with multiple suicide attempts more frequently reported wishing to die at the time of the attempt, regretting recovery, and timing the attempt to avoid intervention than did those with a single attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of suicide increases in adolescents who have a family history of mood disorders",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suicidal behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/77-83\">",
"     77-83",
"    </a>",
"    ]. Twin studies suggest this increased risk has both environmental and genetic components [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/79,84\">",
"     79,84",
"    </a>",
"    ]. However, it is not clear whether the genetic component is primarily responsible for the underlying psychiatric disorder or for the suicide itself. In one study, both a family history of completed suicide and psychiatric illness were risk factors for suicide, and the effect of family suicide history was independent of the family history of psychiatric illness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of suicide attempt may be greater for children who suffer parental suicide than adolescents who experience the same loss. A retrospective study of national registries compared time to hospitalization for suicide attempt in three groups who lost a parent to suicide: children 0 to 12 years of age (N = 10,681), adolescents 13 to 17 years of age (N = 6401), and young adults 18 to 24 years of age (N = 9014) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/85\">",
"     85",
"    </a>",
"    ]. Although the absolute risk of suicide attempt was small, the risk in children was greater than that for young adults, and for offspring who lost a parent during early childhood (ages 0 to 5 years), the risk continued to rise for two decades. By contrast, the risk of suicide attempt in adolescents was comparable to the risk for young adults.",
"   </p>",
"   <p>",
"    In addition, the risk of suicide attempt may be greater for youth who lose their mother to suicide rather than their father. A retrospective study of national registries examined time to hospitalization for suicide attempt, comparing children and adolescents who lost a mother to suicide (N = 5600) with youth who lost a mother to an accident (2872); the study also compared time to hospitalization for suicide attempt in youth who lost a father to suicide (N = 17,847) or to an accident (12,121) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/83\">",
"     83",
"    </a>",
"    ]. Propensity scoring was used to match suicide decedents with fatal accident decedents. Hospitalization for suicide attempt was greater for youth who lost a mother to suicide compared with youth who lost a mother to an accident (adjusted hazard ratio =1.80, 95% CI 1.19-2.74). By contrast, the risk for hospitalization in offspring of paternal suicide and paternal accidental death was comparable (adjusted hazard ratio =1.14, 95% CI 0.96-1.35).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     History of abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sexual abuse increases the likelihood of depression and suicide. In a cohort of 776 randomly selected children who were studied for 17 years, adolescents who were physically maltreated were three times more likely to become depressed or suicidal than those who were not [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/86\">",
"     86",
"    </a>",
"    ]. The risk of repeated suicide attempts was eight times greater among those who had been sexually abused than those who had not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Exposure to violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents who are witnesses to or victims of violence are at increased risk for depression and suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. In the 1995 Massachusetts YRBSS study described above, high school students who were exposed to higher levels of violence or victimization (eg, had been injured or threatened with a weapon, or had sexual contact against their will) were twice as likely to attempt suicide than those who were not (95% CI 1.8-2.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40617?source=see_link\">",
"     \"Peer violence and violence prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link&amp;anchor=H3#H3\">",
"     \"Childhood exposure to intimate partner violence\", section on 'Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Biologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic factors, particularly those that influence brain serotonin, may play a role in suicidal ideation and behavior in individuals with depression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/91-98\">",
"     91-98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies comparing suicide attempters and nonattempters have found lower levels of 5-hydroxyindoleacetic acid (5-HIAA), the major serotonin metabolite, in the CSF or brainstems of suicide attempters than nonattempters [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/99,100\">",
"     99,100",
"    </a>",
"    ], with the extent of metabolite reduction directly related to the lethality of the suicide attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/97\">",
"     97",
"    </a>",
"    ]. In some genetic studies, suicidal acts and low CSF 5HIAA concentrations are related to a polymorphism in the TPH gene, which codes for tryptophan hydroxylase, the rate-limiting enzyme in the synthesis of serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/93,101\">",
"     93,101",
"    </a>",
"    ], but this is an inconsistent finding [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals who commit suicide have fewer serotonin transporter sites, more postsynaptic serotonin receptors, smaller serotonin neurons, and more numerous, less functional neurons than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/97,100\">",
"     97,100",
"    </a>",
"    ]. Such individuals also have increased concentrations of norepinephrine, tyrosine hydroxylase, and alpha-2-adrenergic receptors, and reduced numbers of postsynaptic beta receptors, locus coeruleus neurons, and norepinephrine transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Access to means",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access to means to attempt suicide is a potent precipitating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This is true even after controlling for other risk factors such as depression or substance use. Firearms are the most common means for suicide completion. Other means include medications, illicit drugs, toxic chemicals, carbon monoxide, hanging, and cutting. Almost anything can be used as a means to attempt suicide, but access to the most lethal means often is preventable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14921?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of firearm injuries in children\", section on 'Prevention of firearm injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Firearms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access to firearms increases the risk of completed suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/11,104-106\">",
"     11,104-106",
"    </a>",
"    ]. Firearms are used in almost two-thirds of fatal suicides in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/39\">",
"     39",
"    </a>",
"    ], where the rate of firearm-related suicide is nearly 11 times greater than the pooled rate from other industrialized countries (0.32 versus 0.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/107\">",
"     107",
"    </a>",
"    ]. In a case-control study of adolescent suicide, guns were twice as likely to be present in the homes of suicide victims as attempters or psychiatric controls (adjusted odds ratio 2.1, 95% CI 1.2-3.7 and 2.2, 95% CI 1.4-3.5 for attempters and controls, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/11\">",
"     11",
"    </a>",
"    ]. In another study comparing suicide rates among adolescents (14 to 20 years) from states with and without various types of firearm legislation, a modest decrease (8.3 percent) in suicide rates among 14- to 17-year old children was found in the states with child access prevention laws (5.97 per 100,000 population versus the projected 6.51 per 100,000 population) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/108\">",
"     108",
"    </a>",
"    ]. Prevention of firearm injuries is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14921?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of firearm injuries in children\", section on 'Prevention of firearm injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alcohol and drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol and drug use are known risk factors for suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/70,109-112\">",
"     70,109-112",
"    </a>",
"    ], largely because of their disinhibiting effects. Between 25 and 46 percent of adolescents who complete suicide and approximately 20 percent of those who attempt suicide have alcohol or another drug in their bodies at the time of suicide or suicide attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/10,41\">",
"     10,41",
"    </a>",
"    ]. Increased rates of alcohol and substance use among adolescents since the 1960s, particularly among white males, may be related to the increased suicide rate in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/10\">",
"     10",
"    </a>",
"    ]. Adolescent intoxication, in combination with psychiatric disorder and a firearm in the home, is a particularly high risk and lethal combination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Exposure to suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are exposed to the suicide of a family member or friend are at risk for internalizing symptoms, depression, anxiety,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posttraumatic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. Teenagers who are exposed to relatives who commit suicide may be at particular risk because of exposure to violence, exposure to suicide, and possible genetic predisposition to suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/84,115,116\">",
"     84,115,116",
"    </a>",
"    ]. The individual contribution of each of these factors to the overall risk of suicide is not known. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Family history'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Exposure to violence'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Suicide contagion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether exposure to the suicide of a friend is a risk factor for suicide independent of internalizing symptoms, depression, anxiety,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posttraumatic stress is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/26,114\">",
"     26,114",
"    </a>",
"    ]. Suicidal contagion refers to the process that results in suicide clusters or \"outbreaks\" of suicides in a community [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/117-119\">",
"     117-119",
"    </a>",
"    ]. Clusters of suicide account for approximately 5 percent of youth suicide in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/120\">",
"     120",
"    </a>",
"    ]. These clusters may occur when a vulnerable adolescent reads or hears an account of another suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/121\">",
"     121",
"    </a>",
"    ]. The data suggest that exposure to a suicide attempt is a risk factor for imitation, but most studies show that friends of suicide victims are not at risk for imitation. Adolescents who imitate the suicide of another peer are usually not close friends of the victim and may have deficits in coping skills and lack models for healthy coping strategies. Adolescents and young adults between the ages of 15 and 24 appear to be the group at greatest risk for imitation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/120,122-124\">",
"     120,122-124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Social stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stressful life events typically increase the risk of suicide only in the context of preexisting vulnerability. Nonetheless, adolescents who attempt or complete suicide are more likely to have suffered major stress in their lives than those who do not [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/75,88,125-129\">",
"     75,88,125-129",
"    </a>",
"    ]. Common stressful events for adolescents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interpersonal loss or conflict",
"     </li>",
"     <li>",
"      Economic problems",
"     </li>",
"     <li>",
"      School-related difficulties",
"     </li>",
"     <li>",
"      Workplace problems",
"     </li>",
"     <li>",
"      Legal or disciplinary problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interpersonal problems, such as a relationship breakdown",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    argument with partner, family, or friend(s), are the most commonly cited reason for suicide attempts provided by both previous attempters and their significant others (",
"    <a class=\"graphic graphic_table graphicRef67131 \" href=\"UTD.htm?26/29/27102\">",
"     table 1",
"    </a>",
"    ). Legal difficulties or charges and being in trouble with the police are another important category of stressful life events that are associated with increased risk of adolescent suicide attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical or physical concerns also can be stressful issues for adolescents. These may include the physical changes related to puberty",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic illness, teenage pregnancy, and the threat of sexually transmitted infections (STIs), including human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/131-135\">",
"     131-135",
"    </a>",
"    ]. Although the overall risk of suicide during pregnancy is low [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/136\">",
"     136",
"    </a>",
"    ], teenagers may have a variety of emotional responses to a newly diagnosed pregnancy; those with a previous suicide attempt may be at increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/137\">",
"     137",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Previous attempts'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/31/10744?source=see_link&amp;anchor=H4#H4\">",
"     \"Pregnancy in adolescents\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adopted adolescents also may be at increased risk for suicide. Univariate analysis of data from a subset of adolescents in the National Longitudinal Study of Adolescent Health indicated that adopted adolescents were more likely to have attempted suicide (7.6 versus 3.1 percent) in the past year than had their nonadopted peers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/138\">",
"     138",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8520?source=see_link&amp;anchor=H20#H20\">",
"     \"Adoption\", section on 'Mental health issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other life events that are not typically thought of as negative also can be precipitating stressors for adolescents (eg, birth of sibling, high school graduation, etc). Whether or not an event is potentially stressful depends upon the adolescent's perceptions and interpretations of the event as well as the adolescent's coping repertoire.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Social isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social isolation and alienation are often associated with adolescent suicide. Adolescents who attempt suicide are more likely to isolate themselves than those who only think about committing suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/139\">",
"     139",
"    </a>",
"    ]. Suicidal adolescents who keep thoughts to themselves appear to be at greater risk for suicide attempt than those who discuss their suicidal ideation with others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Sexual orientation",
"    </span>",
"    &nbsp;&mdash;&nbsp;National attention first focused on the prevalence of suicide among homosexual youth in the late 1980s with reports that gay, lesbian, and bisexual adolescents were disproportionately at risk to attempt and commit suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/140\">",
"     140",
"    </a>",
"    ]. Early studies of this issue were flawed by lack of consensus definitions for important terms (eg, suicide attempt and sexual orientation), uncertain reliability and validity of measures of these terms, nonrepresentative samples, and lack of appropriate comparison groups [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/141-144\">",
"     141-144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recent investigations that have attempted to address these methodologic shortcomings, suggest that gay, lesbian, and bisexual youth are more likely to experience suicidal ideation and attempt suicide than their heterosexual peers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/87,145-149\">",
"     87,145-149",
"    </a>",
"    ], although these studies are not without limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/150-153\">",
"     150-153",
"    </a>",
"    ]. Whether increased suicidality is related to other suicide risks (eg, alcohol and substance use, psychiatric disorders, social stress related to bullying, victimization, or isolation), or lack of protective factors is not clear and may vary by sex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/2,145,154-157\">",
"     2,145,154-157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, self-reported data from the Massachusetts 1995 Centers for Disease Control and Prevention Youth Risk Behavior Survey regarding sexual orientation, drug use, and",
"    <span class=\"nowrap\">",
"     violence/victimization",
"    </span>",
"    were analyzed with respect to suicide attempt in the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/87\">",
"     87",
"    </a>",
"    ]. When controlled for other factors, boys who identified themselves as gay, bisexual, or not sure were three to four times more likely to attempt suicide than their heterosexual counterparts (OR, 3.7; 95% CI 1.9-7.3). In contrast, sexual orientation did not predict suicide risk among girls who identified themselves as lesbian, bisexual, or not sure, when other factors were controlled. Among these girls, drug use and violence or victimization may be more important risks for suicidality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Emotional and cognitive factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emotional and cognitive factors that may precipitate suicidal behavior include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hopelessness and helplessness",
"     </li>",
"     <li>",
"      Despair",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      agitation",
"     </li>",
"     <li>",
"      Impaired problem-solving",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before suicide, adolescents often perceive their future to be fundamentally negative and hopeless. They perceive themselves and others as powerless to change their dire circumstances. Suicide is a desperate attempt at a solution for such adolescents whose hopelessness renders them unable to generate or even imagine helpful options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other risk factors include poor self-esteem, impulsivity and risk-taking behavior, aggressiveness, delinquent behavior, family dysfunction, nonintact family, and having run away from home [",
"    <a class=\"abstract\" href=\"UTD.htm?23/17/23834/abstract/158-160\">",
"     158-160",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"       \"Patient information: Depression treatment options for adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2670495\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suicide is the fourth leading cause of death among all children in the United States; in 2004 there were 1985 suicides reported for children younger than 19 years (",
"      <a class=\"graphic graphic_table graphicRef67131 \" href=\"UTD.htm?26/29/27102\">",
"       table 1",
"      </a>",
"      ). There are as many as 50 to 100 suicide attempts for every completed suicide in adolescents. Surveys estimate that the 12-month prevalence of suicide attempts in adolescents is 7 to 9 percent. The reasons reported for suicide attempt vary by sex and age (",
"      <a class=\"graphic graphic_table graphicRef69888 \" href=\"UTD.htm?21/21/21853\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suicidal ideation occurs in prepubertal children, but suicide attempts and completions are rare. After puberty, the rate of suicide among adolescents increases with age (",
"      <a class=\"graphic graphic_figure graphicRef56318 \" href=\"UTD.htm?39/53/40798\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suicidal ideation is more common among high school girls than boys, and females are more likely to have a specific suicide plan. In addition, suicide attempts are more likely in adolescent girls than boys; however, suicide deaths are more common in boys (",
"      <a class=\"graphic graphic_table graphicRef59548 \" href=\"UTD.htm?31/9/31900\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56318 \" href=\"UTD.htm?39/53/40798\">",
"       figure 2",
"      </a>",
"      ). One explanation is that girls tend to choose less lethal means such as overdose or cutting, whereas boys tend to choose firearms and hanging (",
"      <a class=\"graphic graphic_table graphicRef76221 \" href=\"UTD.htm?27/48/28429\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sex'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that increase the risk of suicidal behavior in children and adolescents include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Psychiatric disorders &ndash; especially major depression, but also including bipolar disorder, substance abuse, oppositional defiant disorder, conduct disorder, anxiety disorder, eating disorder, personality disorder, and comorbidity of mood with behavioral or anxiety disorders",
"     </li>",
"     <li>",
"      Previous suicide attempt &ndash; especially a history of multiple attempts",
"     </li>",
"     <li>",
"      Family history of mood disorder",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      suicidal behavior",
"     </li>",
"     <li>",
"      History of physical or sexual abuse",
"     </li>",
"     <li>",
"      Exposure to violence as a witness or victim",
"     </li>",
"     <li>",
"      Antidepressant medications may increase the risk of suicidal ideation and behavior in children and adolescents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=see_link\">",
"       \"Effect of antidepressants on suicide risk in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increased risk posed by these factors can be amplified by additional factors, including access to means (especially firearms), alcohol and drug use, exposure to suicide (eg, family member or friend), social stress and isolation, and emotional and cognitive factors (despair, hopelessness, and impaired problem-solving skills). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/1\">",
"      Catallozzi M, Pletcher JR, Schwarz DF. Prevention of suicide in adolescents. Curr Opin Pediatr 2001; 13:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/2\">",
"      American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with suicidal behavior. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 2001; 40:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/3\">",
"      Beautrais AL. Child and young adolescent suicide in New Zealand. Aust N Z J Psychiatry 2001; 35:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/4\">",
"      McClure GM. Suicide in children and adolescents in England and Wales 1970-1998. Br J Psychiatry 2001; 178:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/5\">",
"      Hawton K, Fagg J, Simkin S, et al. Deliberate self-harm in adolescents in Oxford, 1985-1995. J Adolesc 2000; 23:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Suicide among children, adolescents, and young adults--United States, 1980-1992. MMWR Morb Mortal Wkly Rep 1995; 44:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/7\">",
"      Hamilton BE, Mini&ntilde;o AM, Martin JA, et al. Annual summary of vital statistics: 2005. Pediatrics 2007; 119:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/8\">",
"      Shain BN, American Academy of Pediatrics Committee on Adolescence. Suicide and suicide attempts in adolescents. Pediatrics 2007; 120:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/9\">",
"      Efforts to reduce the toll of injuries in childhood require expanded research. American Academy of Pediatrics. Committee on Injury and Poison Prevention. Pediatrics 1996; 97:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/10\">",
"      Brent DA, Perper JA, Allman CJ. Alcohol, firearms, and suicide among youth. Temporal trends in Allegheny County, Pennsylvania, 1960 to 1983. JAMA 1987; 257:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/11\">",
"      Brent DA, Perper JA, Allman CJ, et al. The presence and accessibility of firearms in the homes of adolescent suicides. A case-control study. JAMA 1991; 266:2989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/12\">",
"      Martin JA, Kung HC, Mathews TJ, et al. Annual summary of vital statistics: 2006. Pediatrics 2008; 121:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/13\">",
"      Kochanek KD, Kirmeyer SE, Martin JA, et al. Annual summary of vital statistics: 2009. Pediatrics 2012; 129:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/14\">",
"      McKeown RE, Cuffe SP, Schulz RM. US suicide rates by age group, 1970-2002: an examination of recent trends. Am J Public Health 2006; 96:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Suicide trends among youths and young adults aged 10-24 years--United States, 1990-2004. MMWR Morb Mortal Wkly Rep 2007; 56:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/16\">",
"      Andrew TA, Fallon KK. Asphyxial games in children and adolescents. Am J Forensic Med Pathol 2007; 28:303.",
"     </a>",
"    </li>",
"    <li>",
"     Russell, P, Paulozzi, L, Gilchrist, J, Tobin, R. Unintentional strangulation deaths from the \"choking game\" among youths aged 6-19 years--United States, 1995-2007. MMWR Morb Mortal Wkly Rep 2008; 57:141. Available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5706a1.htm. Accessed on February 15, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/18\">",
"      Centers for Disease Control (CDC). Attempted suicide among high school students--United States, 1990. MMWR Morb Mortal Wkly Rep 1991; 40:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/19\">",
"      Meehan PJ, Lamb JA, Saltzman LE, O'Carroll PW. Attempted suicide among young adults: progress toward a meaningful estimate of prevalence. Am J Psychiatry 1992; 149:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/20\">",
"      Brener ND, Krug EG, Simon TR. Trends in suicide ideation and suicidal behavior among high school students in the United States, 1991-1997. Suicide Life Threat Behav 2000; 30:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/21\">",
"      Andrus JK, Fleming DW, Heumann MA, et al. Surveillance of attempted suicide among adolescents in Oregon, 1988. Am J Public Health 1991; 81:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/22\">",
"      Grunbaum JA, Kann L, Kinchen SA, et al. Youth risk behavior surveillance--United States, 2001. MMWR Surveill Summ 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/23\">",
"      Grunbaum JA, Kann L, Kinchen S, et al. Youth risk behavior surveillance--United States, 2003. MMWR Surveill Summ 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/24\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance--United States, 2005. MMWR Surveill Summ 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/25\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance--United States, 2007. MMWR Surveill Summ 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/26\">",
"      Hawton K, Rodham K, Evans E, Weatherall R. Deliberate self harm in adolescents: self report survey in schools in England. BMJ 2002; 325:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/27\">",
"      Nock MK, Green JG, Hwang I, et al. Prevalence, correlates, and treatment of lifetime suicidal behavior among adolescents: results from the national comorbidity survey replication adolescent supplement. JAMA Psychiatry 2013; 70:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/28\">",
"      Pfeffer CR, Trad PV. Sadness and suicidal tendencies in preschool children. J Dev Behav Pediatr 1988; 9:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/29\">",
"      Rosenthal PA, Rosenthal S. Suicidal behavior by preschool children. Am J Psychiatry 1984; 141:520.",
"     </a>",
"    </li>",
"    <li>",
"     Goldman, S, Beardslee, WR. Suicide in children and adolescents. In: Harvard Medical School Guide to Assessment and Intervention in Suicide, Jacob, D (Ed). Jossey-Bass, San Franscisco 1998. p.417.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/31\">",
"      Tishler CL, Reiss NS, Rhodes AR. Suicidal behavior in children younger than twelve: a diagnostic challenge for emergency department personnel. Acad Emerg Med 2007; 14:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/32\">",
"      Doshi A, Boudreaux ED, Wang N, et al. National study of US emergency department visits for attempted suicide and self-inflicted injury, 1997-2001. Ann Emerg Med 2005; 46:369.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention (CDC). Deaths: Leading Causes for 2000. National vital statistics reports, vol. 50, no. 16, Sept 16, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/34\">",
"      Shaffer D, Gould MS, Fisher P, et al. Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry 1996; 53:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/35\">",
"      Gr&oslash;holt B, Ekeberg O, Wichstr&oslash;m L, Haldorsen T. Suicide among children and younger and older adolescents in Norway: a comparative study. J Am Acad Child Adolesc Psychiatry 1998; 37:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/36\">",
"      Graber JA, Lewinsohn PM, Seeley JR, Brooks-Gunn J. Is psychopathology associated with the timing of pubertal development? J Am Acad Child Adolesc Psychiatry 1997; 36:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/37\">",
"      Grunbaum JA, Kann L, Kinchen SA, et al. Youth risk behavior surveillance. National Alternative High School Youth Risk Behavior Survey, United States, 1998. J Sch Health 2000; 70:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/38\">",
"      Youth Risk Behavior Surveillance: National College Health Risk Behavior Survey--United States, 1995. MMWR CDC Surveill Summ 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Fatal and nonfatal suicide attempts among adolescents--Oregon, 1988-1993. MMWR Morb Mortal Wkly Rep 1995; 44:312.",
"     </a>",
"    </li>",
"    <li>",
"     Suicide and Suicidal Behavior. In: Synopsis of Psychiatry, 7th ed, Kaplan, HI, Sadock, BJ, Grebb, JA (Eds), Williams &amp; Wilkins, Baltimore 1995. p.2391.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/41\">",
"      Li G, Ling J, DiScala C, et al. Characteristics and outcomes of self inflicted pediatric injuries: the role of method of suicide attempt. Inj Prev 1997; 3:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/42\">",
"      Spicer RS, Miller TR. Suicide acts in 8 states: incidence and case fatality rates by demographics and method. Am J Public Health 2000; 90:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/43\">",
"      Brent DA, Baugher M, Bridge J, et al. Age- and sex-related risk factors for adolescent suicide. J Am Acad Child Adolesc Psychiatry 1999; 38:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/44\">",
"      Mohandie K, Meloy JR. Clinical and forensic indicators of \"suicide by cop\". J Forensic Sci 2000; 45:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/45\">",
"      Hutson HR, Anglin D, Yarbrough J, et al. Suicide by cop. Ann Emerg Med 1998; 32:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/46\">",
"      Brown KM, McMahon RP, Biro FM, et al. Changes in self-esteem in black and white girls between the ages of 9 and 14 years. The NHLBI Growth and Health Study. J Adolesc Health 1998; 23:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/47\">",
"      Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/48\">",
"      Fleming JE, Offord DR. Epidemiology of childhood depressive disorders: a critical review. J Am Acad Child Adolesc Psychiatry 1990; 29:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/49\">",
"      Lewinsohn PM, Clarke GN, Seeley JR, Rohde P. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry 1994; 33:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/50\">",
"      Angold A, Worthman CW. Puberty onset of gender differences in rates of depression: a developmental, epidemiologic and neuroendocrine perspective. J Affect Disord 1993; 29:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/51\">",
"      Centers for Disease Control and Prevention (CDC). Suicide among black youths--United States, 1980-1995. MMWR Morb Mortal Wkly Rep 1998; 47:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/52\">",
"      Kosky R, Silburn S, Zubrick SR. Are children and adolescents who have suicidal thoughts different from those who attempt suicide? J Nerv Ment Dis 1990; 178:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/53\">",
"      Borowsky IW, Ireland M, Resnick MD. Adolescent suicide attempts: risks and protectors. Pediatrics 2001; 107:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/54\">",
"      Press BR, Khan SA. Management of the suicidal child or adolescent in the emergency department. Curr Opin Pediatr 1997; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/55\">",
"      Brent DA. The aftercare of adolescents with deliberate self-harm. J Child Psychol Psychiatry 1997; 38:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/56\">",
"      Foley DL, Goldston DB, Costello EJ, Angold A. Proximal psychiatric risk factors for suicidality in youth: the Great Smoky Mountains Study. Arch Gen Psychiatry 2006; 63:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/57\">",
"      Runeson B. Mental disorder in youth suicide. DSM-III-R Axes I and II. Acta Psychiatr Scand 1989; 79:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/58\">",
"      Beautrais AL, Joyce PR, Mulder RT. Psychiatric illness in a New Zealand sample of young people making serious suicide attempts. N Z Med J 1998; 111:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/59\">",
"      Fergusson DM, Lynskey MT. Suicide attempts and suicidal ideation in a birth cohort of 16-year-old New Zealanders. J Am Acad Child Adolesc Psychiatry 1995; 34:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/60\">",
"      Andrews JA, Lewinsohn PM. Suicidal attempts among older adolescents: prevalence and co-occurrence with psychiatric disorders. J Am Acad Child Adolesc Psychiatry 1992; 31:655.",
"     </a>",
"    </li>",
"    <li>",
"     Berman, AL, Jobes, DA. Adolescent suicide assessment and intervention. Washington, DC: American Psychological Association, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/62\">",
"      Hirschfeld RM, Russell JM. Assessment and treatment of suicidal patients. N Engl J Med 1997; 337:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/63\">",
"      Kelleher I, Lynch F, Harley M, et al. Psychotic symptoms in adolescence index risk for suicidal behavior: findings from 2 population-based case-control clinical interview studies. Arch Gen Psychiatry 2012; 69:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/64\">",
"      Brent DA, Perper JA, Moritz G, et al. Psychiatric risk factors for adolescent suicide: a case-control study. J Am Acad Child Adolesc Psychiatry 1993; 32:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/65\">",
"      Beautrais AL, Joyce PR, Mulder RT, et al. Prevalence and comorbidity of mental disorders in persons making serious suicide attempts: a case-control study. Am J Psychiatry 1996; 153:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/66\">",
"      Windle RC, Windle M. An investigation of adolescents' substance use behaviors, depressed affect, and suicidal behaviors. J Child Psychol Psychiatry 1997; 38:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/67\">",
"      Brent DA, Perper JA, Moritz G, et al. Suicide in affectively ill adolescents: a case-control study. J Affect Disord 1994; 31:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/68\">",
"      Shaffer D, Craft L. Methods of adolescent suicide prevention. J Clin Psychiatry 1999; 60 Suppl 2:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/69\">",
"      Lewinsohn PM, Rohde P, Seeley JR. Adolescent psychopathology: III. The clinical consequences of comorbidity. J Am Acad Child Adolesc Psychiatry 1995; 34:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/70\">",
"      Gould MS, King R, Greenwald S, et al. Psychopathology associated with suicidal ideation and attempts among children and adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/71\">",
"      Hawton K, Fagg J. Suicide, and other causes of death, following attempted suicide. Br J Psychiatry 1988; 152:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/72\">",
"      Miranda R, Scott M, Hicks R, et al. Suicide attempt characteristics, diagnoses, and future attempts: comparing multiple attempters to single attempters and ideators. J Am Acad Child Adolesc Psychiatry 2008; 47:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/73\">",
"      Goldston DB, Daniel SS, Reboussin DM, et al. Suicide attempts among formerly hospitalized adolescents: a prospective naturalistic study of risk during the first 5 years after discharge. J Am Acad Child Adolesc Psychiatry 1999; 38:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/74\">",
"      Hult&eacute;n A, Jiang GX, Wasserman D, et al. Repetition of attempted suicide among teenagers in Europe: frequency, timing and risk factors. Eur Child Adolesc Psychiatry 2001; 10:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/75\">",
"      Stewart SE, Manion IG, Davidson S, Cloutier P. Suicidal children and adolescents with first emergency room presentations: predictors of six-month outcome. J Am Acad Child Adolesc Psychiatry 2001; 40:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/76\">",
"      Rosewater KM, Burr BH. Epidemiology, risk factors, intervention, and prevention of adolescent suicide. Curr Opin Pediatr 1998; 10:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/77\">",
"      Gould MS, Fisher P, Parides M, et al. Psychosocial risk factors of child and adolescent completed suicide. Arch Gen Psychiatry 1996; 53:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/78\">",
"      McKeown RE, Garrison CZ, Cuffe SP, et al. Incidence and predictors of suicidal behaviors in a longitudinal sample of young adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/79\">",
"      Egeland JA, Sussex JN. Suicide and family loading for affective disorders. JAMA 1985; 254:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/80\">",
"      Qin P, Agerbo E, Mortensen PB. Suicide risk in relation to family history of completed suicide and psychiatric disorders: a nested case-control study based on longitudinal registers. Lancet 2002; 360:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/81\">",
"      Brent DA, Bridge J, Johnson BA, Connolly J. Suicidal behavior runs in families. A controlled family study of adolescent suicide victims. Arch Gen Psychiatry 1996; 53:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/82\">",
"      Wiemann CM, Rickert VI, Berenson AB, Volk RJ. Are pregnant adolescents stigmatized by pregnancy? J Adolesc Health 2005; 36:352.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/83\">",
"      Kuramoto SJ, Stuart EA, Runeson B, et al. Maternal or paternal suicide and offspring's psychiatric and suicide-attempt hospitalization risk. Pediatrics 2010; 126:e1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/84\">",
"      Roy A, Segal NL, Centerwall BS, Robinette CD. Suicide in twins. Arch Gen Psychiatry 1991; 48:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/85\">",
"      Kuramoto SJ, Runeson B, Stuart EA, et al. Time to hospitalization for suicide attempt by the timing of parental suicide during offspring early development. JAMA Psychiatry 2013; 70:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/86\">",
"      Brown J, Cohen P, Johnson JG, Smailes EM. Childhood abuse and neglect: specificity of effects on adolescent and young adult depression and suicidality. J Am Acad Child Adolesc Psychiatry 1999; 38:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/87\">",
"      Garofalo R, Wolf RC, Wissow LS, et al. Sexual orientation and risk of suicide attempts among a representative sample of youth. Arch Pediatr Adolesc Med 1999; 153:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/88\">",
"      Dube SR, Anda RF, Felitti VJ, et al. Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the life span: findings from the Adverse Childhood Experiences Study. JAMA 2001; 286:3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/89\">",
"      Silverman JG, Raj A, Mucci LA, Hathaway JE. Dating violence against adolescent girls and associated substance use, unhealthy weight control, sexual risk behavior, pregnancy, and suicidality. JAMA 2001; 286:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/90\">",
"      Lambert, SF. J Adolesc Health 2008; 43:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/91\">",
"      Asberg M, Tr&auml;skman L, Thor&eacute;n P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry 1976; 33:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/92\">",
"      Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 2001; 24:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/93\">",
"      Mann JJ, Malone KM, Nielsen DA, et al. Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Am J Psychiatry 1997; 154:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/94\">",
"      Du L, Faludi G, Palkovits M, et al. Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol Psychiatry 1999; 46:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/95\">",
"      Pandey GN, Dwivedi Y, Rizavi HS, et al. Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 2002; 159:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/96\">",
"      Mann JJ, Stoff DM. A synthesis of current findings regarding neurobiological correlates and treatment of suicidal behavior. Ann N Y Acad Sci 1997; 836:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/97\">",
"      Maris RW. Suicide. Lancet 2002; 360:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/98\">",
"      Zametkin AJ, Alter MR, Yemini T. Suicide in teenagers: assessment, management, and prevention. JAMA 2001; 286:3120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/99\">",
"      Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatr Clin North Am 2000; 23:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/100\">",
"      Arango V, Underwood MD, Mann JJ. Postmortem findings in suicide victims. Implications for in vivo imaging studies. Ann N Y Acad Sci 1997; 836:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/101\">",
"      Nielsen DA, Goldman D, Virkkunen M, et al. Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Arch Gen Psychiatry 1994; 51:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/102\">",
"      Du L, Faludi G, Palkovits M, et al. Tryptophan hydroxylase gene 218A/C polymorphism is not associated with depressed suicide. Int J Neuropsychopharmacol 2000; 3:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/103\">",
"      Abbar M, Courtet P, Amad&eacute;o S, et al. Suicidal behaviors and the tryptophan hydroxylase gene. Arch Gen Psychiatry 1995; 52:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/104\">",
"      Shah S, Hoffman RE, Wake L, Marine WM. Adolescent suicide and household access to firearms in Colorado: results of a case-control study. J Adolesc Health 2000; 26:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/105\">",
"      Grossman DC, Reay DT, Baker SA. Self-inflicted and unintentional firearm injuries among children and adolescents: the source of the firearm. Arch Pediatr Adolesc Med 1999; 153:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/106\">",
"      Brent DA, Perper JA, Moritz G, et al. Firearms and adolescent suicide. A community case-control study. Am J Dis Child 1993; 147:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/107\">",
"      Centers for Disease Control and Prevention (CDC). Rates of homicide, suicide, and firearm-related death among children--26 industrialized countries. MMWR Morb Mortal Wkly Rep 1997; 46:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/108\">",
"      Webster DW, Vernick JS, Zeoli AM, Manganello JA. Association between youth-focused firearm laws and youth suicides. JAMA 2004; 292:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/109\">",
"      Shafii M, Carrigan S, Whittinghill JR, Derrick A. Psychological autopsy of completed suicide in children and adolescents. Am J Psychiatry 1985; 142:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/110\">",
"      Johnsson E, Fridell M. Suicide attempts in a cohort of drug abusers: a 5-year follow-up study. Acta Psychiatr Scand 1997; 96:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/111\">",
"      Pirkola SP, Marttunen MJ, Henriksson MM, et al. Alcohol-related problems among adolescent suicides in Finland. Alcohol Alcohol 1999; 34:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/112\">",
"      M&eacute;an M, Righini NC, Narring F, et al. Substance use and suicidal conduct: a study of adolescents hospitalized for suicide attempt and ideation. Acta Paediatr 2005; 94:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/113\">",
"      Pfeffer CR, Martins P, Mann J, et al. Child survivors of suicide: psychosocial characteristics. J Am Acad Child Adolesc Psychiatry 1997; 36:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/114\">",
"      Brent DA, Moritz G, Bridge J, et al. Long-term impact of exposure to suicide: a three-year controlled follow-up. J Am Acad Child Adolesc Psychiatry 1996; 35:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/115\">",
"      Roy A, Segal NL. Suicidal behavior in twins: a replication. J Affect Disord 2001; 66:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/116\">",
"      Roy A, Nielsen D, Rylander G, et al. Genetics of suicide in depression. J Clin Psychiatry 1999; 60 Suppl 2:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/117\">",
"      Phillips DP, Carstensen LL. Clustering of teenage suicides after television news stories about suicide. N Engl J Med 1986; 315:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/118\">",
"      Brent DA, Kerr MM, Goldstein C, et al. An outbreak of suicide and suicidal behavior in a high school. J Am Acad Child Adolesc Psychiatry 1989; 28:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/119\">",
"      O'Carroll PW, Potter LB. Suicide contagion and the reporting of suicide: recommendations from a national workshop. United States Department of Health and Human Services. MMWR Recomm Rep 1994; 43:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/120\">",
"      Hazell P. Adolescent suicide clusters: evidence, mechanisms and prevention. Aust N Z J Psychiatry 1993; 27:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/121\">",
"      Pirkis J, Blood RW. Suicide and the media. Part I: Reportage in nonfictional media. Crisis 2001; 22:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/122\">",
"      Gould MS, Petrie K, Kleinman MH, Wallenstein S. Clustering of attempted suicide: New Zealand national data. Int J Epidemiol 1994; 23:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/123\">",
"      Gould MS, Wallenstein S, Kleinman MH, et al. Suicide clusters: an examination of age-specific effects. Am J Public Health 1990; 80:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/124\">",
"      Gould MS, Wallenstein S, Kleinman M. Time-space clustering of teenage suicide. Am J Epidemiol 1990; 131:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/125\">",
"      de Wilde EJ, Kienhorst IC, Diekstra RF, Wolters WH. The relationship between adolescent suicidal behavior and life events in childhood and adolescence. Am J Psychiatry 1992; 149:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/126\">",
"      Fernquist RM. Problem drinking in the family and youth suicide. Adolescence 2000; 35:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/127\">",
"      King RA, Schwab-Stone M, Flisher AJ, et al. Psychosocial and risk behavior correlates of youth suicide attempts and suicidal ideation. J Am Acad Child Adolesc Psychiatry 2001; 40:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/128\">",
"      Beautrais AL, Joyce PR, Mulder RT. Risk factors for serious suicide attempts among youths aged 13 through 24 years. J Am Acad Child Adolesc Psychiatry 1996; 35:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/129\">",
"      Whitehead M, Holland P. What puts children of lone parents at a health disadvantage? Lancet 2003; 361:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/130\">",
"      Beautrais AL, Joyce PR, Mulder RT. Precipitating factors and life events in serious suicide attempts among youths aged 13 through 24 years. J Am Acad Child Adolesc Psychiatry 1997; 36:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/131\">",
"      Vajda J, Steinbeck K. Factors associated with repeat suicide attempts among adolescents. Aust N Z J Psychiatry 2000; 34:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/132\">",
"      Druss B, Pincus H. Suicidal ideation and suicide attempts in general medical illnesses. Arch Intern Med 2000; 160:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/133\">",
"      Sur&iacute;s JC, Parera N, Puig C. Chronic illness and emotional distress in adolescence. J Adolesc Health 1996; 19:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/134\">",
"      Favaro A, Santonastaso P. Suicidality in eating disorders: clinical and psychological correlates. Acta Psychiatr Scand 1997; 95:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/135\">",
"      Bayatpour M, Wells RD, Holford S. Physical and sexual abuse as predictors of substance use and suicide among pregnant teenagers. J Adolesc Health 1992; 13:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/136\">",
"      Marzuk PM, Tardiff K, Leon AC, et al. Lower risk of suicide during pregnancy. Am J Psychiatry 1997; 154:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/137\">",
"      Wagner BM, Cole RE, Schwartzman P. Psychosocial correlates of suicide attempts among junior and senior high school youth. Suicide Life Threat Behav 1995; 25:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/138\">",
"      Slap G, Goodman E, Huang B. Adoption as a risk factor for attempted suicide during adolescence. Pediatrics 2001; 108:E30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/139\">",
"      Negron R, Piacentini J, Graae F, et al. Microanalysis of adolescent suicide attempters and ideators during the acute suicidal episode. J Am Acad Child Adolesc Psychiatry 1997; 36:1512.",
"     </a>",
"    </li>",
"    <li>",
"     Gibson, R. Gay male and lesbian youth suicide. Report of the Secretary's Task Force on Youth Suicide, Vol. 3, Prevention and Interventions in Youth Suicide, U.S. Department of Heath and Human Services, Rockville, MD 1989. p.100.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/141\">",
"      Savin-Williams RC. A critique of research on sexual-minority youths. J Adolesc 2001; 24:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/142\">",
"      Savin-Williams RC. Suicide attempts among sexual-minority youths: population and measurement issues. J Consult Clin Psychol 2001; 69:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/143\">",
"      Muehrer P. Suicide and sexual orientation: a critical summary of recent research and directions for future research. Suicide Life Threat Behav 1995; 25 Suppl:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/144\">",
"      Shaffer D, Fisher P, Hicks RH, et al. Sexual orientation in adolescents who commit suicide. Suicide Life Threat Behav 1995; 25 Suppl:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/145\">",
"      Fergusson DM, Horwood LJ, Beautrais AL. Is sexual orientation related to mental health problems and suicidality in young people? Arch Gen Psychiatry 1999; 56:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/146\">",
"      Remafedi G, French S, Story M, et al. The relationship between suicide risk and sexual orientation: results of a population-based study. Am J Public Health 1998; 88:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/147\">",
"      Faulkner AH, Cranston K. Correlates of same-sex sexual behavior in a random sample of Massachusetts high school students. Am J Public Health 1998; 88:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/148\">",
"      Russell ST, Joyner K. Adolescent sexual orientation and suicide risk: evidence from a national study. Am J Public Health 2001; 91:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/149\">",
"      Remafedi G. Suicidality in a venue-based sample of young men who have sex with men. J Adolesc Health 2002; 31:305.",
"     </a>",
"    </li>",
"    <li>",
"     Moscicki, EK. Epidemiology of suicide. In: Harvard Medical School Guide to Assessment and Intervention in Suicide, Jacob, D (Ed). Jossey-Bass, San Franscisco 1998. p.40.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/151\">",
"      Bailey JM. Homosexuality and mental illness. Arch Gen Psychiatry 1999; 56:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/152\">",
"      Remafedi G. Suicide and sexual orientation: nearing the end of controversy? Arch Gen Psychiatry 1999; 56:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/153\">",
"      Friedman RC. Homosexuality, psychopathology, and suicidality. Arch Gen Psychiatry 1999; 56:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/154\">",
"      Herrell R, Goldberg J, True WR, et al. Sexual orientation and suicidality: a co-twin control study in adult men. Arch Gen Psychiatry 1999; 56:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/155\">",
"      Safren SA, Heimberg RG. Depression, hopelessness, suicidality, and related factors in sexual minority and heterosexual adolescents. J Consult Clin Psychol 1999; 67:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/156\">",
"      Wichstr&oslash;m L, Hegna K. Sexual orientation and suicide attempt: a longitudinal study of the general Norwegian adolescent population. J Abnorm Psychol 2003; 112:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/157\">",
"      Eisenberg ME, Resnick MD. Suicidality among gay, lesbian and bisexual youth: the role of protective factors. J Adolesc Health 2006; 39:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/158\">",
"      Weitoft GR, Hjern A, Haglund B, Ros&eacute;n M. Mortality, severe morbidity, and injury in children living with single parents in Sweden: a population-based study. Lancet 2003; 361:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/159\">",
"      Wichstr&oslash;m L. Predictors of adolescent suicide attempts: a nationally representative longitudinal study of Norwegian adolescents. J Am Acad Child Adolesc Psychiatry 2000; 39:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/17/23834/abstract/160\">",
"      Woods ER, Lin YG, Middleman A, et al. The associations of suicide attempts in adolescents. Pediatrics 1997; 99:791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1229 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-197.136.42.3-858ECED34C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23834=[""].join("\n");
var outline_f23_17_23834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2670495\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Race/ethnicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Psychiatric disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antidepressant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Previous attempts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      History of abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Exposure to violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Biologic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Access to means",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Firearms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alcohol and drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Exposure to suicide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Suicide contagion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Social stress",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Social isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Sexual orientation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Emotional and cognitive factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2670495\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1229|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/8/42114\" title=\"figure 1\">",
"      Suicide trends adol females",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/53/40798\" title=\"figure 2\">",
"      Suicide rates adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1229|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/29/27102\" title=\"table 1\">",
"      Causes death children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/21/21853\" title=\"table 2\">",
"      Reasons for adolescent suicide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/9/31900\" title=\"table 3\">",
"      Adolescent suicide Oregon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/48/28429\" title=\"table 4\">",
"      Suicide method by gender",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8520?source=related_link\">",
"      Adoption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=related_link\">",
"      Childhood exposure to intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15736?source=related_link\">",
"      Effect of antidepressants on suicide risk in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=related_link\">",
"      Evaluation and management of suicidal behavior in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40617?source=related_link\">",
"      Peer violence and violence prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/31/10744?source=related_link\">",
"      Pregnancy in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14921?source=related_link\">",
"      Prevention of firearm injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3864?source=related_link\">",
"      The &ldquo;choking game&rdquo; and other strangulation activities in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_17_23835="Symptoms of diabetic neuropathy";
var content_f23_17_23835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of diabetic neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Favors neuropathy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Favors vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Site of pain",
"       </td>",
"       <td>",
"        Feet more than calves",
"       </td>",
"       <td>",
"        Calves, thighs, and buttocks more than feet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quality of pain",
"       </td>",
"       <td>",
"        Sharp, superficial, burning, tingling",
"       </td>",
"       <td>",
"        Deep ache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Present at rest",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Effect of walking",
"       </td>",
"       <td>",
"        Pain improves",
"       </td>",
"       <td>",
"        Pain made worse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain worse in bed",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preceded by recent change in glycemic control",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical features to help distinguish the pain in diabetic neuropathy from that with peripheral vascular disease and intermittent claudication.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23835=[""].join("\n");
var outline_f23_17_23835=null;
var title_f23_17_23836="Diagnosis of COPD - PFTs";
var content_f23_17_23836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnosis of chronic obstructive pulmonary disease: PFTs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Spirometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spirometry is the essential test to confirm the diagnosis and establish the staging of COPD. If values are abnormal, a post-bronchodilator test may be indicated. Airflow limitation that is irreversible or only partially reversible with bronchodilator is suggestive of COPD rather than asthma. A postbronchodilator ratio of FEV1/FVC &lt;0.7 or &lt;LLN of FEV1/FVC is used to establish the presence of airflow limitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         In the presence of a low FEV1/FVC, the percent of predicted FEV1 is used to determine the severity of airflow limitation.",
"        </p>",
"        <p>",
"         GOLD 1: Mild (FEV1 &ge;80 percent predicted)",
"        </p>",
"        <p>",
"         GOLD 2: Moderate (50 percent predicted &le;FEV1 &lt;80 percent predicted)",
"        </p>",
"        <p>",
"         GOLD 3: Severe (30 percent predicted &le;FEV1 &lt;50 percent predicted)",
"        </p>",
"        <p>",
"         GOLD 4: Very severe (FEV1 &lt;30 percent predicted)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Lung volumes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Body plethysmography to assess lung volumes is not necessary except in patients with a low FVC on spirometry (&lt;80 percent predicted) or when concomitant interstitial lung disease is suspected.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Diffusing capacity for carbon monoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Measurement of DLCO can help establish the presence of emphysema, but is not necessary for the routine diagnosis of COPD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Chest radiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Only diagnostic of severe emphysema, but is frequently obtained to exclude other lung diseases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Arterial blood gases (ABGs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mild and moderate airflow obstruction - ABG usually not needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderately severe airflow obstruction - ABG is optional, but oximetry should be done. ABGs are obtained if oxygen saturation is &lt;92 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe and very severe airflow obstruction - ABGs are essential to assess for hypercapnia.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PFTs: pulmonary function tests; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; LLN: lower limit of normal; GOLD: Global Initiative for Chronic Obstructive Lung Disease; DLCO: diffusing capacity for carbon monoxide; ABG: arterial blood gas.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23836=[""].join("\n");
var outline_f23_17_23836=null;
var title_f23_17_23837="Ibutilide sotalol AF flutter";
var content_f23_17_23837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ibutilide is more effective than sotalol for acute reversion of atrial tachyarrhythmias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 252px; background-image: url(data:image/gif;base64,R0lGODlhlwH8AMQAAP///yBzOQAzmf8AAAAAADMzM8zMzKqqqhEREVVVVe7u7oiIiHd3d0RERN3d3ZmZmSIiIru7u2ZmZgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACXAfwAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhG4Eh4iJiouMjY6PkJGSk5SMhZdtBJg2mpueZp2fMaGipV6kpiyoqaxWq60nr7CzTrIAlYt+trS8SLYEA8HCw8TEu3THvcpCv8XOzsly0cvUPM3P2MHTcNvV3pwpwNnY3Ybf50HX49C66O496uvG7e/1OPHywuUxCAgoCQQMPNlnr+AIfPkG2FqA4BADgSYMECiQot+/gAMNahwVLuG8EwcIJBAhYcEJiRRR/1g8ARBiE4Ib6yHMJ2vBxIcjGCAy2fDQAYCHGjgAYNFAgaBDW2aMyVTFTHmyFDRAhOCATQYAph5AWQIgT38QECiIMBGA0lpN08bq6FHfigUAGwA8AEDnw7IAFkBAhLUfVwWHFJx9qbbwQbZtFaJgwEABgAcEShLAqlUiBAAS/V0lClYsWYqDmcA0TO3pOlkHdB6SIEI1ApNmfQI92tefUaSxXYomXdj0uNFpgPPm5Tub8DPHh8MqTo6e8pjMnyUvM/25qejs+lS3Lgp7se1iwHPf9AtXIudbDEwlAIGuVNzjsYj/M//HXgMOCPibyzX+lfraeRGXTaw15JiB/rkSjv95iKCnhUSHQPAAYP4QRYBjCVLxiwAcdujhhx8C2IWIPIQFwAENOYAggrfkkqESG4IoI4gkblGjDv0MtZcDc30WzoswhjPjkB3emIWROBxw1ETurSfUj0D6IiSRQyL5HzJRSokCAVRW6eAbVkYZY5c0fmlOlkaMSaaH0xyl2wuhjdDfEmHSWQ9gGJ4y5ZpsomDTIf64ucJcAFCYW0gjyYnXClO9eQ+W7jRg0wMpjbgnnxzagqgIgqpAKAlxijAnCiEd4ugNdQb5zlEV6rklpn2SKhKnIh3yAABuZvZnWRa1JNFIBuzVEEXqwQcqRrjWSsACUxXg2J8NYQWlNO9ISgD/pV+oiammsyZrgAIW5apfbHRxltuvANzHVVgKQMZaV8geFQFZl0lwrWV5TeYUpO7gCYa2fHKbqKAGirsfAeX2GtCvhqIEISKVjnCWuBTptIBNI202bRypZgjwmgLTagC9yW41LkC3muvrrP2MVVZYQ10EEcV1Leujxlvyi+YQH5NZE1XJRihQqVPZNqzKC89a6lHErtetCKUeMhLNFtc8kb4bc7NzET132XERU6Wc8xxf+9c1lWUDsSTWWYO5NRFnE5n2UtS+zcyl25qZid13vwprpnqzMTd3cXsZINl8p7Mgg4MThnjiPzS+huSKd8f45YfYeQ7lOljSXQCghy76/+ikl2466amWx3jgk5dCwOmwxy576uHIbjrnSeDug+5VvG7777/TviXwo/Oeps7kEa/86cLHsjzoxnONPCa+P299AM2bUL3y0cM9/SXbX8+95s4/3z3P3xcSvvjAZ1/C+sGzXoQC5dIfuevsm0++9ta3iWwMocLMolTVhJA4BjDlsgb+8jc+AvJPfyfYVaD+dxH3nCwgm1JUxE7SkyftoGwSYFoBjpLADy6Qge3b3/v6l4IMdioFn5IYBTX4FpOEpAEKbMLagnK/z6EwhQ5cIQRB0q2jAOVWBtsVRRRmAHQFSz9lKRYBPFgCyEQsJCOc4p9sKKwBHsYJEXCWAvIEj/86+GsG8Pvh7VRIgjTOroVFDAi4JtjECybsYHUcibpeJhZ3mQBFyyLBDbNyrfxcZo8bFMHcUsMYBsQsh3KwFrZk4EY1Fo+NB2GhrAaGkYIl7WB3PJdIGjaRhx1ig/Z6GtRmNRcKZUaAibzFE6Lmk93VgVU0qKQlQ+e+NmqSiJwcGXtK9kqUiYCJ6GqZj2DGEof8kZUIM5QyvajIJ1jsANgkY+foIMlYqmKXbwyiL4dYAgkGjT1DC8q4DHA0ZCrtlFF0WqJEABREuGRTrRzXA4ZFTVk6ATLaLCMdzkhJcMaul5kkJxwItBYnsDMBjXykCX1o0DWKM6HLO18NVDPFgPr/s4CKKOE2KVpR1GFSkb/cQ9roh81s2pKkJRUdQlGq0DwMbl4OiIAKKOXM90xRou87YUxletJbpFQPK2UaZIA6ggzSE2GjCipMh4q9ouqSefIjgk0a4CyEoWAqwrrVii40tk9cdZczbdHqDtcEBhRASfkR6QgMpCKxjMtCHv2oJ85qybQS5wkMcau9mCqCHXlrrBjynFmpesmLKmNua3vXCSymosv0qJ/VnOpQ/UqLuSlgAQwQ20WmKBCfUlF7QmUsZ2eRNgcU4FYMwOFLT4E5zDGWqDCqrW53y9vepk0vovKqQE/xt+LS6La8hFwV3CoCBM52RMaNbqaQCz3lUgEy/ww4wGCfywUuSde4fFWjRtEU2R4S97vFDe8Px4sm0IoWktBF79/Ui0L2AimMOq3ceeW7LepW1bpSkIhc4dtd/sKKvgy074tcC1HGEBZV/zJwf6mr4AzRUrgEtpGEA+bfCieIpS3NKziytWGQdRjAVMBpfocb3xKj7cQohoIClEqAB494vy6uEoxj7IStdnXAECZxjuW2Yx4zwa1wxfBEcTzk41LYyD1GgGBrzF0NN3lGCM6fhxNU3iprwbtXdjJyt+yfz4YWCPYFc5jZVGQoK8EB7kVzhNccojarhaBkUBEiJMsJFzGZzllmH5nT0E0zMOA12iXAipfcYjpP98m8wf+lCBzQLBtbYZLOZXGBHV0kOzel0Oe8jBfY2cjJODLDX+Z0pyFNGoL2JDBeuHAtGb1pVQdafIN+w9pE3QUQt/QAIkbjnG3tad5QeiKWRuqwOX3r6+XazfsSMrFZDe29SZvZxa42cpbt6GYfVdtISMACgp1LbgM62+AeQtGkRWsrT3vM6U4CTi82z5H+ec3ermm8gTDjiSzVy0dS9aPh7Q7fVqLHU/wxwOUjcAHkO6PveHgDj/zWAsR14f9puMSJ9+z/oFurUi7AdjXtbmxT+xsbB6IO92zeRnf748SB+RDM/N52p1rgKY9fwWUeBPsVCsgjIItXTWvjNGuc58tB+g//DFgoJZfAAWHxKn8wq9dam5zg6Mi57b4WwolkEegFSAChEFtWl5/75N7QejiXsMMppoCr5DIUXstu9ZejvRpqPygYxThGFJjSJ2RX63mubXesb07pPvDprGEodYT5iO4lL/xtO+4KxPfAJhCAQAEQsOhmNslYqCX82Q2PcsvzwK0OnmEOjI5z06eWqmVz6wMk5PTVmxvfrtdsTMsGmQg0BAHJFrbocX/30uReB44xAE4w7oqjF38ZeYdd2fDbt3uHOfpY3fnziyDg6pud+KRP+/FxwOCIMr93zg8/3sd/gwsDvQasf/fkI85+G/ga2OfXUPrnr331C+7211d/4COA/0cCgFeGfRaVdQQoHwbYZAhYOpTXOwt4JcMXgNvXCw9oUk3gAI60AG/VcnU3evyngBc4BAwBIa2CagHXeiXYWRMYA7K3LLX3KBV4gC8YCBnYWEygFwBxcSR3c/KnWvTXgkGgZw0AGacSZNZng0SYdE0IBKnRLrDxgysYhLA3hP5nBBwIZx94D372fRaYhY91gy9wgoACgpEngkLYfyO4BDFoE+9XbjXogGRIH3XYAjxYYzOohGDIhGKIgXfIAkaIhPk3BWomeWtIgn9IBEpyAA8whSrIcCy4iC74hIlHY8FHSQ04ZDmIW4rYhkrgY5kWiRk3iaAofpbYA0hmcXt4Y/99SIepeB2B+BYhN3Kk2HymmIiHF4s80GVUKIlWuFlYeIpJQHNyNoecOIsqpYwp4FqwJVu/WIrBuHvDqIuhKGrdF424OI0lFYEawoyLkRKjaHNVeHXEaHy8qAPYlWiZyBHImGOdmFxsaI1K4Iu3iH65eIXzqI89dmZoCITmSI/rl4454Ix1AY33qH/5KIz7yJA7iI17yE64QXRtA5CIyI+7SIlBwFxNB2QXcyJuN3XeVHVpCH7nCH3geALraIsoYEVzxyKht4SwqJFOSJNqw3IqAEjjdlcwKVUymYwEOSIGRwkp6Sf+mAKplCiBp1ivCJQ2OQaHqIYY+WaN5GCjxW7/lzWSMDGUlLB/Aik4XjmVSeB+o2VPFAl5LiAOibGWwxCVJvmVkxOWDrkEIBZC5CZ8lMSWeqkNckmN0tCX3SgFIdF5todGe6mXbhmGJ6kGiemHi0kEHMgYJFSI2nOYbNmYM/mYaICZTqmZQkBLI+mKMKCWlukRnAmPRQkjgFlRZeNrx5iXpdkWp+li8Vhdf7mQfrkEH2kUCXCXeDkKsSmbq2lQ3hgLwwlOHZMfPMFDlPk+wWmax4lWZBOdfcUEIeEAN2QTSSiaL0Caz/kb1Cle04mbgbkEBmQx42hvwPmdUBGe6zWe3MiaTJAfCbAXEZCNCRkL7Nme5CmftxmfxNkE/6mEQzrhm+4Im/tpHO5ZX/AZkGKJBBfzLJBIjqqQoODZnwH6nw46l25jmBZKDguaYA16kRx6Jgj6od8Rolo2olJZotZ2oijalioqaCz6lg/6fx4ao8Ywo7hWo4oJl4yZSzqaohiKnD7qmEAaHEI6pDJapNKpoSSam1qTo0yqEDzqbEeamUkaHl84mlWqD1f6bZkQpvqGozA6pLNZYrX5X1zDlZJAphBXN2eqo2m6YWuKJN6JpnA6cVM6pzFapxJ2p0eQp3S6pxz3OH6KooBqYIKaJl/Kl05anXK6nl+6qPzVqFzzqFYaqeI5qV76qJYqX5gKN5oaqug1qh2aqB9qqv/fharMUKqGqnJ9SqlVyqrS5arpAKuc+p6e2p26CqBG6qigGqs6xzFLWqnEunWD+qsbKqWpSqtMaqvRhatoxqxRWp7GSqXRmqxrR6rDuqsM2qtpaa0t6qyv+q3A+qTZqqoWKq3gBY6E+qfcqnfi2gLxqqjzKn3Liq7Niq2z+qnICq4iKqwBm66Suq7QqqcCu6IEW6v5mn0IC7AOu7A02rDbSrE9OgZn2VDsmqDuml7wSq426qJdIJIVaa8i+6M3Gjkpi6QruwWBF5MJW6gYi6UWq7AG26lhIHc92UbHOrE5y6uZyq/X6p9isJRumrRKu7RM27RO+7RQq1tRkJUnyzf/xclWTrCxMmtdV8sHacZjXatS/wK2ZJstZYtiXxtjYats+9a2bvu2cBu3cju3dJsKAfQiL5QCyZSCdXsDf2cAd4sgOKMR9SQSm5K3JSAuI7ESJkAoTtW3fjdAgUtWg2sQMUQCiHsSLMO3MhSHkEtDMmQA+LQs9eQ0FzJ7UgOSIxSarRBD6GJEtpIsc7Eyi6sZiNAeSuRESyIUFFI025lupoRHo7ucz6IvXGEvDxA1rMsKhbsArytH4YIIP5E0tUsCW0UuAqRHnjERhoIxczsqLTG8c7cZu+IQj0sNrjsrBHMhnUK75nIATgMaXvUrfxEY43K+bgu+GFQWXmEhQ8FQa6OCv8qQvlMTECTTvtRrLg1xn/x7LdmbLtvbVf4gwPumvwIBVkdhEn/SGEvSLntxCAtAwbxAwKEmEAicR+byJ0yDGcOiu0hhKCL8uTI8wzRcwzZ8wzicwzq8wzzcwz78w0AcxEI8xER8CSEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 281 patients with atrial fibrillation or atrial flutter randomized to intravenous ibutilide or intravenous sotalol, both doses of ibutilide were more effective than sotalol for reverting atrial flutter. Among the patients with atrial fibrillation, only the higher dose of ibutilide was significantly more effective than sotalol for restoring sinus rhythm.",
"    <div class=\"footnotes\">",
"     * p &lt;0.05 compared with sotalol.",
"     <br>",
"      &bull; p &lt;0.05 compared with 1 mg ibutilide.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Vos MA, Golitsyn SR, Stangl K, et al. for the Ibutilide/Sotalol Comparator Study Group, Heart 1998; 79:568.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23837=[""].join("\n");
var outline_f23_17_23837=null;
var title_f23_17_23838="Desens biologics";
var content_f23_17_23838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of 12-step desensitization protocol for intravenous infliximab (600 mg dose, 250 mL per solution)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Solution",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Total volume",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Concentration",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 1",
"       </td>",
"       <td colspan=\"2\">",
"        250 mL",
"       </td>",
"       <td colspan=\"2\">",
"        0.024 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        6 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 2",
"       </td>",
"       <td colspan=\"2\">",
"        250 mL",
"       </td>",
"       <td colspan=\"2\">",
"        0.24 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        60 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 3",
"       </td>",
"       <td colspan=\"2\">",
"        250 mL",
"       </td>",
"       <td colspan=\"2\">",
"        2.38 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        600 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Step",
"       </td>",
"       <td class=\"subtitle1\">",
"        Solution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate (mL/hour)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time (minute)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume infused per step (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose administered with this step (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cumulative dose (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        0.012",
"       </td>",
"       <td>",
"        0.012",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1.25",
"       </td>",
"       <td>",
"        0.030",
"       </td>",
"       <td>",
"        0.042",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.50",
"       </td>",
"       <td>",
"        0.060",
"       </td>",
"       <td>",
"        0.102",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        20.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5.00",
"       </td>",
"       <td>",
"        0.120",
"       </td>",
"       <td>",
"        0.222",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1.25",
"       </td>",
"       <td>",
"        0.300",
"       </td>",
"       <td>",
"        0.522",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.50",
"       </td>",
"       <td>",
"        0.600",
"       </td>",
"       <td>",
"        1.122",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        20.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5.00",
"       </td>",
"       <td>",
"        1.200",
"       </td>",
"       <td>",
"        2.322",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        40.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        10.00",
"       </td>",
"       <td>",
"        2.400",
"       </td>",
"       <td>",
"        4.722",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.50",
"       </td>",
"       <td>",
"        5.953",
"       </td>",
"       <td>",
"        10.675",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        20.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5.00",
"       </td>",
"       <td>",
"        11.906",
"       </td>",
"       <td>",
"        22.580",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        40.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        10.00",
"       </td>",
"       <td>",
"        23.811",
"       </td>",
"       <td>",
"        46.392",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        80.0",
"       </td>",
"       <td>",
"        174.38",
"       </td>",
"       <td>",
"        232.50",
"       </td>",
"       <td>",
"        553.609",
"       </td>",
"       <td>",
"        600.000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Each step is administered over 15 minutes. At conclusion of protocol, observe patient for 30 minutes, then give full therapeutic dose by the desired route.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Total time = 339 minutes (5.7 hours).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Standard premedications included diphenhydramine, 25 mg administered intravenously, and famotidine, 20 mg administered intravenously, 20 minutes before desensitization. Medications at the bedside included intramuscular epinephrine (1:1000, 0.3 mg); diphenhydramine, 25 to 50 mg administered intravenously; famotidine, 20 mg administered intravenously; methylprednisolone, 50 mg administered intravenously; aspirin, 325 mg administered orally; montelukast, 10 mg administered orally; albuterol,&nbsp;two puffs; and lorazepam, 0.5 mg administered intravenously.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Desensitization protocol instructions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        1. Confirm written consent is in medical record.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        2. Please ensure preceding dose of beta-blockers was held, unless otherwise advised by supervising clinician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        3. Obtain IV access, and vital signs (temperature, HR, BP, RR, oxygen saturation, peak flow).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        4. Have at bedside: Epinephrine 0.3 mg (for adult) for IM injection, oxygen, normal saline, peak flow meter, and BP cuff, albulterol, injectable preparation of diphenhydramine , and methylprednisolone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        5. A nurse must closely observe the patient throughout the protocol (one-to-one).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         Administration:",
"        </strong>",
"        Hang each solution successively. Each step is administered over 15 minutes, per protocol. There is no reason to wait between bags. Vital signs should be taken and recorded every 15 minutes, and every 30 minutes during the last step.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Monitoring and charting during desensitization:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"7\">",
"        Please clearly document any reaction, including:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"7\">",
"        a. Patient's symptoms, vital signs, and physical findings;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"7\">",
"        b. Exactly when the reaction occurred (ie, what step, how many minutes into that step);",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"7\">",
"        c. Treatment administered, how and when the reaction resolved, and when the protocol was restarted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Treatment of allergic reactions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        <strong>",
"         For mild reactions:",
"        </strong>",
"        In case of isolated itching, flushing, hives, mild chest tightness, nausea, abdominal pain, or back pain, with normal vital signs, stop the infusion and treat with IV diphenhydramine. Observe patient until the reaction subsides, and then resume the protocol by repeating the step at which the reaction occurred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        <strong>",
"         For severe reactions:",
"        </strong>",
"        In case of hypotension, throat swelling, wheezing/respiratory distress, or decreased oxygen saturation, stop the infusion and treat with epinephrine 0.3 mg IM x 1, diphenhydramine and methylprednisolone IV, oxygen, inhaled albuterol for bronchospasm, and IV fluids (normal saline). Place patient in a recumbent position if hypotensive. Consider glucagon 1 to 2 mg IV bolus if patient has taken beta-blockers, followed by infusion at 1 to 5 mg/hour.",
"        <strong>",
"         Immediately alert the housestaff and supervising clinician.",
"        </strong>",
"        When the patient is stable, the protocol will be resumed as instructed by the supervising clinician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         Contact the supervising clinician for ANY severe or prolonged reaction, or any questions regarding the protocol, reactions, and appropriate management.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brennan PJ, Bouza TR, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allerg Clin Immunol 2009; 124:1259. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"     <br>",
"      Instructions courtesy of Mariana Castells, MD, PhD.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23838=[""].join("\n");
var outline_f23_17_23838=null;
var title_f23_17_23839="Ely test";
var content_f23_17_23839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ely test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Ely test detects contracture of the rectus femoris component of the quadriceps muscle. With the patient prone, the examiner gently flexes the knee to 130 degrees. Contracture of the rectus femoris is indicated by simultaneous flexion of the hip, which causes the buttocks to rise off the table.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Aronsson, DD. The pediatric orthopedic examination. In: Lovell and Winter's Pediatric Orthopedics, 5th ed, Morrissy, RT, Weinstein, SL (Eds), Lippincott Williams &amp;Wilkins, Philadelphia, 2001. p. 99.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_17_23839=[""].join("\n");
var outline_f23_17_23839=null;
